PREDICATE,SUBJECT_NAME,OBJECT_NAME,Factuality_Score,Cancer_Type,Category
AFFECTS,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,FGFR2 gene|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"oxoguanine glycosylase 1, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Malignant Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Topoisomerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
PREDISPOSES,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
DISRUPTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,C-reactive protein level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Proliferation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Carcinoma of the Large Intestine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,CD44 gene|CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Estrogen Receptor Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Hormone replacement therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Metabolic Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,"DNA, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,MST1R gene|MST1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lactation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Human Papillomavirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,BCL9 gene|BCL9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK2 gene|CHEK2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Monocyte Chemoattractant Protein-1|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Complication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PTGS2 gene|PTGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GLTSCR2 gene|NOP53,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Polymorphism, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Endocrine therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
PREDISPOSES,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Base Excision Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenesis Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ABCB1 gene|ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antisense RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Total cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Lesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,DNM1 gene|DNM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,educational intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Amino Acyl-tRNA Synthetases|TRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TLR3 gene|TLR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vascular Endothelial Growth Factor Receptor-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Thromboembolic event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,CXCR4 gene|CXCR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"Alpha-MMC protein, Momordica charantia",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Ovarian Serous Adenocarcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,HRH4 gene|HRH4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Carrier of disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,"Fatty Acids, Omega-6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"Estrogens, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Drug resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Alcohol consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endocrine therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Gene Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,FGF10 gene|FGF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Cytokine Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PRKACA gene|PRKACA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Drugs, Investigational",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
CAUSES,Neoplasm Metastasis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TERT gene|TERT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EGFR gene|EGFR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Solvents,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
PREDISPOSES,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ITK gene|ITK,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CLOCK gene|CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CA-15-3 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MicroRNAs,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Methylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ATM Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,inner centromere protein|INCENP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIRN132 gene|MIR132,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCNB1 gene|CCNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Germ-Line Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adverse reactions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BARD1 gene|BARD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB3 gene|ERBB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Somatic mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Klinefelter's Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"Translation, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Cessation of life,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BRCA2 gene|BRCA2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,protein kinase C eta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,anastrozole,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Dietary Modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prostate-Specific Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,Tumor Angiogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tumor Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Chemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Matrix Metalloproteinases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"Herpesvirus 4, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Gene-Environment Interaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Axillary Lymph Node Dissection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRCA1 Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Mammary Tumor Virus, Mouse",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Cytomegalovirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Linoleic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Fibroblast Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Breast Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Deficiency of testosterone biosynthesis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
CAUSES,SV40 T Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Carcinogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Estrogen excess,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AUGMENTS,Aromatase Inhibitors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Vitamin C intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TFF1 gene|TFF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast cancer recurrent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Serum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
CAUSES,v-Ha-ras Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Genes, Dominant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Nuclear Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Breast Fibrocystic Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,ras Oncogene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Egg Food Product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cancer-Predisposing Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Thyroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Fusion procedure,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone replacement therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Cytotoxic Chemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Gene Amplification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast Diseases,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Gonadotropin-Releasing Hormone Analog,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,"Genes, Suppressor",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Fatty Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Cholera Toxin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,Propionate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,alpha-latrotoxin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
COMPLICATES,Acute leukemia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Peptide Nucleic Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,BRCA1 gene|BRCA1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Combination Chemotherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Digitoxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cancer-Predisposing Gene,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Familial cancer of breast,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,C-Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tamoxifen,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Retinoblastoma Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Lymphocyte Specific Protein Tyrosine Kinase p56(lck)|LCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Viral Oncogene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lymphocyte Specific Protein Tyrosine Kinase p56(lck)|LCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Hereditary Malignant Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,vitamin analog,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
DISRUPTS,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hereditary Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Prostaglandins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
PREDISPOSES,stearic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,steroid hormone receptor,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
AUGMENTS,CUL4A gene|CUL4A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ovarian Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,"TACSTD1 protein, human|EPCAM",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Mammary Tumor Virus, Mouse",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Signal Transduction Pathways,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AFP gene|AFP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,FHIT gene|FHIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Merozoite Surface Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Micronutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Hexachlorobenzene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,Growth Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,17-Ketosteroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AUGMENTS,"PTPN6 protein, human|PTPN6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,GSTT1 gene|GSTT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,impression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,hydroxytamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Estrogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AFFECTS,"Fatty Acids, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Somatotropin-Releasing Hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oestrogen deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Butyric Acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,Retinoblastoma Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Apoptosis Inhibiting Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Li-Fraumeni Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Phytic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,anastrozole,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,DNA Sequence,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Nucleotide Sequence
PREDISPOSES,Conjugated Equine Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,EGFR gene|EGFR,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Kinase C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Nutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Epithelial Cell Proliferation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Transgenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTM1 gene|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,TSG101 gene|TSG101,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Nutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Primary carcinoma of the liver cells,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Cellular Retinol Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Down-Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Body Fat Distribution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Thyroid Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Spontaneous abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Mutation, Missense",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Abortion, Induced",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Oestrogen increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"Fatty Acids, Omega-3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Adhesions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Unspecified Abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DNA Damage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Tumor Promoters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Docosahexaenoic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,protein kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Nuclear Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Breast Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Progestogen hormone therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Epidermal growth factor receptor inhibitor,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
AFFECTS,"Oligonucleotides, Antisense",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Infiltrating duct carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Mutation, Nonsense",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Insulin-Like Growth Factor II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,MCM2 gene|MCM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ESTROGEN USE,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,genotoxicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DDT (Insecticide),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Invertebrate
AFFECTS,STK6 gene|AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin E,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Transcriptional Activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thromboembolic event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Encounter due to Screening for malignant neoplasm of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LAG3 gene|LAG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Signal Transduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Transforming Growth Factor beta|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CA9 gene|CA9,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cytotoxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Dietary Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AUGMENTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Encounter due to genetic counseling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Progestational Hormones, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Focal Adhesion Protein-Tyrosine Kinases,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Metabolic Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SULT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Human papillomavirus 16,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
PREDISPOSES,MET gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cholesterol levels raised,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Female Breast Carcinoma,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Dietary restriction NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Polycyclic Hydrocarbons,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Li-Fraumeni Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Estrogen receptor positive tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,migration stimulating factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Chemicals,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ERCC2 gene|ERCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Monoclonal Antibody Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
CAUSES,Arachidonic Acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,apolipoprotein D|APOD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"progesterone, micronized",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,rho GTP-Binding Proteins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RETN gene|RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cancer Promoting Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,HIC1 gene|HIC1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Oestrogen therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fusion Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Molecular Fingerprint of Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Impaired cognition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Disease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transcription Repressor/Corepressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nicotinamide adenine dinucleotide (NAD),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,ETS1 gene|ETS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,S-Phase Fraction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HSF1 gene|HSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,WISP3 gene|WISP3,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Neoplasm Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,LAMR1 gene|RPSA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,osteosarcoma,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TWIST1 gene|TWIST1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,"RNA, Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"RBL2 protein, human|RBL2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SHFM1 gene|SEM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,participation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DNA Repair Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Processed meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,stress-activated protein kinase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Cardiovascular Diseases,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
DISRUPTS,Phytochemical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Angiogenesis Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Phosphoglycerate dehydrogenase|PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Topoisomerase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,Neoplasm progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Point Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lesion,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MicroRNAs,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Carcinogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Pathogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Angiogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin D intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,AXL gene|AXL,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,JTB gene|JTB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,toxicant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Soy Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,HIF1A gene|HIF1A,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metabolic syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Transcription, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Visual Accommodation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cancer prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hormone Receptor,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Hormone
CAUSES,Placental Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,congener,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Xanthine Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,progesterone analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Epidermal Growth Factor Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,CASP8 gene|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Glutathione S-Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BHMT gene|BHMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCL12 gene|CXCL12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Phytochemical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ESTROGEN USE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cyclooxygenase 2 Inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumorigenicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Small Nucleolar RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Protein p53|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Repair Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,gene polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,TP53 gene|TP53,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hypertensive disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Malignant Bone Neoplasm,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Cardiovascular Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,MIRN34A gene|MIR34A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,systemic administration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,progesterone receptor positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Alcohol consumption,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cholesterol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Lipid
AFFECTS,Epidermal growth factor receptor inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Receptor Activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Epidermal growth factor receptor inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Secondary malignant neoplasm of lymph node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,F3 gene|F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RSU1 gene|RSU1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Induction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Paget's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,curdione,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Response Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LOH11CR2A gene|VWA5A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PTPN12 gene|PTPN12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Extracellular Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FOXC1 gene|FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Infiltration,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Neoplasm Metastasis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Hyperandrogenemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RAB8A gene|RAB8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ZYX gene|ZYX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NCOR2 gene|NCOR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ethacrynic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Exertion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"MAPK14 protein, human|MAPK14",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Functional RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Fibroblast Growth Factor Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Dehydration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
CAUSES,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tumor Cell Invasion,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Transforming Growth Factor beta Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Forkhead Transcription Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,zoledronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa|RPS6KB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,vasodilator-stimulated phosphoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,anastrozole,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Transforming Growth Factor beta|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Neoantigen,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Immunologic Factor
PREDISPOSES,TNFRSF6B gene|TNFRSF6B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,prevention through information dissemination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metaplastic Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cytotoxic Chemotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,"Fatty Acids, Omega-3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,CA-15-3 Antigen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Immunologic Factor
AFFECTS,tumor growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Genes,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Signal Transduction Pathways,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RUNX1 gene|RUNX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,hepatocellular carcinoma protein 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Regulatory Element,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MIR gene|MLXIP|MYLIP|MARCH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cytotoxic T-Lymphocyte-Associated Protein 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Malignant neoplasm of breast,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,OBSCN gene|OBSCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,STAT5A gene|STAT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AKT2 gene|AKT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GPR1 gene|GPR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PLAUR gene|PLAUR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,SHH gene|SHH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Phosphoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MicroRNAs,"cellular diagnosis, breast cancer",0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
COMPLICATES,"Lung Diseases, Interstitial",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
CAUSES,BRCA2 gene|BRCA2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,depolarization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MERTK gene|MERTK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin B 12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,Peptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Cyclic AMP-Responsive DNA-Binding Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Variation (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, X-Linked",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"PDGFA protein, human|PDGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Biological function, NOS",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP3A4 gene|CYP3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCL13 gene|CXCL13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Carcinoma, Non-Small-Cell Lung",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Small cell carcinoma of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BRCA1 gene|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Topoisomerase Inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Radionuclide Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cyclooxygenase 2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DNAJC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TYMS gene|TYMS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"sal protein, Drosophila",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Endocrine substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,EGFL6 gene|EGFL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MULTISECTION:FINDING:POINT IN TIME:BREAST:NARRATIVE:MRI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NOTCH1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,blood lipid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,ESR2 gene|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inflammation Mediators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"UBD protein, human|UBD",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Mammary Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogenic effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Membrane Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,cell invasion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,lysophosphatidic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,MMP9 gene|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Postmenopausal syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Succinate Dehydrogenase|SARDH|SDHB|SDS,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogen hormone therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,"Pleural Effusion, Malignant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SULF2 gene|SULF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BAX gene|BAX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone replacement therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Uterine Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"VEGF protein, human|VEGFA",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lactation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,genetic aspects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Sulfuric Acid Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Reexcision,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GSTT1 gene|GSTT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,GSTP1 gene|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,VEGF gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Progesterone Receptor Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Malignant neoplasm of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Up-Regulation (Physiology),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ERCC5 gene|ERCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Secondary malignant neoplasm of liver,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RHOA gene|RHOA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LGMN gene|LGMN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antihypertensive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,"Antigens, CD5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,MicroRNAs,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Tumor Antigens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Recreation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Angiogenesis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Angiotensin-Converting Enzyme Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ablation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Detection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Diseases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Angiotensin-Converting Enzyme Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Estrogen Antagonists,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,IGFBP3 gene|IGFBP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RHOC gene|RHOC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Promoter Regions (Genetics),Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Malignant Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Antidepressive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,mammary tumor virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"KLK15 protein, human|KLK15",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IL6 gene|IL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Positron-Emission Tomography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,PRLR gene|PRLR|PTP4A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LOC118430 gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Endometrial Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Exploration procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SHC1 gene|SHC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,ELF3 gene|ELF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Fatty Acids, Saturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Antidepressive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,BMP7 gene|BMP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Complication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Low Dose Radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HPR gene|HPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Folic Acid Deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"NUP214 protein, human|NUP214",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CCNE1 gene|CCNE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,retinoic acid receptor beta 2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Chemical
PREDISPOSES,CLOCK gene|CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogene Proteins c-akt|AKT1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,pulmonary complications,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,mRNA Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,RHOA gene|RHOA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fine needle aspiration biopsy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Low glycemic index food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Encounter due to In vitro fertilization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ovarian cancer prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Endocrine therapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,HGS gene|HGS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,hypercholesterolemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Gross' disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Mucin 1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Metastatic malignant neoplasm to brain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,abnormal glucose tolerance test,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,PPARG gene|PPARG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LOX gene|LOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Human papilloma virus infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Cyclooxygenase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,C-reactive protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TNF gene|TNF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carcinoembryonic Antigen|CEACAM5|CEACAM3|PSG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,BRCA2 Mutation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,STN gene|EEF1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Depressive disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Ascorbic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Estrogen Receptors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Thyroid dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NMU gene|NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Motion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,breast cancer diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"RNA, circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Metastasis Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Oral contraception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Reduction mammaplasty,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Excision,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,CCND1 gene|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Zn-alpha-2-glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Nuclear Hormone Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KISS1 gene|KISS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Protein Subunits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,zoledronic acid,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
PREDISPOSES,Estrogen Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Tomography, Emission-Computed",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Metals, Heavy",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Migraine Disorders,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
AFFECTS,PRLR gene|PRLR|PTP4A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dioxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cyclooxygenase 2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Antidepressive Agents, Tricyclic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Oncogene Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dissection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,XRCC2 gene|XRCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
DISRUPTS,DNA Repair Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Non-Invasive Lesion,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Blood hormone levels,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Malignant Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Progesterone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Lesion,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Polymorphism, Genetic",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,GH1 gene|GH1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Virus Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Epidermal Growth Factor Receptor|EGFR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Angiogenesis Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,25-hydroxyvitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA topoisomerase II alpha|TOP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,MIRN150 gene|MIR150,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Secondary malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Medroxyprogesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Invasive Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP2D6 gene|CYP2D6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Lipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Serotonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,SMAD3 gene|SMAD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IRF4 gene|IRF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Composition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP2D6 gene|CYP2D6,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,CXCR4 gene|CXCR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA Repair,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnostic radiologic examination,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,collapsin response mediator protein-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin D Deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,GSTT1 gene|GSTT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin A intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Genome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,endogenous steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
DISRUPTS,Hetastarch,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,DNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Noninfiltrating Intraductal Carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,XRCC3 gene|XRCC3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,G-T mismatch-binding protein|MSH6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CCL1 gene|CCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAT3 gene|STAT3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,retinoic acid receptor beta 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ID2 gene|ID2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genetic Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chronic inflammatory disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,PIK3CA gene|PIK3CA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Trans Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Protein phosphatase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,K-ras Oncogene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
AFFECTS,GTP-Binding Protein alpha Subunits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,HOXC6 gene|HOXC6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Peptide Nucleic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Disease or Syndrome
DISRUPTS,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,Growth Hormone Receptor|GHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Proto-Oncogene Proteins c-myc|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Small Inducible Cytokine A18|CCL18,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
AFFECTS,BRCA2 Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Serum Proteins,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,STAR gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, ras",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MAFG gene|MAFG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TWIST1 gene|TWIST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Self-Examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PARVA gene|PARVA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CBFB gene|CBFB|NFYA|NFYB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Arachidonic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Plant Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,leukemia,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gastric Inhibitory Polypeptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Tic disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"RNA, Untranslated",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Disease susceptibility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,"CHEK2 protein, human|CHEK2",Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DNA Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Epstein-Barr Virus Infections,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tumor Cell Invasion,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AUGMENTS,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Aromatase|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,"Receptors, Steroid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,Insulin-Like Growth Factor II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Medication use,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Vascular Endothelial Growth Factor Receptor-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MIRN34A gene|MIR34A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Ascorbic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
DISRUPTS,activated RNA polymerase II transcription cofactor 4|IFRD1|KRT6B|SUB1|PCSK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Methyl-CpG-Binding Protein 2|MECP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,RHOA gene|RHOA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Functional assessment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR99A gene|MIR99A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,27-hydroxycholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,CELF6 gene|CELF6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Menstruation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Mitogen-Activated Protein Kinase 3|MAPK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,DNMT3B gene|DNMT3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,RNA metabolic process,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Vascular Endothelial Growth Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Bilateral Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Paralogous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAK6 gene|PAK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00173 gene|LINC00173,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenic Process,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Phenomenon or Process
AFFECTS,Positron Emission Tomography and Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypertriglyceridemic Waist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,PDZRN4 gene|PDZRN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRD7 gene|BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KDM1A gene|KDM1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR451A gene|MIR451A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC00993 gene|LINC00993,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,JAG1 gene|JAG1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"Leukemia Virus, Bovine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,TP53 gene|TP53,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SFRP2 gene|SFRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,FNDC5 gene|FNDC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CNN1 gene|CNN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FOXK1 gene|FOXK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Variation (Genetics),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
PREDISPOSES,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,GSTM1 gene|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DNA Motifs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Mirn124a microRNA, human",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,SDHC gene|SDHC,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Gene Mutant,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,TFCP2 gene|TFCP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,RWDD4 gene|RWDD4,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
PREDISPOSES,Tumor Escape,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOX10 gene|SOX10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"MET protein, human",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CDYL2 gene|CDYL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Matrix Metalloproteinase 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CBLB gene|CBLB|MMAB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ribonucleotide reductase M2|RRM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,TRDMT1 gene|TRDMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,brown adipose tissue uncoupling protein,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor Suppressor Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,TMPO-AS1 gene|TMPO-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Prune Belly Syndrome,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Human Class I Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,NUDT21 gene|NUDT21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEK10 gene|NEK10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GPER1 gene|GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,letrozole,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,CCL8 gene|CCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,polygene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carbohydrate intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Neoplastic Cell Transformation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MCM3AP-AS1 gene|MCM3AP-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ELAVL2 gene|ELAVL2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,RNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
CAUSES,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,DAPK1 gene|DAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FGFBP1 gene|FGFBP1,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,ZEB1 gene|ZEB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RIOK1 gene|RIOK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Metastatic malignant neoplasm to brain,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"RNA, Messenger",Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,BCL11A gene|BCL11A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,ERR1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LIMK2 gene|LIMK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MLF2 gene|MLF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MALAT1 gene|MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor size,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AMH gene|AMH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CKLF gene|CKLF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PRKN gene|PRKN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Anti-Mullerian Hormone Receptor Type II, Human|AMHR2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Genetic Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNAI1 gene|SNAI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ADIPOR1 gene|ADIPOR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Fibroblast Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Protein, Organized by Structure",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Angiogenic Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,tamoxifen,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,HER-2 protein|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hormone Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,dna genetics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"DNM1L protein, human|DNM1L",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,GSTP1P1 gene|GSTP1P1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FANCM gene|FANCM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SNAI2 gene|SNAI2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Sodium-Glucose Transporter 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AUGMENTS,ZFPM2-AS1 gene|ZFPM2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BBOX1 gene|BBOX1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Conventional Treatment,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Injection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TP53 gene|TP53,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,SERPINE1 gene|SERPINE1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,RASAL2 gene|RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00922 gene|LINC00922,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Processed meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,estrogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
PREDISPOSES,HMGB1 gene|HMGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"PDIA3 protein, human|PDIA3",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR30E gene|MIR30E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MTOR gene|MTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score C,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,RSPO3 Gene|RSPO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,A2M-AS1 gene|A2M-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SALL4 gene|SALL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KCNQ1OT1 gene|KCNQ1OT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,METTL14 gene|METTL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,TUG1 gene|TUG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Alternative Splicing,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PCAT7 gene|PCAT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC01271 gene|LINC01271,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,"RNA, Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,PTEN gene|PTEN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE3C gene|UBE3C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"IL2RB protein, human|IL2RB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ZNF670-ZNF695 gene|ZNF670-ZNF695,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,OXER1 gene|OXER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FBXO22 gene|FBXO22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,TINCR gene|TINCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00665 gene|LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Tumor Promotion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UCHL1 gene|UCHL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK2 gene|CHEK2,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,AGAP2-AS1 gene|AGAP2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Psychosocial Intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SDHC gene|SDHC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MBD2 gene|MBD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC01271 gene|LINC01271,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
CAUSES,Nutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Metric (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,FZD2 gene|FZD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,gambogic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Malignant neoplasm of breast,"Breast Cancer, Familial",0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CPT1A gene|CPT1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,calmodulin-dependent protein kinase III,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SENP3 gene|SENP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,elaidic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CDKN1A protein, human|CDKN1A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ATM gene|ATM,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Heterogeneous-Nuclear Ribonucleoprotein K,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,O(6)-Methylguanine-DNA Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CYTOR gene|CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LRRC3B gene|LRRC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,recreational activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Systemic Inflammatory Response Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"PLK1 protein, human|PLK1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FBXO32 gene|FBXO32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ELF5 gene|ELF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDK15 gene|CDK15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transcription Coactivator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Neoantigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AUGMENTS,FADS1 gene|FADS1,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,hyaluronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Fetal valproate syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,DPP6 gene|DPP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWIST1 gene|TWIST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Intronic Mutation,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PADI1 gene|PADI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR599 gene|MIR599,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FANCA gene|FANCA,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR638 gene|MIR638,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carcinoembryonic Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,ARHGAP1 gene|ARHGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WNT9B gene|WNT9B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,VGLL1 gene|VGLL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Collagen Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HAGLR gene|HAGLR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,cytotoxicity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,KIF23 gene|KIF23,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Consideration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"herstatin protein, human",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CDKN2B-AS1 gene|CDKN2B-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,medication risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,VCAN-AS1 gene|VCAN-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LINC01094 gene|LINC01094,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,epithelial to mesenchymal transition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL27 gene|MYDGF|IL27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,GLUT-1 protein,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC01315 gene|LINC01315,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adhesions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Drug Resistance, Neoplasm",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AFFECTS,NEIL2 gene|NEIL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ursolic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,bone morphogenetic protein 4|BMP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,LINC00922 gene|LINC00922,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,HOXC10 gene|HOXC10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,New medications,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Tumor Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"EIF4EL3 protein, human|EIF4E2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"herstatin protein, human",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"RNA, Small Interfering",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Mucin-1 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,MICAL2 gene|MICAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CD69 protein, human|CD69",malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,HSPA9 gene|HSPA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RBM38 gene|RBM38,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"herstatin protein, human",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Lactation established in non-human animal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDC20 gene|CDC20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prieto X-linked mental retardation syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NFIL3 gene|NFIL3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,KRT19P3 gene|KRT19P3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PTEN gene|PTEN,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,"LATS1 protein, human|LATS1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Genes, cdc",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,omega-3 fatty acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,ADRB2 gene|ADRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"EZH2 protein, human|EZH2",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Antibody Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,hydrogen peroxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Chemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,SRP9 gene|SRP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HTR1A gene|HTR1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00466 gene|LINC00466,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,OPRM1 gene|OPRM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLK3 gene|KLK3,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,DDT (Insecticide),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Invertebrate
AFFECTS,ARHGAP17 gene|ARHGAP17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Duration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Nutrients,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Food
PREDISPOSES,Migraine Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,NEDD4L gene|NEDD4L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR210HG gene|MIR210HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD31 Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,mRNA Expression,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,G-Protein-Coupled Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TRIP13 gene|TRIP13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RAB8A gene|RAB8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PSAT1 gene|PSAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CCR2 gene|CCR2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,RAB8A gene|RAB8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epithelial ovarian cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SREBF1 gene|SREBF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NCAPD2 gene|NCAPD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Manipulation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GTSE1 gene|GTSE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Human B-Lymphocyte Antigen CD20, human|MS4A1|KRT20",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Physical function,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Self-Examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC01287 gene|LINC01287,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ATAD2B gene|ATAD2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXD3-AS1 gene|FOXD3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Triglycerides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,DDX21 gene|DDX21,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"protein TDP-43, human",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,folic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,benzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Hydrogen Sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,2-mercaptoethanesulfonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,PSME2 gene|PSME2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,ZNHIT1 gene|ZNHIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GUSBP11 gene|GUSBP11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,CUEDC2 gene|CUEDC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNA Recognition Motif,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TP53,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Florid red complexion (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Orthologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PON1 gene|PON1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Eosinum, eosin, Homeopathic preparation",malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Androgen Binding Protein|SHBG|CCHCR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Peptides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lymphatic Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,LINC00520 gene|LINC00520,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"RNA, Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,High grade serous carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PIK3CA Gene Mutation,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,TRANSCRIPTION FACTOR,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Rich food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,"RNA, Long Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Colorectal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Antibody-Drug Conjugates,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Carcinogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,BVES gene|BVES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cardiac event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,SLC1A5 gene|SLC1A5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Pharmaceutical Preparations,Carcinoma breast stage IV,0.0,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,BRCA2 gene|BRCA2,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPATA25 gene|SPATA25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Metric (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,Intercellular adhesion molecule 1|ICAM1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IGHG1 gene|IGHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DDX11-AS1 gene|DDX11-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FTO gene|FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"Receptors, Progesterone",Advanced breast cancer diagnosis,0.0,Female Breast Cancer,Hormone
DISRUPTS,"RAF Proto-Oncogene Serine/Threonine-Protein Kinase, human|RAF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Provisional,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Transection (procedure),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Drugs, Non-Prescription",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,SMURF1 gene|SMURF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,insulin-like growth factor 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,GNAO1 gene|GNAO1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCND1 gene|CCND1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,FOXO1 gene|FOXO1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,CCN1 gene|CCNA2|CYR61|PPP3CA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transcription Factor AP-2 Beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SIRT1 gene|SIRT1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,DANCR gene|DANCR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,malignant disease,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,IGF2BP1 gene|IGF2BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,"High Mobility Group Protein HMG-I, Human|HMGA1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,AKTIP gene|AKTIP,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Drug resistance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,HULC gene|HULC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,USP13 gene|USP13,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,NLRP3 gene|NLRP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PHB2 gene|PHB2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,VDR gene|VDR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Amino Sugars,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Meal (occasion for eating),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TTC17 gene|TTC17,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Atrial Fibrillation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Exogenous hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Amino Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,PKMYT1 gene|PKMYT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Specific antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,"DICER1 protein, human|DICER1",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NUMB gene|NUMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sleep duration:Time:Pt:^Patient:Qn,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ursolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Hydroxy Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"SDHD protein, human|SDHD",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,"CTSH protein, human|CTSH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Immune Checkpoint Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,CDK1 gene|CDK1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epithelial proliferation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,COPS6 gene|COPS6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,KIF2C gene|KIF2C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MIR326 gene|MIR326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"HMGA2 protein, human|HMGA2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RNA-Binding Protein Musashi Homolog 1,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Non-Small Cell Lung Carcinoma,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IPO7 gene|IPO7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"TNF protein, human|TNF",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RNA-Binding Protein Musashi Homolog 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Peptides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,PPP1R14B-AS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RNA-Binding Protein Musashi Homolog 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FOXP3 gene|FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,palbociclib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,BRCA2 Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HIPK3 gene|HIPK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,pre-miRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,YOD1 gene|YOD1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,SMYD2 gene|SMYD2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,TUSC2 gene|TUSC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPX4 gene|GPX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Circulating Tumor DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AURKA gene|AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"CREB1 protein, human|CREB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cervical Cancer Screening,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ascorbic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,TMED2 gene|TMED2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HASPIN gene|HASPIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNHG14 gene|SNHG14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lymphatic Invasion,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Allele-Specific Oligonucleotide,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,NR1D1 gene|NR1D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,estrogens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXO3 gene|FOXO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEK2 gene|NEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pharmacologic Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,PAXX gene|PAXX,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Colorectal Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,PIN1 gene|PIN1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,FMO4 gene|FMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fibroblast Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"POSTN protein, human|POSTN",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,TWIST1 gene|TWIST1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Homologous Recombination Repair Gene,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,YBX1 gene|YBX1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Plasma Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FBXO3 gene|FBXO3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Precision Medicine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MTDH gene|MTDH,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,c-src Genes|SRC,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Psychotic Disorders,Carcinoma breast stage IV,0.0,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Ubiquitin-Conjugating Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,TIPARP gene|TIPARP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RAD51 gene|RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Duration,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GALNT7 gene|GALNT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MELK gene|MELK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leukotriene B4 Receptors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Eicosanoid
AFFECTS,GRB2 gene|GRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LIAS gene|LIAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HER2/Neu Positive,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SNORD16 gene|SNORD16,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,FBXO8 gene|FBXO8,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fertility Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Receptor Protein-Tyrosine Kinases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,cadmium chloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ECM1 gene|ECM1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNHG1 gene|SNHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"ORF74 protein, Human herpesvirus 8",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SNORD49B gene|SNORD49B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,YAP1 gene|YAP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"herstatin protein, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HOTAIR gene|HOTAIR,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"ATP8A2 protein, human|ATP8A2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Alzheimer's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Pathogenic Variant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
PREDISPOSES,Alzheimer's Disease,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Disease or Syndrome
AFFECTS,UGT2B7 gene|UGT2B7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HIF1A gene|HIF1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,O(6)-Methylguanine-DNA Methyltransferase|MGMT,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Biological Processes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,GCKR gene|GCKR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDP1 gene|PDP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,FSCN1 gene|FSCN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,"CDK7 protein, human|CDK7",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NODAL gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6, human|CEACAM6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Uridine Diphosphate Glucose Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Oligoribonucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,TCF7L2 gene|TCF7L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NCOA1 gene|NCOA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MLH1 gene|MLH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"GMNN protein, human|GMNN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,Carcinogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,LSP1 gene|LSP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TNFSF6 gene|FASLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Prevention,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,NME1 gene|NME1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,Amyloid beta-Protein Precursor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Compound V,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Pharmaceutical Preparations,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Bacterial Endocarditis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Bacterium
AUGMENTS,activating transcription factor 3|ATF3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immune Cell Activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD47 gene|CD47,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,bone morphogenetic protein 6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NTRK2 gene|NTRK2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,IGKC gene|IGKC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,Vitamin B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Estrogen Receptor beta|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Encounter due to genetic counseling,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,BMP2 gene|BMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen receptor positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, cdc",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"DNA, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,BIRC4 gene|XIAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,MC4R gene|MC4R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Syndrome,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
DISRUPTS,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FOXM1 gene|FOXM1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,PAWR gene|PAWR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Mullerian-inhibiting substance receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,MIRN21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2IP gene|ERBIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RARRES3 gene|RARRES3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Adenocarcinoma of large intestine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,EPSTI1 gene|EPSTI1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Prodrugs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,NRIP1 gene|NRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,platelet-derived growth factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,"TIMP1 protein, human|TIMP1",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Encounter due to genetic counseling,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AFFECTS,APC gene|APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast cancer invasive NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TLR4 gene|TLR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Sialoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK1 gene|CHEK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Organic Chemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,XRCC4 gene|XRCC4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CDH1 gene|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"HGF protein, human|HGF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,STAT5B gene|STAT5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,transcription cofactor activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Wiskott-Aldrich Syndrome Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Proto-Oncogene Proteins c-sis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CA-125 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Epigenetic Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Glutamic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,"Receptors, Tumor Necrosis Factor, Type II",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atrial Fibrillation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cancer of Rectum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,TNFSF10 gene|TNFSF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epstein-Barr virus antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,TSG101 gene|TSG101,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Castration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIRN17 gene|MIR17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SHC1 protein, human|SHC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,In complete remission,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Reproduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Up-Regulation (Physiology),Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Chronic inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SRC gene|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,OLFM4 gene|OLFM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Virus,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Virus
AFFECTS,BRCA2 gene|BRCA2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Exogenous hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,calcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"RARB protein, human|RARB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LEPR gene|LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Exogenous hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Estrogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,"CST6 protein, human|CST6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Fatty Acids, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Vitamin D3 Receptor|VDR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,pyrrolidino-4-iodotamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Transcriptional Activation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Infusion procedures,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Proto-Oncogene Proteins c-akt|AKT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Progesterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Fibroblast Growth Factor 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Immunotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Involution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Enzymes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
CAUSES,neu Differentiation Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,parathyroid hormone-related protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Oncogene, HST|FGF4|HSF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Replacement Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Cytotoxic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,3-hydroxytamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Termination of pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Secondary malignant neoplasm of bone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,EGF gene|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Breast Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Induction,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Malignant transformation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thyroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tissue Polypeptide Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Malignant neoplasm of stomach,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Medroxyprogesterone 17-Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,v-H-ras Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Hair Dyes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Estrogen Antagonists,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Cystic Lesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Contraction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Prostaglandins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Eicosanoid
PREDISPOSES,"Hamartoma Syndrome, Multiple",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estrogenic,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carrier of disorder,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Human Chorionic Gonadotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Complex carbohydrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,SERPINB2 gene|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PTK2B gene|PTK2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,retinoic acid receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Cyclic AMP Receptor Protein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Maternal history,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Insulin-Like Growth-Factor-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,"Herpesvirus 4, Human",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AUGMENTS,DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Lhermitte-Duclos disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,BRCA2 gene|BRCA2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CDKN2A gene|CDKN2A,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Overnutrition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transcription Factor AP-2 Alpha|FABP4|GTF3A|TFAP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SPO11 gene|SPO11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Gene Expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Amplification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,ras Oncogene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Invasive Carcinoma,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,CHGA gene|CHGA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Vascular Endothelial Growth Factor Receptor-1|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,NMU gene|NMU,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,ovarian function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,Gross' disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,"Polycyclic Hydrocarbons, Aromatic",Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vitamin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,glutathione S-transferase M1|CHRM1|MRLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation therapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,bone sialoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Adrenal carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Opioid Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,BRCA1 Protein|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Epoxy Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,ERBB2 gene|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Repressor Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Radioimmunotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
PREDISPOSES,TIE gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Thyroid Hormone Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HDAC1 gene|HDAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,XRCC2 gene|XRCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,EGFR gene|EGFR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,Sporadic Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oleic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,GTPase-Activating Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth-Factor-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Estrogens, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,TP53 gene|TP53,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,parathyroid hormone-related protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fatty food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,CHEK2 gene|CHEK2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,Carcinoma of Male Breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"SKIL protein, human|SKIL",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"retinoic acid binding protein II, cellular",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Carcinoma, Lobular","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,Medroxyprogesterone 17-Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,BRCA1 Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,BIRC5 gene|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Mammary Tumorigenesis,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Hepatocyte Growth Factor|HGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,"JARID1B protein, human|KDM5B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,pregnancy hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Recreation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,peptide I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Malignant neoplasm of prostate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hexachlorobenzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,HFE gene|HFE,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,Single-Stranded Conformational Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Emotional support,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Conjugated Equine Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,beta-ionone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Tumor Protein p53 Binding Protein 2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Estrogenic,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hormone
AFFECTS,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Convenience food,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
PREDISPOSES,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,CYP1A2 gene|CYP1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transcription Initiation Site,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aggressive cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,connective tissue growth factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Dopamine Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
DISRUPTS,Cyclic Peptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AFFECTS,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HSP90 Heat-Shock Proteins|HSP90AA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of breast,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,Trans Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"Diabetes, Gestational",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,intestinal bacteria,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Bacterium
AFFECTS,Neoplasm Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tumor Suppressor Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,IRS1 gene|IRS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PTH gene|PTH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IGF1 gene|IGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
DISRUPTS,"Estrogens, Catechol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Anti-Inflammatory Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Platelet-Derived Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CD44 gene|CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin B Complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Mutation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BRMS1 gene|BRMS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,phospholipid-hydroperoxide glutathione peroxidase,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,alpha-Fetoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TP53 gene|TP53,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53 gene|TP53,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coronary heart disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Serotonin Uptake Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serine Protease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,CHEK2 gene|CHEK2,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
PREDISPOSES,BRCA1 Protein|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,EGFR gene|EGFR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AFFECTS,CCNA2 gene|CCNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Estrogen Receptor beta|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor Cell Invasion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRANSCRIPTION FACTOR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NPY1R gene|NPY1R,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HGS gene|HGS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Ascorbic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Actin bundling protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hypermethylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Oligonucleotides,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Metabolic syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,PGR gene|PGR,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,steroid hormone receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,ANXA1 gene|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NF1 gene|NF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Organic Anion Transport Polypeptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Nucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Polyomavirus Middle T Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
PREDISPOSES,CENPH gene|CENPH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Carcinogens, Environmental",Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Estrogens, Catechol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Cancer Treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CLDN2 gene|CLDN2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Antagonists,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
DISRUPTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Enzyme variant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AUGMENTS,Vascular Endothelial Growth Factor C|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MicroRNAs,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,LEPR gene|LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Migraine Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Mastication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carcinogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Angiogenesis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Increased estrogen level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Oxidation-Reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MicroRNAs,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,CD44 gene|CD44,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Elevated insulin-like growth factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,High Mobility Group Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hydroxide Ion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Angiotensin-Converting Enzyme Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Enzyme
PREDISPOSES,RAD51C gene|RAD51C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TOPBP1 Gene|TOPBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proteins,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,epithelial to mesenchymal transition,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Phosphatidylethanolamine Binding Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PTPN11 gene|PTPN11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AUGMENTS,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tamoxifen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AFFECTS,Sirolimus (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,MicroRNAs,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Malignant neoplasm of cervix uteri,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Integral Membrane Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lead compound,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transfer RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PROTEIN KINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Choline dehydrogenase|CHDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,N-ras Genes|NRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Extravasation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ABCG2 gene|ABCG2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Tumor Necrosis Factor Receptor Superfamily, Member 10B",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vascular Cell Adhesion Molecule-1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BRCA1 gene|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Processed meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,G-Protein-Coupled Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RECQL gene|RECQL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Trans-Activation (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
DISRUPTS,"DICER1 protein, human|DICER1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ovarian ablation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Secondary malignant neoplasm of lymph node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Extracellular Matrix Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Dietary cholesterol intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,TAF7L gene|TAF7L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL8RB gene|CXCR2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Maternal history,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Solid tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Matrix Metalloproteinase Inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,STXBP4 gene|STXBP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Extracellular Matrix Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,EGF gene|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PRDM1 gene|PRDM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epigenetic Process,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,MicroRNAs,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,recombinational repair,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BMP4 gene|BMP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MAS1 gene|MAS1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Housekeeping Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Genes, Developmental",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Genes,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,WNT10B gene|WNT10B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,MIRN200A gene|MIR200A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PVT1 gene|PVT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BRF1 gene|ZFP36L1|BRF1|MST1L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RECQL4 gene|RECQL4,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Malignant neoplasm of stomach,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Sirolimus (substance),Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Substance
PREDISPOSES,Fibroblast Growth Factor Receptor 2|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Vascular Endothelial Growth Factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,FGFR1 gene|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CDK6-associated protein p18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Metastasis Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SKP2 gene|SKP2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,chrysophanic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,SRD5A2 gene|SRD5A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,proto-oncogene protein Spi-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cardiovascular event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Suppressor Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
DISRUPTS,LATS1 gene|LATS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Small Interfering",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CD8B1 gene|CD8B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,endogenous steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,POMC gene|POMC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,genetic locus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PMS2 gene|PMS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TSLP gene|TSLP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ITGB2 gene|ITGB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Extracellular Matrix Proteins,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MFN2 gene|MFN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,brca gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,REST gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth-Factor Binding Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Membrane Transport Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"PER2 protein, mammalian",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,Eicosanoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
AFFECTS,Vision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth Factor II|CD74|GCNT2|TCN2|VIPR1|TAF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,FAS gene|FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,NAT2 gene|NAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nuclear Factor 45 Protein|ILF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"DNA, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,antibody conjugate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,Sterol Regulatory Element Binding Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MYC gene|MYC,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,UGT1A1 gene|UGT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Signal Transduction,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Functional disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Intellectual functioning disability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Epidermal Growth Factor Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Transfer RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,gene therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,lysophosphatidic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,THBS1 gene|THBS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Deoxycholic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
CAUSES,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Malignant neoplasm of endometrium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,dietary intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Neoplastic Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fibroblast Growth Factor Receptor 2|FGF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,"RNA, Messenger",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"DNA, Complementary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Hormones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CXCL1 gene|CXCL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of breast,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,GSTM1 gene|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation therapy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,EGR1 gene|EGR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant Neoplasms,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AFFECTS,Immune response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,BRCA1 gene|BRCA1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Ovarian Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HMGB1 gene|HMGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Growth Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,DNA Methylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF217 gene|ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IRS1 gene|IRS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Organic solvent product,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Chemical
AFFECTS,Inflammation Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Injection procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,JNK Mitogen-Activated Protein Kinases|JUN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BRCA1 gene|BRCA1,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
CAUSES,Heme Oxygenase-1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,participation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FLOT2 gene|FLOT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chronic lymphocytic inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Organic Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,"APEX1 protein, human|APEX1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RRM2 gene|RRM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Hair Dyes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,Renin-angiotensin system inhibition,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MAP Kinase Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Autoantibody NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,Decalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Sulfonylurea Compounds,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
DISRUPTS,Protein-Serine-Threonine Kinases,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin D-Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ursolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TRAN gene|TRA-TGC7-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,receptor for advanced glycation endproducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,AKT1 gene|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,apolipoprotein D|APOD,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Inflammation,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Radiation-Induced Change,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Self-Examination,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BRCA1 gene|BRCA1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,CLCN3 gene|CLCN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ethylmalonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,HTATIP gene|KAT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,Angiotensin-Converting Enzyme Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Enzyme
PREDISPOSES,Untranslated Regions,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MGMT gene|MGMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Serine Protease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,Emergency contraception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carbon ion,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Chemical Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,vitamin supplement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,coenzyme Q10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,MicroRNAs,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Genes,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,PGR gene|PGR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCDC6 gene|CCDC6,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Personal Satisfaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oligonucleotide Arrays,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Ions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BLM gene|BLM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Tamoxifen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,DMBT1 gene|DMBT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Positron-Emission Tomography,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Noninfiltrating Intraductal Carcinoma,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Human Chorionic Gonadotropin|CGA|HTC2|CGB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Steroidal Aromatase Inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Steroid
PREDISPOSES,perfluorooctanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,letrozole,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,MATP gene|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BRCA1 gene|BRCA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Dietary Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
CAUSES,NBS1 gene|NBN|NLRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,[V]Follow-up examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Long chain fatty acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,XRCC5 gene|XRCC5,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Triglycerides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Membrane Glycoproteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Breast composition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,LHX1 gene|LHX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PGRMC1 gene|PGRMC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NAT2 gene|NAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Behcet Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Carrier of disorder,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Egg Food Product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Glutamate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anovulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Ovarian Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Invasive Malignant Neoplasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Free testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Breast cancer invasive NOS,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,MME gene|MME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Excision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endocrine therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,Protein Overexpression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen receptor negative,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BRCA2 Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gall Bladder Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,STAT5A gene|STAT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ionizing radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin-Like Growth Factor I|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MSH6 gene|MSH6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Suspensions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Maternal Mortality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Reaction emotional,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Sulfonylurea Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Undifferentiated carcinoma of ovary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,glutathione S-transferase M1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,brca gene,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cytotoxicity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Tamoxifen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Carcinoembryonic Antigen|CEACAM5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Amino Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Little's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Physiological Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
DISRUPTS,RNA Sequence,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Nucleotide Sequence
AUGMENTS,HIF1alpha protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AUGMENTS,MIRN106A gene|MIR106A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,CDC2 gene|CDK1|POLD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Cancer-Predisposing Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Monomeric GTP-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Endocrine System Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,ataxia telangiectasia mutated protein|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,glutathione S-transferase M1|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,9-deoxy-delta-9-prostaglandin D2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
AUGMENTS,activated RNA polymerase II transcription cofactor 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HGS gene|HGS,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,Formaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Platelet-Derived Growth Factor beta Receptor|PDGFRB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Single Nucleotide Polymorphism,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Homologous Gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SERPINI2 gene|SERPINI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,centromere protein F,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Aging-Related Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
CAUSES,"PTTG1 protein, human|PTTG1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TAGLN2 gene|TAGLN2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Antipsychotic Agents,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Antioestrogen therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Mitochondrial Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CHD4 gene|CHD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gambogic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,RPS27 gene|RPS27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BARD1 gene|BARD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,food product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Functional RNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TTN-AS1 gene|TTN-AS1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"MMP14 protein, human|MMP14",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Lipid Peroxides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,SOX2 Transcription Factor|SOX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP27A1 gene|CYP27A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ENO1 gene|ENO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BRCA2 Gene Mutation,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Hormone use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,RESF1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PPEF1 gene|PPEF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HDAC5 gene|HDAC5,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Colorectal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP7B1 gene|CYP7B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAK2 gene|PAK2|PKN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FTSJ3 gene|FTSJ3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SFRP1 protein, human|SFRP1",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Alternative Splicing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"CD69 protein, human|CD69",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GACAT3 gene|GACAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPRY4-IT1 gene|SPRY4-IT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KLK12 gene|KLK12,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"GOLPH3 protein, human|GOLPH3",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,USP43 gene|USP43,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"CEACAM5 protein, human|CEACAM5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TRIP6 gene|TRIP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Detection,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ERR1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Immune response,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Immunologic Factor
DISRUPTS,FOXN4 gene|FOXN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Soluble fiber (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,High expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"CD69 protein, human|CD69",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MYCN gene|MYCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transforming Growth Factor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Genome,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTTG1 gene|PTTG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gestational Diabetes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CERNA2 gene|CERNA2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,"TP53BP1 protein, human|TP53BP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ALKBH5 gene|ALKBH5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptor alpha,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ECE1 gene|ECE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Invasive Carcinoma,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
CAUSES,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenic Process,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Phenomenon or Process
DISRUPTS,GKLF protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PRR14 gene|PRR14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GKLF protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,RNA-Binding Protein Musashi Homolog 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,KIF15 gene|KIF15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,D Vitamin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Food
PREDISPOSES,LINC00707 gene|LINC00707,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,COTL1 gene|COTL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GPX3 gene|GPX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SLC16A3 protein, human|SLC16A3",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,NME1 gene|NME1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Metastatic malignant neoplasm to brain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Anti-Inflammatory Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Tumor Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TNIP2 gene|TNIP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Alternative Splicing,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,XIST gene|XIST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,ado-trastuzumab emtansine|DMPK|IGHD1-7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Matrix Metalloproteinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Mucin-1 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,OIP5-AS1 gene|OIP5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hyperlipidemia,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Lipid
AFFECTS,Sexual function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnostic radiologic examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CERNA2 gene|CERNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Viral Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Disease Progression,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CMTM5 gene|CMTM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serum Proteins,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MSH2 gene|MSH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCNAP1 gene|PCNAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00346 gene|LINC00346,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Signaling Protein,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ANGPTL4 gene|ANGPTL4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Negative Regulation of Apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,cyclooxygenase 2|PTGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAD21 gene|RAD21,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,DYRK2 gene|DYRK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Water consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Product containing glucagon-like peptide 1 receptor agonist (product),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR100HG gene|MIR100HG,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Infiltration,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Thyroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Acetylserotonin N-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AFFECTS,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,MicroRNA 205-5p,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Acidosis,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical
AFFECTS,Intercellular adhesion molecule 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KIF15 gene|KIF15,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,K-ras Oncogene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Circulating Tumor DNA,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,NRG1 gene|NRG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PPP2R2B gene|PPP2R2B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FN1 gene|FN1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPM6B gene|GPM6B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,HHEX gene|HHEX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Apoptosis Inducing Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BTF3 gene|BTF3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Metastatic malignant neoplasm to brain,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ST8SIA6-AS1 gene|ST8SIA6-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,A2M-AS1 gene|A2M-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR22HG gene|MIR22HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,27-hydroxycholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Detection,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,DSCAM-AS1 gene|DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PGK1 gene|PGK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Neuropeptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor size,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
DISRUPTS,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"WFDC2 protein, human|WFDC2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Proliferation (morphologic abnormality),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,SMAD2 gene|SMAD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IL6ST gene|IL6ST,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,TRIM6 gene|TRIM6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"UBASH3A protein, human|UBASH3A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PALB2 gene|PALB2,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,YY1 gene|YY1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LAGE3 gene|LAGE3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00885 gene|LINC00885,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF385B gene|ZNF385B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CHFR gene|CHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Trans Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,IL20RA gene|IL20RA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Functional Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,AQP5 gene|AQP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00511 gene|LINC00511,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
CAUSES,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,OLFML2A gene|OLFML2A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gene Mutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Volatile Organic Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,USP6NL gene|USP6NL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Transcription, Genetic",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HOXB5 gene|HOXB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone Therapy,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
DISRUPTS,MTUS1 gene|MTUS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SF3B3 gene|SF3B3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"LCN2 protein, human|LCN2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ATP5F1B gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Cancer Prognostic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estrogen Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoantigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Matrix Metalloproteinases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Autoimmune Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Radiation,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Candidate Disease Gene,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,RAD51 gene|RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"HIF1A protein, human|HIF1A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,high density lipoprotein binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,HOXB7 gene|HOXB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Infiltration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PIR gene|PIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDC25C gene|CDC25C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,CLEC2D gene|CLEC2D,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"MEN1 protein, human|MEN1",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ACSL4 gene|ACSL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IDO1 gene|IDO1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Immune response,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AFFECTS,DPP3 gene|DPP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PQBP1 gene|PQBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antihypertensive Agents,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Responsive Disease,Locally advanced breast cancer,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,CEP295 gene|CEP295,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,tissue polypeptide specific antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,PBXIP1 gene|PBXIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Duration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Axillary node METASTASIS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR655 gene|MIR655,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Pathogenic Variant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AUGMENTS,"E2F1 protein, human|E2F1|UBE2L3",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,IL27 gene|MYDGF|IL27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Gene Mutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MARCHF5 gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,GLI1 gene|GLI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LGALS8-AS1 gene|LGALS8-AS1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Drug resistance,Carcinoma breast stage IV,0.0,Female Breast Cancer,Pharmacologic Substance
CAUSES,HOXD9 gene|HOXD9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,POTEH-AS1 gene|POTEH-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAT3 gene|STAT3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,FAM111B gene|FAM111B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Growth Differentiation Factor 15|PAEP,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TSPAN1 gene|TSPAN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Elevated Expression,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KLF5 gene|KLF5,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,SETDB1 gene|SETDB1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Circular",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"TNFSF10 protein, human|TNFSF10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"WNK1 protein, human|WNK1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ENPP1 gene|ENPP1,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
AFFECTS,METTL14 gene|METTL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NDUFV1 gene|NDUFV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NOLC1 gene|NOLC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ADRB2 gene|ADRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SEP15 protein, human|SELENOF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HOXC-AS3 gene|HOXC-AS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mutant Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Architectural Distortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,EPB41L4A-AS1 gene|EPB41L4A-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Consideration,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Circulating Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Elevated Expression,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,KCNQ1OT1 gene|KCNQ1OT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hormone Receptor,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Hormone
PREDISPOSES,fusion transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Protein Subunits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PPP1R14C gene|PPP1R14C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Ovarian hyperstimulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Cancer Therapeutic Procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NFIB gene|NFIB,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathogenic Variant,"Breast Cancer, Familial",0.0,Female Breast Cancer,Virus
AUGMENTS,RAC2 gene|RAC2,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,GSDMB gene|GSDMB,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hypercholesterolemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,LINC00092 gene|LINC00092,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Agent,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Organic solvent product,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Chemical
AFFECTS,DDX5 gene|DDX5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmacologic Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,secretory protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol consumption,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"IL17A protein, human|IL17A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LINC00472 gene|LINC00472,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Diffusion Kurtosis Imaging,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCNB2 gene|CCNB2,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Adenocarcinoma in Situ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Carcinoma, Lobular","Breast Cancer, Familial",0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"CD69 protein, human|CD69","Breast Cancer, Familial",0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RBMS1 gene|RBMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,genetic risk factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SNHG3 gene|SNHG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HMGB1 gene|HMGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Processes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Phenomenon or Process
AFFECTS,Gene Silencing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MEDAG gene|MEDAG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PIK3CA gene|PIK3CA,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,FBXW7 gene|FBXW7,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Mitochondrial mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GLI4 gene|GLI4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Convenience food intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Cancer Therapeutic Procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PEDS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PAFAH1B1 gene|PAFAH1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proto-Oncogene Protein c-kit,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCDC102B gene|CCDC102B,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,RACK1 gene|RACK1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Imbrication (procedure),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"RNA, Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Responsive Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"IL17A protein, human|IL17A",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ZNF276 gene|ZNF276,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TIMM8A gene|TIMM8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FER1L4 gene|FER1L4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Vitamin D Deficiency,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Food
AUGMENTS,UBE2C gene|UBE2C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FRG1 gene|FRG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NF2 gene|NF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Observation parameter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"PIK3CB protein, human|PIK3CB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,METTL14 gene|METTL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Selective Estrogen Receptor Down Regulator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Diffusion weighted imaging,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ARL11 gene|ARL11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,MIR217 gene|MIR217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERBB2 Overexpression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FOXN3 gene|FOXN3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ellagic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,"Retinol-Binding Proteins, Cellular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cancer-Related Death,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cell-Free DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Duration,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Matrix Metalloproteinase 9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,HDAC7 gene|HDAC7,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IGF2BP2 gene|IGF2BP2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,BCL2A1 gene|BCL2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GNAS gene|GNAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,hexanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,RMI2 gene|RMI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SCAMP3 gene|SCAMP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPC25 gene|SPC25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,KDM4A gene|KDM4A,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmaceutical Preparations,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,CBX7 gene|CBX7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PRAF2 gene|PRAF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Malignant neoplasm of breast,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Genetic Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,FKBP12-rapamycin associated protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"FABP1 protein, human|FABP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,gamma-aminobutyric acid,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Chemical
CAUSES,Mouse mammary tumor virus infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estrogen receptor positive,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,KAT7 gene|KAT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNF43 gene|RNF43,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CPVL gene|CPVL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TMEM105 gene|TMEM105,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SIRT7 gene|SIRT7,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,RHD gene|RHD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,STAT1 gene|STAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Axillary node METASTASIS,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,HHEX gene|HHEX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Kanglaite Injection,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SIRT7 gene|SIRT7,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,SDC1 gene|SDC1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Long Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Agent,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,human papillomavirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,"Ribonucleoprotein, U1 Small Nuclear",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,USP29 gene|USP29,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Galanin peptides, human (123 aa, ~13 kDa)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NDC80 gene|NDC80,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLF2 gene|KLF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"PDCD1 protein, human|PDCD1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,VEGFA gene|VEGFA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NUCB2 gene|NUCB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Mouse mammary tumor virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Oligonucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Betaretrovirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,epithelial to mesenchymal transition,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDH12 gene|CDH12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Invasive Ductal Breast Carcinoma,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,RNA-Binding Protein Musashi Homolog 2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ectonucleotide pyrophosphatase phosphodiesterase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,NR2F1-AS1 gene|NR2F1-AS1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,MCM6 gene|MCM6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAP7D3 gene|MAP7D3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SPDEF gene|SPDEF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FAM171A1 gene|FAM171A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HNRNPA2B1 gene|HNRNPA2B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EYA4 gene|EYA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RHOV gene|RHOV,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,LINC01140 gene|LINC01140,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Progression,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,"TNFSF10 protein, human|TNFSF10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TYMSOS gene|TYMSOS,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Decreased Expression,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,medroxyprogesterone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,SEMA3B-AS1 gene|SEMA3B-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Anti-HER2 Monoclonal Antibody|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,C-reactive protein,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR122 gene|MIR122,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAF1 gene|MAF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,perfluorooctanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Oncogenes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,CD82 gene|CD82,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Matrix Metalloproteinases,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,MicroRNA Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PSMD14 gene|PSMD14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00702 gene|LINC00702,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Phytochemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,DNPH1 gene|DNPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IMPA2 gene|IMPA2,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXO3 gene|FBXO3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Neuroleptic Malignant Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Crohn Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,HMGB3 gene|HMGB3,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Markers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"COPEB protein, human|KLF6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"PIK3CB protein, human|PIK3CB",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Radiation-Sensitizing Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PALMD gene|PALMD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NOTCH3 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WASF3 gene|WASF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR203A gene|MIR203A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Secondary malignant neoplasm of liver,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Macrophage Activation Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,post surgery radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Pathogenic Variant,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Virus
CAUSES,Plasma Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ARHGAP6 gene|ARHGAP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ELAVL1 gene|ELAVL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FRY gene|FRY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IDO1 gene|IDO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CLEC11A protein, human|CLEC11A",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Polynucleotide Adenylyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Breast Fibrocystic Disease,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,OGG1 gene|OGG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PDZK1 gene|PDZK1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,MTCH2 gene|MTCH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Infiltration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KLRK1 gene|KLRK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01572 gene|LINC01572,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Dickkopf-Related Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,RAMP2-AS1 gene|RAMP2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA1 gene|BRCA1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLCO1B1 gene|SLCO1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NR2F2 gene|NR2F2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Nanotubes, Carbon",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,AGRN gene|AGRN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NKAIN1 gene|NKAIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,S14 gene|PSMD8|RPS14|THRSP|LOC107228383,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TCF7L2 gene|TCF7L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Prostaglandins,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Eicosanoid
DISRUPTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TAL1 gene|TAL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Tumor Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DNMT3B gene|DNMT3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RHOC gene|RHOC,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Human plasma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
AFFECTS,glycosylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogen Antagonists,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Steroid 17-alpha-monooxygenase|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Necrosis Factor Ligand Superfamily Member 6|FASLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Benzoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Estrogen Receptor alpha,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,SMARCA4 gene|SMARCA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radioisotope scan of lymphatic system,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RHOA gene|RHOA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Folic acid supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ESTROGEN USE,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AFFECTS,recombinational repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,APC2 gene|APC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Metaplastic carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Suicide Gene Therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDX2 gene|CDX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DUSP4 gene|DUSP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FLT1 gene|FLT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nucleic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cancer Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,High fiber food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Malignant neoplasm of breast,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CADMIUM EXPOSURE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AFFECTS,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,VEGF gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"Fatty Acids, Saturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,transcription factor PEA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TLR4 gene|TLR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Genes, Homeobox",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
PREDISPOSES,PCAF gene|KAT2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BIRC5 gene|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNASE3L gene|DROSHA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen excess,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AUGMENTS,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MULTISECTION:FINDING:POINT IN TIME:BREAST:NARRATIVE:MRI,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Genes, Homeobox",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,BIRC7 gene|BIRC7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATR gene|ATR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,TSLP gene|TSLP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,S100A9 gene|S100A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast Cancer Treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CTNNB1 gene|CTNNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Soy Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCR3 gene|CXCR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PTPN11 gene|PTPN11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of endometrium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Disease Outcome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Sulfuric Acid Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,BMPR2 gene|BMPR2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Protein-Serine-Threonine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Environmental Effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Environmental Effect of Humans
AFFECTS,Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Insulin-Like Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,cDNA Library,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
COMPLICATES,Toxic effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,TACSTD2 gene|TACSTD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cystic Breast Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,BRCA1 gene|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,LAMR1 gene|RPSA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BCAS1 gene|BCAS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cysteine Proteinase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,mutant gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Prostaglandin-Endoperoxide Synthase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Eicosanoid
CAUSES,mammary tumor virus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Medroxyprogesterone,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Hormone
PREDISPOSES,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,hybrid gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCND1 gene|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SHBG gene|SHBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Anovulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,FGF3 gene|FGF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serum Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
CAUSES,Female Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DNA biosynthesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"TFF1 protein, human|TFF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"serine repeat antigen, Plasmodium",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AUGMENTS,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Pharmaceutical Preparations,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Pharmacologic Substance
PREDISPOSES,Animal protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Proto-Oncogene Proteins p21(ras)|HRAS,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Antagonists,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,FGF3 gene|FGF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,international differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Genes, Suppressor",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Burden,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BCL-2 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,IGF2 gene|IGF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Secondary malignant neoplasm of bone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pathogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Advanced cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ascorbic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,"Antigens, Viral",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
DISRUPTS,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
DISRUPTS,AFP gene|AFP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,HRAS gene|HRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Breast cancer invasive NOS,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lymph node excision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Genes, Regulator",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radionuclide Imaging,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AFFECTS,alpha-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,MLH1 gene|MLH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transfection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Linoleic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Carcinoma in Situ,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,"Fatty Acids, Unsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,ETS Variant Gene 6 Protein|ETV6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,"Genes, Regulator",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HIV Infections,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,response to hormone stimulus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,glycosylation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cell Communication,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chronic Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Protein Overexpression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CDC25A gene|CDC25A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Isotopes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Sterol Regulatory Element Binding Protein 1c,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,fluorodeoxyglucose positron emission tomography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NFKBIA gene|NFKBIA,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fibroblast Growth Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,ral Guanine Nucleotide Exchange Factor|RALGDS,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Transcription Coactivator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Serine Protease,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Enzyme
AFFECTS,BRCA1 gene|BRCA1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,Family history of breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Amino Acid Substitution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ERCC4 gene|ERCC4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,VEGF gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Micronutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,Polypeptides,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Cancer-Predisposing Gene,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,CD82 gene|CD82,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Kinase C Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NQO1 gene|NQO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm Metastasis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,repair enzyme,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Enzyme
AFFECTS,Orthologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CASP1 gene|CASP1,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,TNFRSF1B gene|TNFRSF1B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tamoxifen,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,cyclooxygenase 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL8 gene|CXCL8,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Steroidal Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Fibroblast Growth Factor 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Aromatase Inhibitors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
CAUSES,CAV1 gene|CAV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Tamoxifen,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
CAUSES,Single Nucleotide Polymorphism,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,CLCA2 gene|CLCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Xanthine Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Glutathione S-Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,HPSE gene|HPSE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Retinoblastoma Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Adaptor Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen Receptor alpha|EREG|ESR1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fertility Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Apolipoprotein E|APOE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CXCL12 gene|CXCL12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PLAT gene|PLAT,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Vitamin E,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,CXCL12 gene|CXCL12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Primary Prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SHFM1 gene|SEM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"PSMD10 protein, human|PSMD10",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Receptors, Progesterone|PGR",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Gastric Adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clonal Expansion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADH1B gene|ADH1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TNFSF11 gene|TNFSF11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Transfection,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,K-ras Oncogene|KRAS,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Carcinogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,gene polymorphism,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,estrogen receptor gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Single Nucleotide Polymorphism,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,TRANCE protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,KL gene|KL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Receptors|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Agent,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,"Fatty Acids, Omega-6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,SP1 gene|SP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,G-Protein-Coupled Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hypermethylation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,IL8 gene|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ANP32B gene|ANP32B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERR1 protein|ESRRA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Bone Morphogenetic Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PTH protein, human|PTH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Anabolic steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
CAUSES,NOTCH4 gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Growth retardation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,chromosome decondensation factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MAPK14 gene|MAPK14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Protein Isoforms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,amsonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Alcoholic Liver Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,AKT1 gene|AKT1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,protein-tyrosine kinase c-src|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,vasodilator-stimulated phosphoprotein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Phosphatidylethanolamine Binding Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Aromatase Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
PREDISPOSES,Pharmaceutical Preparations,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AUGMENTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BCL6 gene|BCL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,KLF9 gene|KLF9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Hyperbaric Oxygenation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,USP21 gene|USP21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hexachlorobenzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,CRHBP gene|CRHBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Myeloid Leukemia, Chronic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SMAD3 gene|SMAD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"20-hydroxy-5,8,11,14-eicosatetraenoic acid",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,PROTEIN KINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,letrozole,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,BRCA1 gene|BRCA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Lipogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant meningitis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Promoter Regions (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,iron ion homeostasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oxygen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LRRC3B gene|LRRC3B,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,MET gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,protein tyrosine phosphatase 1B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Heat Shock Protein 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cell invasion,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Heightened perception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Functional RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Malignant tumor of colon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PGR gene|PGR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serotonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,ANG gene|ANG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CALCA gene|CALCA,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Agent,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Dyslipidemias,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Neoplasm Metastasis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,OGG1 gene|OGG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Endocrine therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Epithelial antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AUGMENTS,"BCAR1 protein, human|BCAR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin B6 intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,Fibroblast Growth Factor Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Adenocarcinoma of esophagus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Homologous Recombination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,RNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,hepatocellular carcinoma protein 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RELN gene|RELN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Urine protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,intervention program,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Total estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,PGR gene|PGR,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,CCL20 gene|CCL20,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ITK gene|ITK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CD29 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Forkhead Transcription Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogen Receptors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Orthologous Gene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,NBS1 gene|NBN|NLRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Apoptosis Inhibiting Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Cervix carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,progesterone receptor negative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Soybean preparation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CDC42 gene|CDC42,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SENP2 gene|SENP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,H2AFX gene|H2AFX,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,CDH1 gene|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CXCR4 gene|CXCR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MSH6 gene|MSH6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCND2 gene|CCND2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GLS gene|GLS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TXNIP gene|TXNIP,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
DISRUPTS,MAPK8 gene|MAPK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"PER2 protein, mammalian",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"RNA, Satellite",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,CD80 gene|CD80,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Precursors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cancer cachexia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,disease stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,BCAR3 gene|BCAR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,genetic locus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,AR gene|AR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,FGFR2 gene|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLK10 gene|KLK10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Oncogene Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MLL gene|KMT2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDH1 gene|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Antineoplastic Agents,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TNF protein, human|TNF",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Mutation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,Epidermal Growth Factor Receptor|EGFR,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biologically Active Substance
AFFECTS,Dissection,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hexachlorobenzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,receptor expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Generalized obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Malignant disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,Tamoxifen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,DDT (Insecticide),Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Invertebrate
PREDISPOSES,Medication use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Composition,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Depressive disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,SYK gene|SYK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,DHFR gene|DHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,IGF1 gene|IGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Maternal status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Vascular Endothelial Growth Factor Receptor-1|FLT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,IRS2 gene|IRS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fine needle aspiration biopsy,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ERBB2 gene|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Soy Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD40 gene|CD40,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Acquired Immunodeficiency Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,KISS1 gene|KISS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCNE1 gene|CCNE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,Progesterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,MIRN27A gene|MIR27A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Aberrant DNA Methylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,aldehyde dehydrogenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"ribosomal protein S6 kinase, 70kD, polypeptide 2|RPS6KB2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,S100A9 gene|S100A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Speech reception threshold,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOD2 gene|SOD2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,Metaplastic Breast Carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Testosterone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Squamous cell carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Functional disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Biological function, NOS",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,SMARCE1 gene|SMARCE1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PTEN gene|PTEN,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTT1 protein|SLC25A4|CD5|IL1RL1|TRAPPC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GSTT1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Microinvasive carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Pharmaceutical Preparations,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AFFECTS,Cell fusion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Invasive Malignant Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MMP9 gene|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,trastuzumab,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,PGR gene|PGR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Rare Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,PGRMC1 gene|PGRMC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alcohol consumption,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RNASEL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carcinogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,MIRN223 gene|MIR223,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TERT gene|TERT,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prophylactic immunotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,TP53 gene|TP53,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,RNA I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,HTATIP2 gene|HTATIP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL10 gene|IL10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cyclooxygenase 2|XK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,S-Adenosylmethionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LUM gene|LUM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Extravasation of lymph,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CAV1 gene|CAV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PRKDC gene|PRKDC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCB1 gene|ABCB1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,BAX gene|BAX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIRN21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclooxygenase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alcohol interaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Angiography, Digital Subtraction",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CDK2AP1 gene|CDK2AP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD28 gene|CD28,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease Outcome,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Primary tumor size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Genes,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,S100A9 gene|S100A9,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,breast cancer prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TNFRSF1B gene|TNFRSF1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammatory Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fertilization in Vitro,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"TERT protein, human|TERT",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Conjugated Equine Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,steroid sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,RNA Interference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,glutathione S-transferase M1|CHRM1|MRLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Regional Disease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Total cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,Chlorogenic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,AANAT gene|AANAT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD2 gene|CD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TIAM1 gene|TIAM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Examination of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Detection,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDKN1C gene|CDKN1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chemoprevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cosmic Radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Peptide Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,zoledronic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
DISRUPTS,DMBT1 gene|DMBT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Female Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ABCG2 gene|ABCG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adaptation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Paget's Disease,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Disease or Syndrome
AFFECTS,MIRN107 gene|MIR107,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
AFFECTS,Thioctic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Regulatory Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"ESR1 protein, human|ESR1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,tumor growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,autoimmune thyroid disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Proto-Oncogenes|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thymine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Tumor Markers,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KRT19 gene|KRT19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Latent Virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Malignant neoplasm of breast,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,EVI1 gene|RUNX1|MECOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Periodontal Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,K-ras Oncogene|KRAS,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Induction,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Little's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Estrogen receptor negative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fatty acid glycerol esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Infiltration,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Small Inducible Cytokine A18|CCL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Antisense RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,"Antigens, Fos-Related|FOS",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,RFP2 gene|TRIM13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Green Fluorescent Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FSIP1 gene|FSIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Steroid 17-alpha-monooxygenase|CYP17A1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estrogen receptor positive,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Chronic inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,UBE2D2 gene|UBE2D2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TGFB1 gene|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CYP24A1 gene|CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Red Meat Consumption,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,E2F1 gene|E2F1|UBE2L3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Estrogens, Conjugated (USP)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CUL5 gene|CUL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Apocrine adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOSL1 gene|FOSL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ribosomal RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,betulinic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
DISRUPTS,11-beta-Hydroxysteroid Dehydrogenase Type 2|HSD11B2|RNU1-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Implantation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Polycystic Ovary Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,GTPase-Activating Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ATP8A2 gene|ATP8A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AUGMENTS,estrogens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,GTPase-Activating Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Tumor-Associated Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Hepatolenticular Degeneration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LHX1 gene|LHX1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,MIR195 gene|MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,UGT2B7 gene|UGT2B7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC02657 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ZEB1-AS1 gene|ZEB1-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Substance with phenol structure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,"TFF1 protein, human|TFF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SETD3 gene|SETD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GADD45A gene|GADD45A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LSR gene|LSR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,27-hydroxycholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Accumulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Radiopharmaceuticals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
CAUSES,DNA Minor Groove Binding Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Sex Hormone-Binding Globulin,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,GSTT1 gene|GSTT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,NOP2 gene|NOP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,E2F3 gene|E2F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gamma-linolenic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,PLSCR1 gene|PLSCR1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,glutathione S-transferase pi|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR454 gene|MIR454,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Basaloid squamous cell carcinoma,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,apolipoprotein D|APOD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TXNIP gene|TXNIP,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"EIF2C2 protein, human|AGO2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,S100A14 gene|S100A14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,LINC00261 gene|LINC00261,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Methyl-CpG-Binding Protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CTHRC1 gene|CTHRC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"POU5F1 protein, human|POU5F1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR622 gene|MIR622,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TFEB gene|TFEB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aromatase,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Enzyme
AFFECTS,RB1CC1 gene|RB1CC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,aggressive cancer,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LOXL4 gene|LOXL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"RNA, Messenger",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,MIR145 gene|MIR145,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HOPX gene|HOPX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TMED3 gene|TMED3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPC1 gene|GPC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Malignant neoplasm of breast,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Negative Regulation of S Phase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SALL4 gene|SALL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Immunoregulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,IL31 gene|IL31,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,fos-related antigen 1|FOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,SAMD4A gene|SAMD4A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Treatment modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SMAD7 gene|SMAD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Residual Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Low Density Lipoprotein Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,UGT1A1 gene|UGT1A1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SKA3 gene|SKA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Nucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,HOMER1 gene|HOMER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Blood Proteins,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hypomethylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cytokine,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,fructose,Carcinoma breast stage IV,0.0,Female Breast Cancer,Carbohydrate
PREDISPOSES,CYFIP1 gene|CYFIP1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,HER2-negative breast cancer,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"GPER protein, human|GPER1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Deubiquitinating Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,"CRYAB protein, human|CRYAB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"YAP1 protein, human|YAP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,DSCC1 gene|DSCC1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclin-Dependent Kinase Inhibitor Proteins,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ATXN8OS gene|ATXN8OS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHPF gene|CHPF,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,palbociclib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AFFECTS,epithelial to mesenchymal transition,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SLC12A8 gene|SLC12A8,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,thioguanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"Receptor, Transforming Growth Factor-beta Type I|TGFBR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GOLPH3L gene|GOLPH3L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cystathionine beta-Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,KIF15 gene|KIF15,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,KIF3B gene|KIF3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,DNA Methyltransferase Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Agent,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,mitogen-activated protein kinase kinase kinase 11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KIF3B gene|KIF3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Squalene monooxygenase,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AFFECTS,Hormone Receptor Positive Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,"ABCG2 protein, human|ABCG2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Genes,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,ITM2A gene|ITM2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TOX3 gene|TOX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR22 gene|MIR22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol consumption,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SHISA3 gene|SHISA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSEC gene|GSEC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,ST7-AS1 gene|ST7-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KIAA1109 gene|KIAA1109,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACTL8 gene|ACTL8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Stimulation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AUGMENTS,"RNA, Small Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,LGMN gene|LGMN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SLAMF7 gene|SLAMF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,calcium ion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fatty-acid synthase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
AUGMENTS,SRSF1 gene|SRSF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PVR gene|PVR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,E-Box Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FBXO5 gene|FBXO5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SRSF1 gene|SRSF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,CEP55 gene|CEP55,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Crotoxin,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Chemical
AFFECTS,Antigen Processing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,DPP4 gene|DPP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Portal Hypertension,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIR526B gene|MIR526B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,Heparin Binding Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,EN1 gene|EN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IFI30 gene|IFI30,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EGR1 gene|EGR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DPP10 gene|DPP10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Glycosphingolipids,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Lipid
AUGMENTS,ANLN gene|ANLN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC01089 gene|LINC01089,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SMUG1 gene|SMUG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNA modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ataxia telangiectasia mutated protein|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,NOL10 gene|NOL10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,TMEM238L gene|TMEM238L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Drug Combinations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR155 gene|MIR155,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Monocyte Chemoattractant Protein-1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TCOF1 gene|TCOF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,TBX15 gene|TBX15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNAs,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,disorder control (procedure),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,H1-5 gene|HIST1H1B,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,tRNA modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRCA1 Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR4521 gene|MIR4521,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,lead,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,Polyunsaturated fatty acid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,hyaluronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,LIG1 gene|LIG1|LRIG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ARHGAP9 gene|ARHGAP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RPS6KA3 gene|RPS6KA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Matrix Metalloproteinase 11,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,RTL8C gene|RTL8C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,JAM2 gene|JAM2|JAM3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,progesterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,SYVN1 gene|SYVN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Constitutive skin pigmentation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Genetic Profile,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,MALAT1 gene|MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FAM189A2 gene|FAM189A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Lipoxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VIRMA gene|VIRMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MRPS30-DT gene|MRPS30-DT,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HOXC-AS3 gene|HOXC-AS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LPAR6 gene|LPAR6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Anti-Bacterial Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Injections, Intraperitoneal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,EIF6 gene|EIF6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,ANKDD1A gene|ANKDD1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MEOX2 gene|MEOX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR660 gene|MIR660,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,UHRF1 gene|UHRF1,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,mRNA Precursor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,"IL22 protein, human|IL22",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Homologous Recombination Deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,STAMBPL1 gene|STAMBPL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC00472 gene|LINC00472,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GZMK gene|GZMK,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,CDK16 gene|CDK16,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Indicators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,Protein p53|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AUGMENTS,ATP6AP2 gene|ATP6AP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LMNB1 gene|LMNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Secondary malignant neoplasm of bone,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Neoplastic Process
AUGMENTS,MARK2 gene|MARK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RBIS gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ovarian Stimulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Mouse mammary tumor virus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,History of previous events,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,C17orf49 gene|C17orf49,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,MYC gene|MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,RUNX2 gene|RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNHG14 gene|SNHG14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,intracellular protein transport,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,WNT2 gene|WNT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Food, Preserved",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Malignant Neoplasms,"Breast Cancer, Familial",0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Elevated Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KIF11 gene|KIF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Lactic acid dehydrogenase isoenzyme 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,ANLN gene|ANLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,COL11A1 gene|COL11A1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Melanocyte stimulating hormone,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Hormone
PREDISPOSES,ACTA2-AS1 gene|ACTA2-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"IRS1 protein, human|IRS1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Tumor Necrosis Factor Signaling Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IMPA1 gene|IMPA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC01194 gene|LINC01194,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,perfluorooctane sulfonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Sulfonic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Disease,Refractory Breast Carcinoma,0.0,Other,Disease or Syndrome
AFFECTS,New medications,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,ascorbic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Matrix Metalloproteinase 9|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Generalized obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IMPA1 gene|IMPA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider},Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Membrane Transport Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,E2F6 gene|E2F6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,TP53 gene|TP53,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACBD3 gene|ACBD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GAS6-AS1 gene|GAS6-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SERPINA12 gene|SERPINA12,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,SEMA3B-AS1 gene|SEMA3B-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLC3A2 gene|SLC3A2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RYK gene|RYK,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Matrix Metalloproteinase 2|MMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,FRY gene|FRY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"ERCC5 protein, human|ERCC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MYCL gene|MYCL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL14 gene|CXCL14,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,AURKB gene|AURKB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSPB2 gene|HSPB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RECQL4 gene|RECQL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EXO1 gene|EXO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Pathogenic Variant,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Virus
PREDISPOSES,glutathione S-transferase pi|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LINC00473 gene|LINC00473,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXA1 gene|FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,glutathione,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antiplatelet Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,USP37 gene|USP37,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,PPARA gene|PPARA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,boswellic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,SOX8 gene|SOX8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00536 gene|LINC00536,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CBX3 gene|CBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Anti-Inflammatory Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Interventional procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SOAT2 gene|SOAT2,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,FRMD3 gene|FRMD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IMPACT gene,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,SDC1 gene|SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Circulating MicroRNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,TINCR gene|TINCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIR497HG gene|MIR497HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Responsive Disease,Carcinoma breast stage IV,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,LAPTM5 gene|LAPTM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CLDN6 gene|CLDN6,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,TAF15 gene|TAF15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RHOV gene|RHOV,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,GABRD gene|GABRD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SIRT7 gene|SIRT7,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Disease/diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,MYBL2 gene|MYBL2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,NOTCH1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,COMMD3 gene|COMMD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NPY1R gene|NPY1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sugar-Sweetened Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
CAUSES,"herstatin protein, human",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Adaptor Proteins, Signal Transducing",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,PLPP4 gene|PLPP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TIPARP gene|TIPARP,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,GJA1 gene|GJA1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathogenic Variant,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Virus
CAUSES,Phytochemicals,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
AFFECTS,C1QL4 gene|C1QL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Food Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Noninfiltrating Intraductal Carcinoma,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
CAUSES,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Heat Shock Protein 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Sulfhydryl Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,IDO2 gene|IDO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NDC80 gene|NDC80,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,reproductive hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,ADAR gene|ADAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GPT2 gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Long Interspersed Nucleotide Element-1,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PTCSC3 gene|PTCSC3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SCRIB gene|SCRIB,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Infiltration,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Tumor Microenvironment of Metastasis Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IRF7 gene|IRF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HDAC1 gene|HDAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,MED1 gene|MED1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MAPK1 gene|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinogenesis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Multiple tumors,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
DISRUPTS,ZNF831 gene|ZNF831,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MC1R gene|MC1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,estrogens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,Non-alcoholic Fatty Liver Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"estrogens, conjugated (USP)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MIR429 gene|MIR429,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"ATF2 protein, human|ATF2",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,FTO gene|FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,trastuzumab deruxtecan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,KLF5 gene|KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Screening for malignant neoplasm of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FAM83D gene|FAM83D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RACK1 gene|RACK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,A1BG-AS1 gene|A1BG-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ANO6 gene|ANO6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AFF4 gene|AFF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PROS1 gene|PROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,testosterone,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,Lesch-Nyhan Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,CAVIN1 gene|CAVIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TDRKH-AS1 gene|TDRKH-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"IMP3 protein, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"MFGE8 protein, human|MFGE8",Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Organic solvent product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,TTPAL gene|TTPAL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FOXK1 gene|FOXK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR205 gene|MIR205,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Non-alcoholic Fatty Liver Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Implants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biomedical or Dental Material
AFFECTS,FTO gene|FTO,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,GNAO1 gene|GNAO1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXQ1 gene|FOXQ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PARK7 gene|PARK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PPARGC1B gene|PPARGC1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TPM2 gene|TPM2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RSRC2 gene|RSRC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
COMPLICATES,Sarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"CD69 protein, human|CD69",Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Estrogen Receptor alpha,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SIK2 gene|SIK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,magnesium cation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplastic Cell Transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MIR205 gene|MIR205,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLC7A11 gene|SLC7A11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Expression,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,MT-RNR1 gene|RNR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RAB5A gene|RAB5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CAT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCDC150 gene|CCDC150,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MXRA5 gene|MXRA5,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,NF2 gene|NF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,translation factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,WWOX gene|WWOX,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,EP300 gene|EP300,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leucine-Rich Repeat Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,EYA2 gene|EYA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PKMYT1 gene|PKMYT1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,ME1 gene|ME1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CACNG4 gene|CACNG4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,obeticholic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,CCL20 gene|CCL20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MBD2 gene|MBD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"IL1A protein, human|IL1A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,IL22 gene|IL22,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Human Class I Antigens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AFFECTS,DNA Replication,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CCNB1 gene|CCNB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,pyruvate dehydrogenase kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SLC38A5 gene|SLC38A5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FGF11 gene|FGF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,4-aminohippuric acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ZBTB10 gene|ZBTB10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Combination Chemotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,GRB7 gene|GRB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CCL18 gene|CCL18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,EPHA10 gene|EPHA10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cancer-Predisposing Gene,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,MAP3K1 gene|MAP3K1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,CYP1A1 gene|CYP1A1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,"WBSCR22 protein, human|BUD23",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Renal Cell Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Oxygen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Enhancer Elements (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIRN143 gene|MIR143,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RAD51C gene|RAD51C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,AATF gene|AATF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Selective serotonin re-uptake inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AFFECTS,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,8-Oxoguanine DNA Glycosylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Tumor Suppressor Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,IL18 gene|IL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Carcinoma, Ductal, Breast",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cytotoxicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,NRIP1 gene|NRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Microtubule-Associated Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Phosphoglycerate dehydrogenase|PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Epidermal Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,STC1 gene|STC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ir Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin-Like Growth Factor Receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,ADRA2A gene|ADRA2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Expression Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"ST13 protein, human|ST13",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,FABP5 gene|FABP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Follicle Stimulating Hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,PRLR gene|PRLR|PTP4A3,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTA1 gene|GSTA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth Factor I,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
CAUSES,Viral Tumor Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,cytokine,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Central Nervous System Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Human papillomavirus 16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Malignant mixed salivary gland tumor,Cancer en cuirasse,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Human Platelet Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,reproductive hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Alcohol consumption,bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Agent,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,CTTN gene|CTTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Atypical proliferation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Polyunsaturated Fatty Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,CD44 gene|CD44,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,PRLR gene|PRLR|PTP4A3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LALBA gene|LALBA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,"TFF1 protein, human|TFF1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Epidermal Growth Factor Receptor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Caloric Restriction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hodgkin Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,cDNA Library,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,RBBP1L1 Protein|ARID4B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FGF4 gene|FGF4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Malignant Carcinoid Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypolipidemia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Lipid
CAUSES,Tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Hormone manipulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Transgenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Replacements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,ATM gene|ATM,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Noninfiltrating Intraductal Carcinoma,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,PPARBP gene|MED1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin-Like Growth Factor I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,whey protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TP53 gene|TP53,bilateral breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Osteoclastic resorption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SYK gene|SYK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TFF1 gene|TFF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Postmenopausal Hormone Replacement Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Tumor Angiogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,matrix metalloproteinase 26,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,glutathione S-transferase pi|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Germ-Line Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,alpha-Fetoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BIN1 gene|BIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BIRC5 gene|BIRC5,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Encounter due to Unspecified general medical examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Parkinson Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,CD82 gene|CD82,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Tumor Suppressor Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TNFSF10 gene|TNFSF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Transforming Growth Factor alpha|TGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Tumor Suppressor Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Bone Resorption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phytoestrogens,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AUGMENTS,SNCG gene|SNCG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Fatty Acids, Monounsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,H-ras Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Carcinoembryonic Antigen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AUGMENTS,REL gene|REL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tamoxifen,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
CAUSES,"BCAR1 protein, human|BCAR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,AKT3 gene|AKT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Opioid Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,8-hydroxyguanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Fatty Acids, Omega-6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Antidepressive Agents, Tricyclic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,LIG4 gene|LIG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNCG gene|SNCG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tamoxifen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,BRCA1 Protein|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"NOS2A protein, human|NOS2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carcinoma in Situ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PTEN gene|PTEN,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Glutathione S-Transferase|SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Embolism, Tumor",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Myocardial Infarction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmaceutical Preparations,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Estrogenic effect,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AUGMENTS,FGF3 gene|FGF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Eicosapentaenoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Cytokinesis of the fertilized ovum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Obstruction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Genes,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,Epithelial Cell Proliferation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Monocyte Chemoattractant Protein-1|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Palmitic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"STK6 protein, human|AURKA",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,N-6 fatty acid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Malignant neoplasm of prostate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Chronic Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TNFSF6 gene|FASLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ERBB3 gene|ERBB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Testosterone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AUGMENTS,Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MERTK gene|MERTK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Oncogenes,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"RNA, Small Interfering",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Conjugated Equine Estrogens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AUGMENTS,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Antihormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,HIVEP2 gene|HIVEP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Platelet-Derived Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Non-esterified cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,reproductive hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,IFNG gene|IFNG,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,bone morphogenetic protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epidermal Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Specific antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AUGMENTS,CHEK2 gene|CHEK2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,CA-125 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Gene Expression,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Glutathione S-Transferase|SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,STK11 gene|STK11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptors,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Communication,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ERBB2 gene|ERBB2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,Compound Q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Human Chorionic Gonadotropin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HMMR gene|HMMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,OTP gene|OTP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Expression,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CYP1B1 gene|CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Convenience food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,"Cations, Divalent",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HMMR gene|HMMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Molecular Fingerprint of Tumor,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
AUGMENTS,Cullin Proteins,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRMS1 gene|BRMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PLXNB1 gene|PLXNB1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,"SMO protein, human|SMO",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell-cell adhesion molecule,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Apocrine adenocarcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,MYB gene|MYB,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Germ-Line Mutation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Spontaneous abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PLG gene|PLG,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,FASTK Gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,S100A11 gene|S100A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CDC25A gene|CDC25A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chemoprevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TP53BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,ATM gene|ATM,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacologic Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,ALCAM gene|ALCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SPDEF gene|SPDEF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptors, Steroid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
CAUSES,SERPINE1 gene|SERPINE1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Cancer Promoting Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,CXCL10 gene|CXCL10,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MMP9 gene|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"TIMP2 protein, human|TIMP2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MAP Kinase Gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CD44 gene|CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Gallic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Lipids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Lipid
DISRUPTS,FBXW7 gene|FBXW7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,hypercholesterolemia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Lipid
AUGMENTS,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,COX7A2L gene|COX7A2L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,F3 gene|F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCL22 gene|CCL22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vascular Endothelial Growth Factor C|VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Primary carcinoma of the liver cells,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Tumor Suppressor Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,Proto-Oncogene Proteins c-myc|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FGF1 gene|FGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Alport's syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,ERCC1 gene|ERCC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Malignant neoplasm of prostate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CASP9 gene|CASP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCL13 gene|CCL13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,C-terminal binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Immune response,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,Malignant neoplasm of urinary bladder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Polyaromatic hydrocarbon,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Protein phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Proto-Oncogene Proteins c-akt|AKT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, Regulator",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Inactivation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Docosahexaenoic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,CDX2 gene|CDX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,MIRN34A gene|MIR34A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammation,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast cancer invasive NOS,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Fatty Acids, Omega-3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Primary carcinoma of the liver cells,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Membrane Transport Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,topical application,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"KLK5 protein, human|KLK5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ESR2 gene|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCL4 gene|CCL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Oligonucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Antiepileptic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Progesterone level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,zinc-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Proliferation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transcriptional Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Epidermal Growth Factor Receptor|EGFR,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
AFFECTS,Thyroid Hormone Receptor Alpha-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,FOXC1 gene|FOXC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,polycylic aromatic hydrocarbons-DNA adduct,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Neoplastic Syndromes, Hereditary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,APOE gene|APOE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ATP phosphohydrolase|DNAH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Metabolic syndrome,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
AFFECTS,Angiogenesis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiofrequency ablation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDC2 gene|CDK1|POLD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Apolipoprotein A-I|APOA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CHES1 gene|FOXN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,S100A8 gene|S100A8,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAD51C gene|RAD51C,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Anti-Anxiety Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Polyunsaturated Fatty Acids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,P-Glycoprotein,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hormone replacement therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
PREDISPOSES,Recreation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA1 gene|BRCA1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Replacement Therapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,LACRT gene|LACRT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Health promotion behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"IGFBP2 protein, human|IGFBP2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Excision,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,somatotropin-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Aromatase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,Mutation,bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCND1 gene|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serum Albumin,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Body Substance
PREDISPOSES,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MMP14 gene|MMP14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Air Pollution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Carcinoma, Ductal, Breast",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Primary Lesion,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Punctate calcium deposition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hodgkin Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Endotoxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,IRS1 gene|IRS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,STN gene|EEF1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Thyroid Hormones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Drug Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,CCL5 gene|CCL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Nuclear Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Personal Satisfaction,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Steroidal Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Family history of breast cancer,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rare Diseases,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Telomere Maintenance Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,conjugation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Sirolimus (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,NR3C1 gene|NR3C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,BRCA3 gene|BRCA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Red Meat Consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CSH2 gene|CSH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Actin bundling protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IL8 gene|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ribonucleotide reductase M2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Cadmium Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Mutation,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmaceutical Preparations,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,Disorder of pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,RRM2 gene|RRM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Sirolimus (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,Gene Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MMP11 gene|MMP11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mammographic microcalcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MIRN93 gene|MIR93|MIR9-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Protein p53|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Tumor Suppressor Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gonadal Steroid Hormones,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,Diffusion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Co-morbid conditions,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,C-KIT Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MICE gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol consumption,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CHD5 gene|CHD5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,EGF gene|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoma in situ of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,"CHEK1 protein, human|CHEK1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,ERCC2 gene|ERCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
AFFECTS,Radiation,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fluorodeoxyglucose F18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,CCND1 Gene Amplification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,aldehyde dehydrogenase 1|ALDH1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Membrane Transport Proteins,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Breast arterial calcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FBXW7 gene|FBXW7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,palmitoleic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,PROTEIN KINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,C14orf166 gene|RTRAF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EGFR Protein Overexpression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FBXO31 gene|FBXO31,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FABP4 gene|FABP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GATA3 gene|GATA3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Reexcision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Encounter due to breast augmentation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MAPK12 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,tacrolimus binding protein 4|FKBP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Signal Transduction Pathways,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Cancer Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ellagic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,FGFR1 gene|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,BRCA2 gene|BRCA2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Cancer Promoting Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"MAPK14 protein, human|MAPK14",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen Receptor Status,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,"Fatty Acids, Saturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Onions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Androstenedione,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ID2 gene|ID2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,mannuronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,KRT19 gene|KRT19,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Ectopic Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MFAP5 gene|MFAP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CCL20 gene|CCL20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,SDC1 gene|SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gamma-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,CD44 gene|CD44,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Skin Lymphangiosarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Coronary heart disease,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
AFFECTS,MAFG gene|MAFG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,ADAMTS1 gene|ADAMTS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antigens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,Malignant Neoplasms,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Antisense RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Metals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,mRNA Expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SDC1 gene|SDC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,GLI3 gene|GLI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tissue-Specific Gene Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Egg Food Product,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
AFFECTS,Valproic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Proto-Oncogene Proteins c-jun|JUN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Medication use,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,"PER2 protein, mammalian",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIRN192 gene|MIR192,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Extracellular Matrix Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,transcription factor PML,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Carcinosarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tumor stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Monocyte Chemoattractant Protein-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Transcription Repressor/Corepressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,RUNX2 gene|RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,APRIN gene|PDS5B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,BMX gene|BMX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mitogen-Activated Protein Kinase 3|MAPK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Alternative Splicing,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,GABRA3 gene|GABRA3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Trans Fatty Acids,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Chemical
AFFECTS,TGFB1 gene|TGFB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nance-Horan syndrome,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,intrauterine disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,mercury,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AUGMENTS,CLDN11 gene|CLDN11,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MicroRNAs,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,RHPN1-AS1 gene|RHPN1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BRCA2 gene|BRCA2,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,opium alkaloids and derivative combination cough suppressants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tamoxifen,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Pharmacologic Substance
AFFECTS,letrozole,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Mutation,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SIRT4 gene|SIRT4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,MIR221 gene|MIR221,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Invasive carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LINC00963 gene|LINC00963,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"TGFB1 protein, human|TGFB1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR221 gene|MIR221,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BHLHE40-AS1 gene|BHLHE40-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLX4IP gene|SLX4IP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MTOR gene|MTOR,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,SOX21-AS1 gene|SOX21-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Detection,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,STAT1 gene|STAT1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,Gonadal Steroid Hormones,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,Immunohistochemistry,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,"CISH protein, human|CISH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NOP2 gene|NOP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SNHG3 gene|SNHG3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,MDC1 gene|MDC1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXP1 gene|FOXP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE2M gene|UBE2M,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MLKL gene|MLKL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAT3 gene|STAT3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,HER2-positive carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hemangiosarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,HEXIM1 gene|HEXIM1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hormone Receptor Positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,"Genes, Modifier",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proliferation (morphologic abnormality),Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC00160 gene|LINC00160,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,KLHL22 gene|KLHL22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cytotoxic Chemotherapy,HER2-negative breast cancer,0.0,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,HSP90 Heat-Shock Proteins|HSP90AA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Pathogenic,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Virus
PREDISPOSES,information seeking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,RB1CC1 gene|RB1CC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RUNX3 gene|RUNX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCR2 gene|CXCR2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SIRT6 gene|SIRT6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ion Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Eukaryotic Initiation Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SIRT1 gene|SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vitamin D3 24-Hydroxylase|CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,BHLHE40 gene|BHLHE40,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"KRT10 protein, human|KRT10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,UBE2D2 gene|UBE2D2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CST3 gene|CST3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PRS gene|PRS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,C8A gene|C8A,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Radionuclide Imaging,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cancer-Predisposing Gene,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,steroid glycoside,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Steroid
PREDISPOSES,SNAI3 gene|SNAI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,FZD7 gene|FZD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,ZFPM2-AS1 gene|ZFPM2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Visual Accommodation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,CTHRC1 gene|CTHRC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,UBR1 gene|UBR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"HLA Class I Histocompatibility Antigen, Alpha Chain G",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,angiotensin converting enzyme 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,"YAP1 protein, human|YAP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lipids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Lipid
DISRUPTS,GPER1 gene|GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,JMJD6 gene|JMJD6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Regulatory Sequences, Nucleic Acid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PPP2R2B gene|PPP2R2B,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,HHEX gene|HHEX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ERRFI1 gene|ERRFI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"CD9 protein, human|CD9",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ZFAS1 gene|ZFAS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"CREB1 protein, human|CREB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RCC2 gene|RCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HER2-targeting Agent,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Anti-Angiogenesis Effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Volatile Organic Compounds,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Chemical
AUGMENTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,MST1 gene|MST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol dehydrogenase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TRIM6 gene|TRIM6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tissue Inhibitor of Metalloproteinase-3|TIMP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,HNF1A-AS1 gene|HNF1A-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,human MUC1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GZMK gene|GZMK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,COL10A1 gene|COL10A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IFNG gene|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Nicotinate-nucleotide pyrophosphorylase (carboxylating),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,lipid mediator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,VPS35 gene|VPS35,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TNFRSF11A gene|TNFRSF11A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01977 gene|LINC01977,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,WNT7B gene|WNT7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CYTOR gene|CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MTERF3 gene|MTERF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,estrogen receptor-positive breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GLUCOSE-6-PHOSPHATASE,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Carbohydrate
CAUSES,atmospheric pollution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sphingolipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Pathologic Neovascularization,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PFKFB4 gene|PFKFB4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Metastatic malignant neoplasm to brain,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Angiogenesis Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FABP4 gene|FABP4,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
AFFECTS,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Agent,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Long Intergenic Non-Protein Coding RNA,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TRPV6 gene|TRPV6,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MMP11 gene|MMP11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AMD1 gene|AMD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,E2F1 Transcription Factor|E2F1|UBE2L3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,3F8 antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,"Food, Organic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Epstein-Barr virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Breast Cancer Therapeutic Procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,TBX15 gene|TBX15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Kynurenine 3-monooxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PIM1 gene|PIM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone Therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Hormone
AFFECTS,AIFM2 gene|AIFM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,RPPH1 gene|RPPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"protein tyrosine phosphatase, non-receptor type 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,estrogen use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,PALB2 gene|PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,epithelial to mesenchymal transition,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adverse Event Emergency Room Visit,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,SNHG3 gene|SNHG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TUBA4A gene|TUBA4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WDR43 gene|WDR43,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,AMIGO2 gene|AMIGO2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,SNHG1 gene|SNHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Intronic Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit 1, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,glucose high,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Elevation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,GATA3 gene|GATA3,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,TMEM130 gene|TMEM130,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Plasma Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RASSF1 gene|RASSF1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,BNIP3 gene|BNIP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,fibroblast activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Elevated Expression,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,COMT gene|COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PTPN2 gene|PTPN2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,FERMT2 gene|FERMT2,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptor Tyrosine-Protein Kinase ErbB-4, human|ERBB4",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Aromatase Inhibitors,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Hormone
AFFECTS,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SHMT2 gene|SHMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EIF3B gene|EIF3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIR21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Suspensions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,mRNA editing,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Transcription Coactivator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lymphatic Invasion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Precision Medicine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MicroRNAs,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,IRAK1 gene|IRAK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TSPAN8 gene|TSPAN8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genetic Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nicotinate-nucleotide pyrophosphorylase (carboxylating),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Confirmation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,ALDH2 gene|ALDH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NTN4 gene|NTN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CCL18 gene|CCL18,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,TLN1 gene|TLN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Cell-Free DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,HAUS5 gene|HAUS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC01315 gene|LINC01315,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,DLGAP1-AS2 gene|DLGAP1-AS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chromosomal translocation,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOX10 gene|SOX10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,lipid mediator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,terminal differentiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UBE2T gene|UBE2T,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Intraoperative Radiation Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GHET1 gene|GHET1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PGM5P3-AS1 gene|PGM5P3-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,cancer care,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hereditary Breast and Ovarian Cancer Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ZNF582-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EBF1 gene|EBF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Recurrent infections,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CENPW gene|CENPW,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GP5 gene|GP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CYP2W1 gene|CYP2W1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Matrix Metalloproteinases,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CDK6 gene|CDK6,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,MFNG gene|MFNG,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Amino Acids, Branched-Chain",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fast Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,MCM10 gene|MCM10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SFN protein, human|SFN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,tao hong si wu decoction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KDM4A gene|KDM4A,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,FOXF2 gene|FOXF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CENPW gene|CENPW,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,GJA1 gene|GJA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Long Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,MELK gene|MELK,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,CASP9 gene|CASP9,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Phytochemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,PFKFB3 gene|PFKFB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chemicals,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Chemical
COMPLICATES,Acquired Immunodeficiency Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Acute infectious disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,SLC6A14 gene|SLC6A14,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RPS6KB1 gene|RPS6KB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SULT1A1 gene|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,medication use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,CUEDC2 gene|CUEDC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,estrogens,Advanced breast cancer diagnosis,0.0,Female Breast Cancer,Hormone
AFFECTS,"LATS1 protein, human|LATS1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KIF11 gene|KIF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IRS2 gene|IRS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Expression,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK2 gene|CHEK2,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lymph-vascular invasion,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NR1H3 gene|NR1H3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"HMGB3 protein, human|HMGB3",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MTNR1B gene|MTNR1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Morbidity - disease rate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"DNA Breaks, Double-Stranded",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Observation - diagnostic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Female Breast Carcinoma,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Tumor Microenvironment,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Hepatocyte Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,SAFB2 gene|SAFB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MicroRNA 367-3p,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Substance P Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
CAUSES,Vascular Endothelial Growth Factors|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,PARP9 gene|PARP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sentinel node (disorder),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Cancer/Testis Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DDX3X gene|DDX3X,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,PTPN13 gene|PTPN13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,KAT7 gene|KAT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"RNA, Circular",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,IMPACT gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IGF2BP1 gene|IGF2BP1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Degenerative polyarthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PRMT2 gene|PRMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PCAT19 gene|PCAT19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,SFXN1 gene|SFXN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,glycyrrhetinic acid,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Chemical
AFFECTS,TWIST1 gene|TWIST1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SFXN2 gene|SFXN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proliferation (morphologic abnormality),HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Reproductive tract infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Apolipoprotein A-I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SOX9 gene|SOX9,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ETV7 gene|ETV7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"FRAP1 protein, human|MTOR",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,New Target Lesion Identification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SMIM10L2A gene|SMIM10L2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Premenstrual Tension,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,"CDK7 protein, human|CDK7",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC02568 gene|LINC02568,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Invasive carcinoma of breast,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KCNQ1OT1 gene|KCNQ1OT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERBB2 gene|ERBB2,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cardiac dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SNHG11 gene|SNHG11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Mental disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,SLC7A11 gene|SLC7A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tn antigen,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Immunologic Factor
AFFECTS,TIPARP gene|TIPARP,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TNK2 protein, human|TNK2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Lymph Node Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,glycosylation,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Indicators,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,MIR182 gene|MIR182,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,receptor for advanced glycation endproducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATP2C1 gene|ATP2C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,malignant disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypofractionated radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FOXA1 gene|FOXA1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,postmenopausal syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,SIGLEC15 gene|SIGLEC15,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,MIDEAS gene|ELMSAN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Amino Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,OTUB1 gene|OTUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,High Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,VEGFA gene|VEGFA,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,LAYN gene|LAYN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PIK3CB gene|PIK3CB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,RHOT1 gene|RHOT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,STAT3 gene|STAT3,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,UHRF1 gene|UHRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAXX gene|PAXX,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Consideration,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ANXA9 gene|ANXA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SF3B1 gene|SF3B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Positive Regulation of Oxidative Stress Process,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CERS4 gene|CERS4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"MMP11 protein, human|MMP11",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"MAP3K8 protein, human|MAP3K8",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Squalene monooxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RIN2 gene|RIN2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,G protein-coupled receptor kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,INSM1 gene|INSM1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"PTGS2 protein, human|PTGS2",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,AZGP1 gene|AZGP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CIB1 gene|CIB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,NCBP1 gene|NCBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NEU1 gene|NEU1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ELAVL2 gene|ELAVL2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,APOBEC3A gene|APOBEC3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ROS1 gene|ROS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORD49B gene|SNORD49B,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Details of education,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MYC gene|MYC,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SIPA1 gene|SIPA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"ORF74 protein, Human herpesvirus 8",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RBM24 gene|RBM24,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXO3 gene|FOXO3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,NT5DC2 gene|NT5DC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CERNA2 gene|CERNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PTPRG-AS1 gene|PTPRG-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmaceutical Preparations,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SF3A2 gene|SF3A2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SLC7A11 gene|SLC7A11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDK1 gene|PDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lipidome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,BAIAP2L1 gene|BAIAP2L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cell Cycle Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Endocrine System Diseases,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,Hormone Receptor,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Hormone
DISRUPTS,NUDT1 gene|NUDT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CONOTRUNCAL ANOMALY FACE SYNDROME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Corticotropin-Releasing Hormone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,receptor for advanced glycation endproducts,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Intravascular Metastasis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,MAPK8 gene|MAPK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL12 gene|CXCL12,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,ATF3 gene|ATF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,BCL-2 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TRAF4 gene|TRAF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast cancer metastatic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Chronic inflammation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,EPHA10 gene|EPHA10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"FRAP1 protein, human|MTOR",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CYP2B6 protein, human|CYP2B6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Transferase Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA repair protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NCOA1 gene|NCOA1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
CAUSES,SRC gene|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Secondary malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TRANCE protein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,AMOT gene|AMOT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Estrogen Receptor beta|EREG|ESR1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CYP2C19 gene|CYP2C19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GIT1 gene|GIT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Estrogens,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hormone
PREDISPOSES,25-hydroxyvitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,mdm2 protein|MDM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Medroxyprogesterone 17-Acetate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Detection,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Carcinogens, Environmental",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Breast Microcalcification,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HNRPM gene|HNRNPM,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,PARP1 gene|PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BIRC7 gene|BIRC7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BCL2L11 gene|BCL2L11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Squamous cell carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Seafood,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Mammographic microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MicroRNAs,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Genes, Suppressor",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Intercellular adhesion molecule 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Colorectal Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S100 Proteins|S100A1|S100B,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BRCA3 gene|BRCA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,S100A8 gene|S100A8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Finding of antibody titer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Evolution,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MIRN10B gene|MIR10B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CTSL gene|CTSL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,ERBB4 gene|ERBB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Selective Estrogen Receptor Modulators,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Serum Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Genome,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Detection,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aromatase Inhibitors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,Prostate-Specific Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Retinoblastoma Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,leukemia inhibitory factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phytochemical,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Lactoylglutathione Lyase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BRCA2 gene|BRCA2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
DISRUPTS,TNFSF11 gene|TNFSF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Deletion Mutation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Blind Vision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,N-Acetylneuraminic Acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Malignant Neoplasms,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Milk Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ductal Carcinoma,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,ASK Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Carcinoma,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,CEACAM5 gene|CEACAM5,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,HPR gene|HPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Polyomavirus Middle T Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AFFECTS,trastuzumab,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,"VEGF protein, human|VEGFA",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,sex hormone-binding globulin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Indicators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
CAUSES,Tumor Suppressor Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PBP gene|DOCK3|PEBP1|PKD1|MED1|PPBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,National origin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Antigens,Breast cancer stage II,0.0,Female Breast Cancer,Immunologic Factor
CAUSES,tumor growth,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Protease Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Protease Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Cell Cycle Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CD4 gene|CD4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CA-15-3 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,Growth Factor Receptors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Endometrial Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vascular Endothelial Growth Factor Receptor-2|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,riboflavin-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Progesterone increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Micronutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Detection,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,c-myc Proto-Oncogenes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenesis Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epithelial-Stromal Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immunization,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hydrocarbons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Preventive Services - Orthodontics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,EPSTI1 gene|EPSTI1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,AKT2 gene|AKT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transgenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Protein Kinase C|PRRT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Endocrine therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,"CBFB protein, human|CBFB|NFYA|NFYB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MSN gene|MSN,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Human Chorionic Gonadotropin|CGA|HTC2|CGB5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,VEGF gene|VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,BARD1 gene|BARD1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Renal tubular disorder,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Dinucleotide Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,GADD45A gene|GADD45A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TSG101 gene|TSG101,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,progesterone analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Mouse mammary tumor virus infection,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Abnormal digestive tract function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
COMPLICATES,Poland Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,STK11 gene|STK11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BIN1 gene|BIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dopamine Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AFFECTS,IL6ST gene|IL6ST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cell Adhesion Molecules,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hereditary Malignant Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CASP8 gene|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Pulmonary toxicity,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,IGFBP1 gene|IGFBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Carcinogenicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,APOE gene|APOE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,5'-AMP-activated protein kinase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Transforming Growth Factor beta Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,syndecan 1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Recombinant Transforming Growth Factor-Beta 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RHOC gene|RHOC,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Antihypertensive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,catenin p120(ctn) protein|CTNND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PTN gene|PTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SCTR gene|SCTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Repetitive Region,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NBS1 gene|NBN|NLRP2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,steroid hormone receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Excretory function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Serum Folate Level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
DISRUPTS,of 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Nucleotide Excision Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bone morphogenetic protein 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Transgenes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dyslipidemias,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,PROTEIN KINASE|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KL gene|KL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,nucleic acid inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogens,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
CAUSES,Breast cancer metastatic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Proto-Oncogene Proteins c-akt,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,estrogen receptor gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MAPK8 gene|MAPK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FGFR2 gene|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,P-Glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,sarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Protein phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CD44 gene|CD44,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transcription Factor 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MAPK12 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,S100A2 gene|S100A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,antiangiogenesis therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Monocyte Chemoattractant Protein-1|CCL2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Heat Shock Protein 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Transforming Growth Factor Beta 2|NEUROD1|TUBB4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,"FRAP1 protein, human|MTOR",Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KLF9 gene|KLF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TNFRSF10B gene|TNFRSF10B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Germ-Line Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Fibroblast Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Ion Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolic syndrome,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AFFECTS,Evolution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Promoter Regions (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cholesterol levels raised,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Lipid
AFFECTS,Malignant neoplasm of breast,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,Protein C Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Nicotinamide adenine dinucleotide (NAD),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,NR4A1 gene|NR4A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TWIST1 gene|TWIST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NUCB2 gene|NUCB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Risk Reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CXCL9 gene|CXCL9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GPR116 gene|ADGRF5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Docosahexaenoic Acids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
DISRUPTS,Protein phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Colorectal Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,GIT1 gene|GIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,chemoprotection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation therapy,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RGS2 gene|RGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm progression,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CLDN2 gene|CLDN2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BRMS1 gene|BRMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acute myocardial infarction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,radiosensitization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP2B6 gene|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,membrane-type 1 matrix metalloproteinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,PLAT gene|PLAT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptor Status,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Benzoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,CYC1 gene|CYC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"ABCG2 protein, human|ABCG2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Thiazolidinediones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,tumor growth,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,calmodulin-dependent protein kinase II|CAMK2G,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,calmodulin-dependent protein kinase II|CAMK2G,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Oncogenes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,FGF2 gene|FGF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KRAS gene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL1 gene|CXCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Amino Acids, Branched-Chain",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ALDH1A3 gene|ALDH1A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prostaglandin-Endoperoxide Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
PREDISPOSES,Arachidonic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Vitamin D Analog,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
AUGMENTS,MST1R gene|MST1R,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,BCL2 gene|BCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Endogenous Retroviruses,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,PRLR gene|PRLR|PTP4A3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"ESR1 protein, human|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Proto-Oncogene Proteins c-jun|JUN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,GGN gene|GGN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CLOCK gene|CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BCAS3 gene|BCAS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MCM10 gene|MCM10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Aromatase,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Enzyme
AUGMENTS,Linoleic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,TRANSCRIPTION FACTOR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ARNT2 gene|ARNT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,lysophosphatidic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,PTK6 gene|PTK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Nuclease Sensitive Element Binding Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNAs,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,S100A9 gene|S100A9,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,MIRN205 gene|MIR205,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Viral Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SNW1 Gene|SNW1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,RBX1 gene|RBX1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CEACAM5 gene|CEACAM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Cytostatic Agents,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,Vascular Endothelial Growth Factor Receptor-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Heat-Shock Proteins 70|HSPA4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Carrier of disorder,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
PREDISPOSES,Ions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Mammary Carcinoma, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Serine Proteinase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Tumor Necrosis Factor Ligand Superfamily Member 6|FAS,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypical proliferation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,C-Peptide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,letrozole,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
DISRUPTS,Total cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Multivitamin preparation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,ERCC5 gene|ERCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Non-infiltrating lobular carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Heat-Shock Proteins 70|HSPA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Growth Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,"Transcription, Genetic",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Eicosapentaenoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Adrenal Cortex Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Long chain fatty acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
PREDISPOSES,Specific antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,GPR30 gene|GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Detection,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Contralateral breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,GDI2 gene|GDI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Osteogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Klinefelter's Syndrome,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
PREDISPOSES,LIG4 gene|LIG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hypertension induced by pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,APOB gene|APOB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Neoplasm progression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cytokine,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Biologically Active Substance
PREDISPOSES,Vitamin B12 intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AUGMENTS,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,aldehyde dehydrogenase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,biological_process,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,TYRP1 gene|TYRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Receptor alpha,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HORMONE REPLACEMENT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Disease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Residual Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Antigens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Immunologic Factor
AFFECTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Chemical Viewed Functionally
AUGMENTS,Mixed Function Oxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Protein Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MDM4 gene|MDM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cadmium,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,XRCC5 gene|XRCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,transduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,trastuzumab,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,AXILLARY LYMPH NODE METASTASIS,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
PREDISPOSES,Sleep Apnea Syndromes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,regional differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Isoenzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,HP gene|HP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast cancer invasive NOS,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AFFECTS,Second Primary Cancers,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Localized Malignant Neoplasm,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Physical function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,snail transcription factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,claudin 1 protein,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,volatile substances,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Substance
AFFECTS,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Diabetes, Gestational",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fine needle aspiration biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Large Neutral Amino Acid-Transporter 1|SLC7A5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Monomeric GTP-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,APEX1 gene|APEX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Primary disease,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
CAUSES,Phyllodes Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"EZH2 protein, human|EZH2",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Blood Coagulation Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Seeks information,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Adverse event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,FOLR1 gene|FOLR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL8RB gene|CXCR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inflammation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aminolevulinic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Diffusion Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypoglycemic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Echocardiography, Three-Dimensional",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CHEK2 gene|CHEK2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,ESTROGEN+PROGESTERONE RECEPTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Hormones,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
PREDISPOSES,Alkylating Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Prevention,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,breast implant procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biomedical or Dental Material
DISRUPTS,Anti-Anxiety Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,DNA,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PVT1 gene|PVT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Solid tumor,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTPN1 gene|PTPN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sugar candy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Plasma glucose result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
PREDISPOSES,advanced disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Atypical proliferation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SP1 gene|SP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,activated RNA polymerase II transcription cofactor 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Progesterone Receptor Status,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Anticholesteremic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,TSC1 gene|TSC1|CCL26,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Materials,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Substance
CAUSES,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"CHEK2 protein, human|CHEK2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Juvenile carcinoma of the breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Disease recurrence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Collagen Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Excision Repair Protein ERCC-5|ERCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,XBP1 gene|XBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Burden,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tumor Immunity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,HIF1alpha protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LARP4 gene|LARP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, circular",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,SMAD4 gene|SMAD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant Neoplasms,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,LOXL1-AS1 gene|LOXL1-AS1,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,"2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,PAK4 gene|PAK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAM83H-AS1 gene|FAM83H-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,folic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Protein Isoforms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"PTGS2 protein, human|PTGS2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Phosphoglycerate dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genome,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"PKN1 protein, human|PKN1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ELF5 gene|ELF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Mutant Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,apolipoprotein D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,TRANSCRIPTION FACTOR,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KISS1R gene|KISS1R,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Sentinel node (disorder),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Insoluble fiber (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,Carbon Ion Radiotherapy,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,H19 gene|H19|HILS1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,BCL11A gene|BCL11A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,PPFIA1 gene|PPFIA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PPFIA1 gene|PPFIA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PARP1 gene|PARP1,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,SOX9 gene|SOX9,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Polycystic Ovary Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,RNF111 gene|RNF111,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,steroid receptor coactivator AIB1|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,new information,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Blood Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,S-adenosylmethionine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Malignant Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polypeptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MNX1-AS1 gene|MNX1-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,N-Myc Downstream Regulated Protein 1|NDRG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Dicarboxylic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,ENC1 gene|ENC1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,NORAD gene|NORAD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Mammary Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Genes,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CA10 gene|CA10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NME1 gene|NME1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR326 gene|MIR326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PART1 gene|PART1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,YTHDF3 gene|YTHDF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,S100A14 gene|S100A14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TMPRSS13 gene|TMPRSS13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,nervous system disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,TRIO gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSD17B4 gene|HSD17B4,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoma of Male Breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"CCND2 protein, human|CCND2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,UBR1 gene|UBR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCR5 gene|CCR5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptor Tyrosine-Protein Kinase ErbB-4, human|ERBB4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CAVIN3 gene|CAVIN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,epithelial to mesenchymal transition,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"TFF1 protein, human|TFF1",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Neoplasm Metastasis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AUGMENTS,estrogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
AUGMENTS,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Transforming Growth Factor beta,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biologically Active Substance
COMPLICATES,contralateral breast cancer,Right-Sided Breast Neoplasms,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PRMT5 gene|PRMT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA replication checkpoint,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fermented Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,NF2 gene|NF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PLEKHA7 gene|PLEKHA7,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Ultraviolet B radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,STRN3 gene|STRN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Transcription factor genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ZMYND8 gene|ZMYND8,Refractory Breast Carcinoma,0.0,Other,Gene or Genome
AUGMENTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SOX6 gene|SOX6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RSPO2 gene|RSPO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PEBP1 gene|PEBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RARRES2 gene|RARRES2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,EIF4A1 gene|EIF4A1,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,CA13 gene|CA13,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Adverse event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,FOXK1 gene|FOXK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NUP43 gene|NUP43,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MYCN gene|MYCN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,HNRNPK gene|HNRNPK,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,ERRFI1 gene|ERRFI1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,STUB1 gene|STUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,S100A7 gene|S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Elevated C-reactive protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BTNL9 gene|BTNL9,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,CDC25C gene|CDC25C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HMGB1 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,PDCD4 gene|PDCD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MDM2 gene|MDM2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF132 gene|ZNF132,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Pathogenic Variant,"Breast Cancer, Familial",0.0,Female Breast Cancer,Virus
DISRUPTS,NRBP2 gene|NRBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCAT1 gene|PCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Borg Category-Ratio 10 Perceived Exertion Score 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,TPT1-AS1 gene|TPT1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KIAA1755 gene|KIAA1755,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00467 gene|LINC00467,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone Therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,Homeobox Protein ARX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,NORAD gene|NORAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HAGLR gene|HAGLR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proto-Oncogene Proteins c-sis|PDGFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,nucleoside diphosphate kinase A|NME1,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00894 gene|LINC00894,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR373 gene|MIR373,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BABAM2-AS1 gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Migration, Cell",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CXCL13 gene|CXCL13,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cigarette smoke (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
CAUSES,Oncogene Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,OVOL1 gene|OVOL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factor beta,Carcinoma breast stage IV,0.0,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Matrix Metalloproteinase 3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PTPN11 gene|PTPN11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,DPP9 gene|DPP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAU2 gene|STAU2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,OMA1 gene|OMA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IL17RB gene|IL17RB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Extraction,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Protein-Lysine 6-Oxidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hypermethylation,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RABIF gene|RABIF,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEIL2 gene|NEIL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,AKR1C1 gene|AKR1C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01094 gene|LINC01094,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CASQ2 gene|CASQ2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmaceutical Preparations,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Platinum Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Raw Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,TUBA1C gene|TUBA1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,LINC02381 gene|LINC02381,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SH3BGRL gene|SH3BGRL,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,RGMA gene|RGMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SEMA6D gene|SEMA6D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,HSPA5 gene|HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mucin-1 Antigen,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Immunologic Factor
PREDISPOSES,BARD1 gene|BARD1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,NDRG2 gene|NDRG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXP3 gene|FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell secretion,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HSPA5 gene|HSPA5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,LPAR6 gene|LPAR6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PELI1 gene|PELI1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,KPNA2 gene|KPNA2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZMIZ2 gene|ZMIZ2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,UBA6-AS1 gene|UBA6-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nutritional status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MALAT1 gene|MALAT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 6|IGFBP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cancer-Predisposing Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ANKDD1A gene|ANKDD1A,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,BNIP3 gene|BNIP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Candidate Disease Gene,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,HCAR1 gene|HCAR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MED1 gene|MED1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Environmental Estrogen,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
CAUSES,PROX1 gene|PROX1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Stat3 protein,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ZFR gene|ZFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNMT1 gene|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RUNX2 gene|RUNX2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Signal Transduction,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HSPBP1 gene|HSPBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MSH2 gene|MSH2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,First relationship,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CDK1 gene|CDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tumor suppressor activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Acute Promyelocytic Leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,B3GNT5 gene|B3GNT5,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,Tumor Suppressor Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00662 gene|LINC00662,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,KIF4A gene|KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Inflammation Mediators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LINC01234 gene|LINC01234,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic immunosuppression,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAD51D gene|RAD51D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ALYREF gene|ALYREF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,perfluorononanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"POSTN protein, human|POSTN",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RAD51B gene|RAD51B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PNO1 gene|PNO1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Oncogenes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,PIK3R1 gene|PIK3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,OTUD6A gene|OTUD6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCL14 gene|CXCL14,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDKN2A gene|CDKN2A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Immunoregulation,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Complement System Proteins,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Large Neutral Amino Acid-Transporter 1|SLC7A5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Serum autoantibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
AUGMENTS,LINC00520 gene|LINC00520,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,TPD52L2 gene|TPD52L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Glucosephosphate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ATP6AP1 gene|ATP6AP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR1294 gene|MIR1294,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Psychosocial Intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SLC31A1 gene|SLC31A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNase P,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,TGFB2-AS1 gene|TGFB2-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,inhibitor-of-apoptosis protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MYCL gene|MYCL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DIO3OS gene|DIO3OS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,centromere protein F,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,N4BP3 gene|N4BP3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOD2 gene|SOD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF667-AS1 gene|ZNF667-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RECQL5 gene|RECQL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RBCK1 gene|RBCK1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Fatty Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,MIR506 gene|MIR506,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZSWIM1 gene|ZSWIM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vascular Endothelial Growth Factors|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,MIR21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PALB2 gene|PALB2,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,MCF2L-AS1 gene|MCF2L-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Low Dose Radiation Therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"pregna-4,17-diene-3,16-dione, (17Z)-isomer",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NR1H3 gene|NR1H3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inflammation,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Aryl Hydrocarbon Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ALDH2 gene|ALDH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cytotoxic T-lymphocyte antigen 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCSK1 gene|PCSK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Drug Repositioning,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Pharmacologic Substance
AFFECTS,YBX1 gene|YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00536 gene|LINC00536,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HNF1A gene|HNF1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,CALML5 gene|CALML5,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,RBCK1 gene|RBCK1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,MYO6 gene|MYO6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Metric (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,TLE5 gene|AES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HAR1A gene|HAR1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TMED3 gene|TMED3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Anaplastic carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,NUMB gene|NUMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,internal risk factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Fasting blood sugar result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,CENPL gene|CENPL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Long Intergenic Non-Protein Coding RNA,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PCAT19 gene|PCAT19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Food antioxidant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,oleanolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EIF4A3 gene|EIF4A3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Antibody-Drug Conjugates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,SOD1 gene|SOD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"ANGPT1 protein, human|ANGPT1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Resistance Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
CAUSES,CYP1B1 gene|CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Degenerative polyarthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Matrix Metalloproteinase 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,GPR141 gene|GPR141,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HFM1 gene|HFM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,tamoxifen,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
AFFECTS,LGALS3 gene|LGALS3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Physiologic calcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZSCAN18 gene|ZSCAN18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NNAT gene|NNAT,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Radioimmunotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
DISRUPTS,CREBZF gene|CREBZF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,OTUD1 gene|OTUD1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,HMMR gene|HMMR,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RNA Sequence,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Nucleotide Sequence
PREDISPOSES,BCKDK gene|BCKDK,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Noninfiltrating Intraductal Carcinoma,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Anesthetics, Inhalation",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tumor Antigens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AFFECTS,Caffeic Acid Phenethyl Ester,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,MicroRNAs,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,INSM1 gene|INSM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FUNDC2 gene|FUNDC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,ubiquitin-protein ligase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,NOX4 gene|NOX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Stereotactic Body Radiation Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NT5E gene|NT5E,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,FOXQ1 gene|FOXQ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2 Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLRB1 gene|KLRB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MAPK1 gene|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transfer RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,e protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Collagen Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,DNAJA1 gene|DNAJA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SMAD4 gene|SMAD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LRRC37A2 gene|LRRC37A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FZD8 gene|FZD8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,VASP gene|VASP,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Responsive Disease,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Nail-Patella Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,CREB3L1 gene|CREB3L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PSME3 gene|PSME3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MDH2 gene|MDH2,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
AFFECTS,PFKP gene|PFKP,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,RNF185 gene|RNF185,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,RNA I,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Genes,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oncogene Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,PARD3 gene|PARD3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP4 gene|USP4,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,STING1 gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,mitogen-activated protein kinase p38,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SLC38A3 gene|SLC38A3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,METTL7A gene|METTL7A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TNF protein, human|TNF",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ASAH2 gene|ASAH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DCTD gene|DCTD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malate dehydrogenase (decarboxylating),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,AICARDI-GOUTIERES SYNDROME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,DNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
AUGMENTS,Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ST14 gene|ST14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RENBP gene|RENBP,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cigarette smoke (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,NAT10 gene|NAT10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORD16 gene|SNORD16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ARID1A gene|ARID1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,NUDCD1 gene|NUDCD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PKD2 gene|PKD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Body composition measure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplastic Cell Transformation,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,ZMIZ1 gene|ZMIZ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Emotional hypersensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HER2-positive carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,KDM1A gene|KDM1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,nervous system disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,PRMT6 gene|PRMT6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,YY1 gene|YY1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIRN181A gene|MIR181A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Huntington Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Rare Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Leukotrienes,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Eicosanoid
AUGMENTS,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,BRCA1 gene|BRCA1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Ovulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm Metastasis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CCAAT-Enhancer-Binding Protein-beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ESR1 gene|ESR1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,FLT1 gene|FLT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"CRK protein, human|CRK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Progestational Hormones, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CCR5 gene|CCR5,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,HOXD10 gene|HOXD10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,KLF8 gene|KLF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Supplementation,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,methylcobalamin-coenzyme M methyltransferase|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Protein Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Chemical Viewed Functionally
CAUSES,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MYC Family Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HSP90 Heat-Shock Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,mitogen-activated protein kinase p38|CRK|MAPK14|MAPK1|AIMP2|GRAP2|AHSA1|POLDIP2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Ki antigen|PSME3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Hormone Receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,IRAK4 gene|IRAK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Heart Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,cDNA Library,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,AXILLARY LYMPH NODE METASTASIS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,tau Proteins|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"NAT1 protein, human|NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,low protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,C-KIT Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"TRIP10 protein, human|TRIP10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SRD5A2 gene|SRD5A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,XRCC2 gene|XRCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCNA2 gene|CCNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MDC1 gene|MDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gene polymorphism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,TWIST1 gene|TWIST1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"NOS3 protein, human|NOS3",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Effective communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Phospholipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,Common Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,DNA,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,peptide hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PROTEIN KINASE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
DISRUPTS,"SOD2 protein, human|SOD2",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Neoplasm Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Exogenous hormones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,LMO7 gene|LMO7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antigens,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Immunologic Factor
PREDISPOSES,peptide hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TP53 gene|TP53,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,HOXA1 gene|HOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,dihydroxy-vitamin D3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
CAUSES,Virus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
CAUSES,spasmolytic polypeptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,3-hydroxytamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Steroid Use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,Low-Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ESTROGEN USE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Therapeutic Abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Fatty Acids, Nonesterified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Augmentation mammoplasty,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Malignant neoplasm of breast,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AFFECTS,MICE gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, vpr",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genome, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,mucinous carcinoma-associated antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mixed Function Oxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,PCAF gene|KAT2B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,CCND1 gene|CCND1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SHBG gene|SHBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoembryonic Antigen,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Immunologic Factor
AFFECTS,Ionizing radiation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Serine Protease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
CAUSES,SH Protease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
CAUSES,Breast cancer recurrent,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,3-hydroxytamoxifen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
CAUSES,Secondary malignant neoplasm of liver,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,cytokine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,Histocompatibility Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,PGR gene|PGR,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Epidermal Growth Factor|EGF,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Vascular Endothelial Growth Factor C,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,DNA Polymerase I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,ZNF217 gene|ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,riboflavin-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Carcinoma in Situ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,EIF3S6 gene|EIF3E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SAFB gene|SAFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenesis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Primary Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tumor Markers,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Hyperlipidemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Germ-Line Mutation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MYC gene|MYC,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
DISRUPTS,"TACC1 protein, human|TACC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Hydrocarbons, Halogenated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Genetic syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Hormones,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AFFECTS,Pathologic Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,ELF3 gene|ELF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PLAUR gene|PLAUR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Thyrotropin-Releasing Hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,AXIN2 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CCL2 gene|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bone sialoprotein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Thiazolidinediones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EZH2 gene|EZH2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
DISRUPTS,antireticular cytotoxic serum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,restriction enzyme,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SEPT9 gene|SEPT9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Steroids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Steroid
PREDISPOSES,betaIG-H3 protein|TGFBI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PTHLH gene|PTHLH,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,T gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Gonadal Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,IRS2 gene|IRS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Small RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PSIP1 gene|PSIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CA9 gene|CA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Antidepressive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,IGF2 gene|IGF2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,SCTR gene|SCTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogens,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
AFFECTS,"Shc1 protein, mouse|SHC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Selective Estrogen Receptor Modulators,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PP5 protein-serine-threonine phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Lesion,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,IGFBP3 gene|IGFBP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Vascular Endothelial Growth Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,N-3 fatty acid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,cell invasion,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,TRANCE protein|TNFSF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Genes, Homeobox|LBX1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NDRG1 gene|NDRG1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Combination Drug Therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Secondary malignant neoplasm of bone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,genetic element,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"DICER1 protein, human|DICER1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Xanthine Dehydrogenase|XDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,NOTCH1 gene,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,Cell Adhesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CCL18 gene|CCL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PTK2B gene|PTK2B,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,ABCB1 gene|ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Signal Transduction Pathways,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCL2 gene|CCL2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Receptor Protein-Tyrosine Kinases,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RGS Proteins|PITX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TNFSF11 gene|TNFSF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PRS gene|PRS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Receptors, Progesterone|EREG|ESR1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,cell fate determination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Gene Expression Alteration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cessation of life,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Human Papilloma Virus Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,JTB gene|JTB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,Protein Overexpression,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Systemic disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Candidate Disease Gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Extravasation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alkaline phosphatase isoenzyme,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,Hormone Receptor Test,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Interleukin Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,AXL gene|AXL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CD100 antigen|SEMA4D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,TIAM1 gene|TIAM1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Tumor Suppressor Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2 gene|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stiff-Person Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Ethacrynic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Sweet's Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Prions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PTPN12 gene|PTPN12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Antigens, CD25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,PLK1 gene|PLK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fibroblast Growth Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Intercellular adhesion molecule 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,5'-AMP-activated protein kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Metals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,WT1 gene|WT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIRN96 gene|MIR96,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,PVT1 gene|PVT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"Receptors, Progesterone|PGR",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,CD47 gene|CD47,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,mitogen-activated protein kinase 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TGFBR2 gene|TGFBR2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Reactive Oxygen Species,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"ESR2 protein, human|ESR2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CPEB4 gene|CPEB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,triplet codon-amino acid adaptor activity,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Hydroxamic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phospholipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Infrared radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"STC1 protein, human|STC1",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HMGA2 gene|HMGA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Breast cancer stage III,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Glycerol-3-Phosphate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Adhesions,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"MFNG protein, human|MFNG",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Placental Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,HGF gene|HGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RBBP1L1 Protein|ARID4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TERT gene|TERT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,hypercholesterolemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,RETN gene|RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LIMK1 gene|LIMK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutant Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Dioxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RET gene|RET,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Immunotoxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,DNA,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,NRF1 gene|NRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"8-oxoguanine-DNA glycosylase, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PCDH10 gene|PCDH10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"NOS3 protein, human|NOS3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NOTCH1 gene,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,CDK4 gene|CDK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Prostaglandins E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
CAUSES,CD4 gene|CD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TOLLIP gene|TOLLIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CASP10 gene|CASP10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmaceutical Preparations,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,CCNB1 gene|CCNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BARD1 gene|BARD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic Intervention,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FOXC1 gene|FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Alternative Therapies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"NAT2 protein, human|NAT2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LTB4R2 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dopamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,Insulin-Like Growth-Factor-Binding Proteins|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BRCA1 gene|BRCA1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,XPA gene|XPA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIRN384 gene|MIR384,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAL gene|CD8A|MAL|MKL1|TIRAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,TRANCE protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hodgkin Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Candidate Disease Gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen receptor negative,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Malnutrition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Transplantation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin-Like Growth Factor I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor Promoters,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Indicators,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,HYAL1 gene|HYAL1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Cell division,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,letrozole,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AUGMENTS,Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sexual function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Carcinoma in Situ,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIRN21 gene|MIR21,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carcinoembryonic Antigen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AUGMENTS,PRL gene|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RARA gene|RARA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,progesterone receptor B|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,biological_process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,MAP Kinase Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,soy protein isolate,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Polycyclic Hydrocarbons, Aromatic",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ARHI gene|DIRAS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Superior Vena Cava Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,S100 Proteins|S100A1|S100B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Precancerous lesions,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,WNT5A gene|WNT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"ESR1 protein, human|ESR1",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa|UBASH3B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ING1 gene|ING1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PRKD1 gene|PRKD1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,TIAM1 gene|TIAM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,PTEN gene|PTEN,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,biological_process,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Phenomenon or Process
AFFECTS,Adenoid Cystic Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MRPS18A gene|MRPS18A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin B2 intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,ATM gene|ATM,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mineralocorticoid Receptor|DHCR24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Antilipemic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,ITK gene|ITK,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,CXCL10 gene|CXCL10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MicroRNAs,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,antibody therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Pancreatic carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KIF4A gene|KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Repair Gene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Microcalcification,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL1B gene|IL1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL4R gene|IL4R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Enhancing Lesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Sulfuric Acid Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,CXCL13 gene|CXCL13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AUGMENTS,ERBB3 gene|ERBB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Amyloid beta-Protein Precursor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CAPN9 gene|CAPN9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KIAA1199 gene|CEMIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACE gene|ACE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,alpha2HS glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Microdissection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VEGF gene|VEGFA,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Malathion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"VEGF protein, human|VEGFA",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Encounter due to breast reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Detection,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Elongation Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FOXC1 gene|FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,patient retention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,USF1 gene|USF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,WWOX gene|WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,usnic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Folic Acid Antagonists,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,toxicant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Cacodylic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Antirheumatic Drugs, Disease-Modifying",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,PTH gene|PTH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SDC1 gene|SDC1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,TOP2A gene|TOP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTM1 gene|GSTM1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptor alpha,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Thromboembolic event,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Phenomenon or Process
AFFECTS,G-T mismatch-binding protein|MSH6,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Therapeutic Intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP2D6 gene|CYP2D6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"PHEMX protein, human|TSPAN32",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Abnormal protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Malignant meningitis,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,SMAD7 gene|SMAD7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"NRIP1 protein, human|NRIP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CD71 antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,Factor VIII-Related Antigen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
DISRUPTS,CYGB gene|CYGB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Food,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
AFFECTS,Manual reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,PARVA gene|PARVA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
PREDISPOSES,Pancreatic Polypeptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"MPP3 protein, human|MPP3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Apolipoprotein A-I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Taking medication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,N-Acetylneuraminic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,MicroRNAs,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CYP2C8 gene|CYP2C8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Heat-Shock Proteins 70,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,bone morphogenetic protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,parathyroid hormone-related protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,cell transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Thyroid Hormone Receptor Beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Macrophage Activation Syndrome,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"CEACAM5 protein, human|CEACAM5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neurophysiology - biologic function,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,zoledronic acid,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Chemical
AFFECTS,Metaplastic carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB3 gene|ERBB3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00520 gene|LINC00520,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,TRIP6 gene|TRIP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Enzyme Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cholesterol hydroxylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,MIR182 gene|MIR182,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,COL10A1 gene|COL10A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ZNF10 gene|ZNF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KDM5B gene|KDM5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genome,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sex Hormone-Binding Globulin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AFFECTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAQR4 gene|PAQR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PTTG1 gene|PTTG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormones,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AUGMENTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
CAUSES,"Breast Cancer, Familial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ASAP1 gene|ASAP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRPM4 gene|TRPM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNORA71B gene|SNORA71B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MARS gene|MARS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Positive Transcriptional Elongation Factor B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ENO1 gene|ENO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SCUBE2 gene|SCUBE2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Proliferation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MKI67 gene|MKI67,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"T-Cell Surface Glycoprotein CD4, human|CD4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TMEM165 gene|TMEM165,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Tumor-Associated Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CDC2 Protein Kinase|CDK1,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MMP10 gene|MMP10,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,ENC1 gene|ENC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"AGR3 protein, human|AGR3",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Smoked food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HLCS gene|HLCS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Functional Food,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UNC5B gene|UNC5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ITPKC gene|ITPKC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Stat3 protein,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PART1 gene|PART1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SPRY4-IT1 gene|SPRY4-IT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Extranodal Extension,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ADAMTS8 gene|ADAMTS8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Obstruction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chronic Obstructive Airway Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,mammary gland involution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIR100HG gene|MIR100HG,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,PALB2 gene|PALB2,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,MIR497 gene|MIR497,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,YY1 gene|YY1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,HAND2-AS1 gene|HAND2-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Expression procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SRCIN1 gene|SRCIN1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Eicosanoids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Eicosanoid
PREDISPOSES,Adipose Tissue Deposition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PLEKHA7 gene|PLEKHA7,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,CDC25B gene|CDC25B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MKI67 gene|MKI67,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,estrogens,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
CAUSES,"RNA, Circular",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Transcription, Genetic",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,HLA-F-AS1 gene|HLA-F-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,DSCAM-AS1 gene|DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,APLN gene|APLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RING1 gene|RING1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,K-ras Oncogene|KRAS,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,"Metabolic Process, Cellular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,EIF3A gene|EIF3A,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,PFKL gene|PFKL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genes,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Sleep Disorders, Circadian Rhythm",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Chemotherapy Regimen or Agent Combination,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZEB1 gene|ZEB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Long Interspersed Nucleotide Element-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Heat shock proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,CDKN2B gene|CDKN2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ACTL8 gene|ACTL8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BCL6 gene|BCL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dietary Modification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SIRT3 gene|SIRT3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXO6 gene|FOXO6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"STK11 protein, human|STK11",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AUGMENTS,KIF18B gene|KIF18B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDLIM7 gene|PDLIM7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RFX5 gene|RFX5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PUM1 gene|PUM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gene interaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,prevention effectiveness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AFAP1-AS1 gene|AFAP1-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IMPACT gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,EEF1E1 gene|EEF1E1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CD69 protein, human|CD69",Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Transformation, function",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CASC16 gene|CASC16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CDC20 gene|CDC20,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,multidrug resistance-associated protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CD9 protein, human|CD9",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR937 gene|MIR937,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERBB2 gene|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,RAD54B gene|RAD54B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"GPER protein, human|GPER1",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LRP6 gene|LRP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pregnancy-Associated Plasma Protein-A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SCUBE2 gene|SCUBE2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Physical function,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MORC2 gene|MORC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,G-Protein-Coupled Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GATA3 Transcription Factor|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,IL18 gene|IL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABI1 gene|ABI1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,"BCAR3 protein, human|BCAR3",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SHARPIN gene|SHARPIN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Antitumor Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"DKK3 protein, human|DKK3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Matrix Metalloproteinase 13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LIG3 gene|LIG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,WLS gene|WLS,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Positron-Emission Tomography,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PLB1 gene|PLB1,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP41 gene|USP41,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SP7 gene|SP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"CDK7 protein, human|CDK7",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Oligonucleotides,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,BCL6B gene|BCL6B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWSG1 gene|TWSG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SPARC gene|SPARC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CTNNB1 gene|CTNNB1,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,BCL6B gene|BCL6B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MYD88 gene|MYD88,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Poly-L-lactic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Hormone Therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
PREDISPOSES,"TNFSF13 protein, human|TNFSF13","Breast Cancer, Familial",0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"RNA, Long Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Effective Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,glucose oxidase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Carbohydrate
PREDISPOSES,MIR10B gene|MIR10B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MIR139 gene|MIR139,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,CDC20 gene|CDC20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"CTGF protein, human|CTGF",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"CD69 protein, human|CD69",Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TPI1 gene|TPI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acclimatization,Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MKI67 gene|MKI67,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TPI1 gene|TPI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CDK6 gene|CDK6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,MAP1LC3C gene|MAP1LC3C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathogenic Variant,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Virus
DISRUPTS,Pseudogenes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,TTYH3 gene|TTYH3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,cyclooxygenase 2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Proliferation (morphologic abnormality),Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HSPG2 gene|HSPG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC01234 gene|LINC01234,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ELP3 gene|ELP3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Methylation Site,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DST gene|DST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CYP2S1 gene|CYP2S1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High glycemic index food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Tomography, Emission-Computed",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ULBP2 gene|ULBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MEF2C gene|MEF2C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Plasma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
CAUSES,"Mammary Carcinoma, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bioavailable testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,SPOP gene|SPOP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CUL4B gene|CUL4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MMP13 gene|MMP13,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
PREDISPOSES,TIMM8A gene|TIMM8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"TRIM25 protein, human|TRIM25",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MicroRNA 205-5p,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CLIC1 gene|CLIC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSPA8 gene|HSPA8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,aflatoxin B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"ZFP36 protein, human|ZFP36",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Decreased Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ERBB2 gene|ERBB2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00473 gene|LINC00473,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WBP2 gene|WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,microphthalmia-associated transcription factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,WNT9B gene|WNT9B,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Menopausal syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,CXCR4 gene|CXCR4,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,LINC00667 gene|LINC00667,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation Abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Animal feed (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,SPON2 gene|SPON2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,CRABP2 gene|CRABP2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BTG4 gene|BTG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZSCAN1 gene|ZSCAN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP20 gene|USP20,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,AFAP1-AS1 gene|AFAP1-AS1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,PFKFB3 gene|PFKFB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,treatment options,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,hydroxybenzoic acid,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
AFFECTS,Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Toxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Immunoregulation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Singlet Oxygen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Bone Morphogenetic Protein Receptors,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,ZNF451 gene|ZNF451,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"Genes, env|ERVW-1|ERVK-20|ERVK-18|ERVK-32",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,RAD52 gene|RAD52,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CCR7 gene|CCR7,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXXC5 gene|CXXC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TYMSOS gene|TYMSOS,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,systemic administration,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cancer Relapse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IMPACT gene,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Axillary node METASTASIS,Breast cancer stage II,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,NR1D1 gene|NR1D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,anastrozole,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
AFFECTS,HLA-G gene|HLA-G,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,DLGAP5 gene|DLGAP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"IL5 protein, human|IL5",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Transformation, function",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BCPR Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,EZH2 gene|EZH2,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,BHLHE41 gene|BHLHE41,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,medroxyprogesterone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,SHC4 gene|SHC4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,USP4 gene|USP4,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SRRM4 gene|SRRM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PTK2 gene|PTK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SKP2 gene|SKP2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP30 gene|USP30,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AIMP2 gene|AIMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,FOXO1 gene|FOXO1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWIST1 gene|TWIST1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,"PIK3CB protein, human|PIK3CB",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"TLR2 protein, human|TLR2",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,NSUN2 gene|NSUN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXA2 gene|FOXA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXO8 gene|FBXO8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORA73B gene|SNORA73B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SCARNA4 gene|SCARNA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PLK4 gene|PLK4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR130A gene|MIR130A,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
CAUSES,"membrane protein, SARS-CoV-2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Mutant Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,progesterone,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
AUGMENTS,Protease Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,RBMS3 gene|RBMS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Non-infiltrating lobular carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SF3A2 gene|SF3A2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,COL5A1 gene|COL5A1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MTA1 gene|MTA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,obeticholic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Hypolipidemic Agents,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Cessation of life,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ETNK1 gene|ETNK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,Steroids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Steroid
AUGMENTS,Protein Isoforms|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,protein-tyrosine kinase c-src|SRC,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Human Papilloma Virus Vaccine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AFFECTS,Testosterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Bicarbonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carcinomatous peritonitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RAI3 gene|GPRC5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Metastasis Suppressor Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,VIP gene|VIP,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
DISRUPTS,STK11 gene|STK11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,C-Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Carcinogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,IRF2 gene|IRF2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
CAUSES,"Embolism, Tumor",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,DNA Methyltransferase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,SMAD2 gene|SMAD2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
DISRUPTS,BRCA2|BLID,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,neuropeptide Y|NPY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SMAD2 gene|SMAD2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,"DNA, Double-Stranded",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,SMAD3 gene|SMAD3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AFFECTS,Systemic disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,"Genes, Immunoglobulin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Progesterone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,DDX26 gene|INTS6|DDX56,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ADORA2B gene|ADORA2B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, env|ERVW-1|ERVK-20|ERVK-18|ERVK-32",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Oral Solution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
CAUSES,MIRN205 gene|MIR205,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fusion Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Hepatitis C virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Invasive Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Eukaryotic Initiation Factor-4E|EIF4E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of gastrointestinal tract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,MIRN200B gene|MIR200B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TP53BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pharmaceutical Preparations,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MMP14 gene|MMP14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptors, Tumor Necrosis Factor, Type II",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FGF1 gene|FGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lymphatic Diseases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,VEGFC gene|VEGFC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of cervix uteri,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DOCK1 gene|DOCK1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIRN203 gene|MIR203A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Promoter Regions (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,aldehyde dehydrogenase 1|ALDH1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD29 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Antagonists,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,ABCC1 gene|ABCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tamoxifen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,KIF20A gene|KIF20A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Glucosephosphate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRCA2 gene|BRCA2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,WBP2 gene|WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Regulatory Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,mdm2 protein|SLURP1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Cholangiocarcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Gene Mutation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,"12-Hydroxy-5,8,10,14-eicosatetraenoic Acid",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Relationship problems,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Secondary malignant neoplasm of axilla,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Malignant disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,leukemia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,S-Phase Fraction,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,sterculic acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,Aflatoxin B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,fibrosarcoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cellular Retinoic Acid Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cerebellar degeneration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Response Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,dromostanolone propionate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Ductal Breast Carcinoma,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,FGFR1 gene|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,blood lipid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,placental protein 11|ENDOU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
COMPLICATES,Pleural effusion disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Specific antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,Sulfhydryl Compounds,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Chemical
PREDISPOSES,Carcinogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,"Genital Diseases, Female",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Small T-Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,NME1 gene|NME1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Serine Protease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,sarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prostate-Specific Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,Cyclin Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Immunotoxins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Tumor Suppressor Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NRG1 gene|NRG1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,cyclooxygenase 2,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Nucleic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,COMT gene|COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, Homeobox",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AR gene|AR,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,SHBG gene|SHBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Amplification,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Transcriptional Repression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LTA gene|LTA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nuclear Matrix-Associated Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neuropeptide Y Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"ESR1 protein, human|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Testosterone Propionate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,Peptide Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Matrix Metalloproteinases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,5-lipoxygenase-activating protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Thyroid Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Tissue-Inhibitor of Metalloproteinase-1|TIMP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,VEGF gene|VEGFA,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fluctuation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnostic radiologic examination,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Adhesions,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,EP300 gene|EP300,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTN gene|PTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Malignant neoplasm of prostate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Ha-ras Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Testicular Diseases,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
PREDISPOSES,"Receptors, Progesterone|PGR",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,Tissue factor antibody,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Insulin-Like Growth Factor II|CD74|GCNT2|TCN2|VIPR1|TAF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"LGALS3BP protein, human|LGALS3BP",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin E,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
AFFECTS,Hormone Receptor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,LGI1 gene|LGI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BMI1 gene|BMI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SKI gene|SKI,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Functional RNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TNFSF11 gene|TNFSF11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Encounter due to drug use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"Receptors, Progesterone|EREG|ESR1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Aromatase Inhibitors,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Hormone
DISRUPTS,letrozole,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Estrogens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SKP2 gene|SKP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IL2 gene|IL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TP53 gene|TP53,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,"Histiocytoma, Malignant Fibrous",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cellular process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,ALK gene|ALK,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Drug resistance,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,"Cholesterol, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,HIF1A gene|HIF1A,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,LDL Cholesterol Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ERBB4 gene|ERBB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Retinoblastoma Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,"DNA, Single-Stranded",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Estrogens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AFFECTS,epidermal growth factor receptor VIII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Angiogenesis Inhibitors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,GAPD gene|GAPDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Oncogene ErbB2|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proto-Oncogene Proteins p21(ras),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,protein kinase C zeta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,parathyroid hormone-related protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CNS disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Cytotoxic T-Lymphocyte-Associated Protein 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Vitamin D Deficiency,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,APP gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,IL4 gene|IL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KLF8 gene|KLF8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Membrane Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,KNG1 gene|KNG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fibroblast Growth Factor Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Acute inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Proteins,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,COX7A2L gene|COX7A2L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,mead acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Metabolic syndrome,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
AFFECTS,Protein antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MIRN182 gene|MIR182,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Sulfonylurea Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,bone morphogenetic protein 4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BMI1 gene|BMI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antihypertensive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,apolipoprotein E-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Dyslipidemias,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Lipid
AFFECTS,"Cystadenocarcinoma, Serous",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Inflammatory disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,MFAP5 gene|MFAP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Expression,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SMAD3 gene|SMAD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Secretory Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cilium biogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fatty Acid-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Benzene,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Tumorigenesis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,KISS1 gene|KISS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sleep Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,copper-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ID2 gene|ID2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIRN21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tamoxifen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,ARHGEF5 gene|ARHGEF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SENP2 gene|SENP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Fibroblast Growth Factor Receptor 1|FGFR1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Thioctic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,DNA amplification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,BCL2 gene|BCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factor beta,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Pathogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinogenesis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,ETS1 gene|ETS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Need for isolation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Colorectal cancer metastatic,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,E2F4 gene|E2F4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DMBT1 gene|DMBT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,retinoic acid receptor beta 2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Chemical
AFFECTS,Phosphoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cyclic AMP-Responsive DNA-Binding Protein|CAMP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,attenuation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3|IGFBP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GAB2 gene|GAB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant Neoplasms,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tumor Promoters,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BRCA1 Protein|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Transcription Repressor/Corepressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Local excision,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,G22P1 gene|XRCC6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Invasive Lesion,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Disease Progression,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"TERT protein, human|TERT","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CBS gene|CBS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,childhood brain tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,EEF1A2 gene|EEF1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gonadal Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,SKP2 gene|SKP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Malignant neoplasm of breast,bilateral breast cancer,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alcohol consumption,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Testosterone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,GLO1 gene|GLO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GNRHR gene|GNRHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"RNA, Messenger","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TACSTD2 gene|TACSTD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CXCR3 gene|CXCR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epstein-Barr Virus Infections,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Proteins,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IL23R gene|IL23R,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BRCA2 gene|BRCA2,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AUGMENTS,MIRN27A gene|MIR27A,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,AR gene|AR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,vitamin supplement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,RHOC gene|RHOC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ionizing radiation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vaccination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,WNT2 gene|WNT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Agent,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Sequence,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Nucleotide Sequence
PREDISPOSES,STK11 gene|STK11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,ADM gene|ADM,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vascular Endothelial Growth Factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Gonadal Steroid Hormones,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AFFECTS,FOS gene|FOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MIRN370 gene|MIR370,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,mRNA Expression,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Prevention,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cyclooxygenase 2 Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Estrogen Receptors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IL1A gene|IL1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of breast,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
PREDISPOSES,apolipoprotein E-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Sirolimus (substance),Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Substance
AFFECTS,Cessation of life,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,proto-oncogene protein c-crk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Materials,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,TCF4 gene|TCF4|TCF7L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Functional RNA,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Insulin-Like Growth Factor I|IGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Phosphatidylethanolamine Binding Protein|ZHX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Fibroblast Growth Factor 7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,YARS gene|YARS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK2 gene|CHEK2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,calcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,methionine synthase reductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carcinoma in Situ,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Sexual Dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MIRN210 gene|MIR210,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCL2 gene|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KISS1 gene|KISS1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Dissociation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"PTTG1 protein, human|PTTG1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CA-15-3 Antigen,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Immunologic Factor
AFFECTS,Protein Expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"PER2 protein, mammalian",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bilateral breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estrogen Receptor Status,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TP53 gene|TP53,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,MAPK12 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Promoter (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Single Nucleotide Polymorphism,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Endometrial Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Aryl Hydrocarbon Receptor|AHR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,aldehyde dehydrogenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PTGS2 gene|PTGS2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,PROTEIN KINASE|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,E2F5 gene|E2F5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Fertility Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,TOP2A gene|TOP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCND1 gene|CCND1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,disorder control,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,PTPRC gene|PTPRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL14 gene|CXCL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Bone Morphogenetic Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ELK3 gene|ELK3|KCNH8,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,"Metabolic Detoxication, Drug",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Infiltration,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Nuclear Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PDCD1 gene|PDCD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Peptide YY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Malignant neoplasm of breast,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CUL2 gene|CUL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PIK3CA protein, human|PIK3CA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lymphocytic infiltration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Carbon Dioxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CLDN1 gene|CLDN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SIDT1 gene|SIDT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Respiration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Minerals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,"Translation, Genetic",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Ablation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tacrolimus binding protein 4|FKBP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"FBXW7 protein, human|FBXW7",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,protein kinase C nu|DIO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Genes, Regulator",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SFN gene|SFN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,B lymphocyte-induced maturation protein 1|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Desire for food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Short Sleeper Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Matrix Metalloproteinase 9,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Messenger",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Pharmaceutical Preparations,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Pharmacologic Substance
AFFECTS,TP53,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Breast Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"CD69 protein, human|CD69",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,hydroxybenzoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Household composition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ELAVL1 gene|ELAVL1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNA 335-5p,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Stat3 protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"RNA, Long Untranslated",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TSIX gene|TSIX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCL18 gene|CCL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RPS6KA6 gene|RPS6KA6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Growth Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,elements of cancer genetics risk assessment and counseling,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Clinical information:Finding:Point in time:^Patient:Narrative,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PLSCR1 gene|PLSCR1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXXC5 gene|CXXC5,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,MYH10 gene|MYH10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Single Nucleotide Polymorphism,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,BRCA1 Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNASE1L2 gene|DNASE1L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Syndrome,"Breast Cancer, Familial",0.0,Female Breast Cancer,Disease or Syndrome
AFFECTS,WDR41 gene|WDR41,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEUROD1 gene|NEUROD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZNF326 gene|ZNF326,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,C5 gene|C5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Fatty Acids, Essential",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
CAUSES,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TGFB1 gene|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RCC2-AS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPX gene|SPX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNF5 gene|RNF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chronic inflammatory disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Tumor Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Peptide Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Beta protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,AGTR1 gene|AGTR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Educational Status,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC01705 gene|LINC01705,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATF3 gene|ATF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CONOTRUNCAL ANOMALY FACE SYNDROME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
COMPLICATES,parathyroid hormone,Carcinoma breast stage IV,0.0,Female Breast Cancer,Hormone
CAUSES,PDCD4-AS1 gene|PDCD4-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR30E gene|MIR30E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SLC6A2 protein, human|SLC6A2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,cytokine,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,SETD5 gene|SETD5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CPEB1 gene|CPEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR497 gene|MIR497,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SYVN1 gene|SYVN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,SOX4 gene|SOX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CYP27A1 gene|CYP27A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SEMA7A gene|SEMA7A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Hemeproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cellular signal transduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FABP7 gene|FABP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Advanced Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ZC3H13 gene|ZC3H13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ING4 gene|ING4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GAS6 gene|GAS6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NUDT3 gene|NUDT3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,hormone response element,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,LINC00511 gene|LINC00511,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IQGAP1 gene|IQGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CARNS1 gene|CARNS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWIST1 gene|TWIST1,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,IMPACT gene,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,HNF1A-AS1 gene|HNF1A-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,cyclic compound,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,GFUS gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,SEMA7A gene|SEMA7A,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00665 gene|LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00665 gene|LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lupus Coagulation Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"GAS41 protein, human|YEATS4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Epigenome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PCAT1 gene|PCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCC9 gene|ABCC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Piwi-Interacting RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,SNHG6 gene|SNHG6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,POU4F1 gene|POU4F1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PPARGC1B protein, human|PPARGC1B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC00511 gene|LINC00511,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Matrix Metalloproteinase 9,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MIR137 gene|MIR137,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FZD2 gene|FZD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NME1 gene|NME1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,MALAT1 gene|MALAT1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,IMPACT gene,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,DNAJA1 gene|DNAJA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,hyaluronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,LRRC3B gene|LRRC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Non-Cancer Related Death,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HSP90AA2P gene|HSP90AA2P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,STAT5A gene|STAT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"IL5 protein, human|IL5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,FOXP3 gene|FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"WWTR1 protein, human|WWTR1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CDKL3 gene|CDKL3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
COMPLICATES,FBXL16 gene|FBXL16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"CD69 protein, human|CD69",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Primary MicroRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,CDH4 gene|CDH4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SEPTIN9 gene|SEPT9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AFFECTS,RUNX2 gene|RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Teratogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZNF24 gene|ZNF24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SNAI2 gene|SNAI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,H1-5 gene|HIST1H1B,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,STC1 gene|STC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Carcinomatosis,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TRIM31 gene|TRIM31,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclin-Dependent Kinase Inhibitor Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,DNA Modification Methylases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Integral Membrane Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,cholesterol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Lipid
AFFECTS,Functional modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,YAP1 gene|YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MCM4 gene|MCM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EIF4EBP1 gene|EIF4EBP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stat3 protein,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Protein Phosphatase 2A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CDK1 gene|CDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Growth Differentiation Factor 15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aryl Hydrocarbon Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Cancer Model,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AUGMENTS,VEGFA gene|VEGFA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Promoter Regions, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit 1, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,SP6 gene|SP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRIM32 gene|TRIM32,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,ATP11B gene|ATP11B,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,ATG4A gene|ATG4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"TFF3 protein, human|TFF3",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ATP2B1 gene|ATP2B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MRPS30-DT gene|MRPS30-DT,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MIR342 gene|MIR342,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"BMI1 protein, human|BMI1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,STING1 gene,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,CLTC gene|CLTC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,WTAP gene|WTAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PPP1R14C gene|PPP1R14C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,DSTN gene|DSTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRIM28 gene|TRIM28,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,PSAT1 gene|PSAT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00466 gene|LINC00466,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,NAA25 gene|NAA25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CD29 Antigen|B3GNT2|B3GNTL1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
DISRUPTS,TLN1 gene|TLN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,DANCR gene|DANCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,WASF3 gene|WASF3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATP6AP2 gene|ATP6AP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PINK1 gene|PINK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,AKAP3 gene|AKAP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SETDB1 gene|SETDB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLF8 gene|KLF8,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NEK2 gene|NEK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MAFG-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FOXD3-AS1 gene|FOXD3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ADGRF1 gene|ADGRF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,MND1 gene|MND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MAFG-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CDK11A gene|CDK11A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,oleanolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,MBNL1-AS1 gene|MBNL1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SDC1 protein, human|SDC1",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC02620 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Scorpion Venoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Toxic Epidermal Necrolysis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Primary Sj??gren's syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,TRIM4 gene|TRIM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MFNG gene|MFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Heat-Shock Proteins 70,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Angiogenic Process,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Phenomenon or Process
AUGMENTS,MAZ gene|MAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FANCM gene|FANCM,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,BIRC5 gene|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NR2E1 gene|NR2E1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,TNFRSF9 gene|TNFRSF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NAT10 gene|NAT10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IGHE gene|IGHE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,NUP210 gene|NUP210,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR409 gene|MIR409,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CENPK gene|CENPK,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Operation on breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TRIO gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Positron Emission Tomography and Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,JMJD6 gene|JMJD6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE2C gene|UBE2C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ROBO3 gene|ROBO3,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,"TRIM25 protein, human|TRIM25",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,trastuzumab,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"GTP-Binding Nuclear Protein Ran, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Polypeptides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PTPN7 gene|PTPN7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,COL11A1 gene|COL11A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GNG5 gene|GNG5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acclimatization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ICOS gene|ICOS,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Neonicotinoid insecticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Invertebrate
PREDISPOSES,SYNJ2BP-COX16 gene|SYNJ2BP-COX16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IL1RN gene|IL1RN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,WFDC21P gene|WFDC21P,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AUGMENTS,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,TBATA gene|TBATA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WNT9B gene|WNT9B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,SAV1 gene|SAV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNF126 gene|RNF126,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAC1 protein|PDC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hormones,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Hormone
AFFECTS,DNA Binding Agent,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,PFKP gene|PFKP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADCY5 gene|ADCY5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,PRDM16 gene|PRDM16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adult Liver Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGF2BP2 gene|IGF2BP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Cancer/Testis Antigen,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AFFECTS,Adverse reaction to drug,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Lymphatic Invasion,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,laser irradiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Endocrine Disruptors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,"DNA, Catalytic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PHGDH gene|PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Selective Estrogen Receptor Down Regulator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"PON2 protein, human|PON2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,KLF9 gene|KLF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,RNF43 gene|RNF43,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CLDN4 gene|CLDN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Receptor alpha,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of endometrium,hereditary breast/ovarian cancer - BRCA1,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHMP4A gene|CHMP4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PCAT19 gene|PCAT19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of lung,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,vitamin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Very low density lipoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"NEK9 protein, human|NEK9",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PZP gene|PZP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AEBP1 gene|AEBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,dose-response relationship,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GABRD gene|GABRD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR93 gene|MIR93|MIR9-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antisense RNA,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,RNA,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Tn antigen,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Immunologic Factor
AFFECTS,Apoptosis Inhibiting Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cell-Free DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Structural modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,KRT1 gene|KRT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SOAT1 gene|SOAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,bone morphogenesis,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proto-Oncogene Proteins p21(ras)|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cervical Cancer Screening,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,SNHG11 gene|SNHG11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Peptides,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of breast,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
CAUSES,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,CD24 gene|CD24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MIR195 gene|MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPATA13 gene|SPATA13,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Untranslated",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Carcinoembryonic Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"IL7 protein, human|IL7",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,fos-related antigen 1|FOS,Carcinoma breast stage IV,0.0,Female Breast Cancer,Immunologic Factor
PREDISPOSES,USP10 gene|USP10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Administration, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CKS2 gene|CKS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TIPARP gene|TIPARP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CDC2 Protein Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,LILRB1 gene|LILRB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TENM1 gene|TENM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of breast,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,ULBP2 gene|ULBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PDGFRB gene|PDGFRB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Suppressor Genes,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHRNA6 gene|CHRNA6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC-ROR gene|LINC-ROR,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPNMB gene|GPNMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,POU4F1 gene|POU4F1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,BCSC-1 Protein|VWA5A,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,FNDC5 gene|FNDC5,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORA73B gene|SNORA73B,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,"PIK3CB protein, human|PIK3CB",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,paired basic amino acid cleaving enzyme,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Hypolipidemic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,HDAC2 gene|HDAC2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Cancer Prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"BSG protein, human|BSG",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,HINT1 gene|HINT1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LILRB2 gene|LILRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,pyruvate dehydrogenase kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Low-Density Lipoproteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"PKN1 protein, human|PKN1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,cyclooxygenase 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,caffeic acid phenethyl ester,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Secondary malignant neoplasm of skin NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"MCL1 protein, human|MCL1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BUB1 gene|BUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Protein Isoforms|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Pharmaceutical Preparations,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,CCAAT-Enhancer-Binding Proteins|EBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Methylation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RAD51C gene|RAD51C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FGF10 gene|FGF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TACC2 gene|TACC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,targeted prevention,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MicroRNAs,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,MIRN23A gene|MIR23A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin D,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Food
PREDISPOSES,Vegetable Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RBM5 gene|RBM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,perfluorooctanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Docosahexaenoic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Agent,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,MIRN326 gene|MIR326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SP1 gene|SP1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Chemotherapeutic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Carcinogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,SP1 gene|SP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Excision,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adaptor Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,HOXA9 gene|HOXA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIRN195 gene|MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,XRCC5 gene|XRCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PAWR gene|PAWR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,N-Acetylneuraminic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Metalloproteases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Radioisotopes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Sporadic Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MYC Family Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ERBB2 gene|ERBB2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Developmental Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,K-ras Oncogene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Growth Factor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High energy food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Malignant transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nucleic Acids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,"Leukemia, Myelocytic, Acute",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Metals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Serine Proteinase Inhibitors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,bone sialoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Maximal Voluntary Ventilation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NCOA2 gene|NCOA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hepatocyte Growth Factor,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
AFFECTS,Acylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Conception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glucose Transporter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Drug resistance,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Cesarean section (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GSTO2 gene|GSTO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Complement System Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptors|EREG|ESR1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Carcinoma, Cribriform","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Endocrine Surgical Procedures,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,PROTEIN INTAKE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ras Oncogene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,Malignant Neoplasms,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immunologic Deficiency Syndromes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Estrogenic,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,"Markers, DNA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Serum,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Body Substance
AFFECTS,monoclonal antibody CC49,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AUGMENTS,Fibroblast Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Radiation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,impaired glucose tolerance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
CAUSES,leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Stabilization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ras Oncogene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,N-Acetylneuraminic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,SYK gene|SYK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Estrogens, Catechol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vitamin E intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,parathyroid hormone-related protein|PTHLH,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,alpha-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,BCAS2 gene|BCAS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ingestion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,P-Glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tetranucleotide Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Endometrial adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SMAD4 gene|SMAD4,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,ETS Variant Gene 6 Protein|ETV6,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,parathyroid hormone-related protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Leukemia P388,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Cardiovascular Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Peptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Chemotherapeutic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Lymphocyte antigen CD82|CD82,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,GSTP1 gene|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PTEN gene|PTEN,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Dissection,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Agent,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Chemical Viewed Functionally
AUGMENTS,Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Epidermal Growth Factor Receptor|EGF,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Biologically Active Substance
CAUSES,Malignant Neoplasms,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
DISRUPTS,BCL2 gene|BCL2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Restriction fragment length polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Transforming Growth Factor alpha,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Prostaglandins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
AFFECTS,WWOX gene|WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Selective Estrogen Receptor Modulators,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"Cell Transformation, Neoplastic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"PRSS8 protein, human|PRSS8",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Axillary Lymph Node Dissection,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Radioisotopes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Gene Amplification,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmaceutical Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Protein Tyrosine Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"Estrogens, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Growth Factor Receptors,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
DISRUPTS,"Linoleic Acids, Conjugated",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ubiquitin-protein ligase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Specific antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AUGMENTS,glutathione S-transferase pi,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"O-(glucuronic acid 2-sulfate)-(1--3)-O-(2,5)-andydrotalitol 6-sulfate",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Tumor Suppressor Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Polymorphism, Genetic",Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL12 gene|CXCL12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Fibroblast Growth Factor Receptor 2|FGF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,STK6 gene|AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Regulatory Sequences, Nucleic Acid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Environmental Estrogen,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hormone
PREDISPOSES,Disease,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
AFFECTS,CDK10 gene|CDK10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Benzene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,APC gene|APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"FOLR1 protein, human|FOLR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HSD17B2 gene|HSD17B2|HSD17B7P2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dietary Modification,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Second Primary Cancers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Glial Fibrillary Acidic Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Oncogene Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Tumor proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CYP2C19 gene|CYP2C19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,S-Adenosylmethionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NCSTN gene|NCSTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DEK gene|DEK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Long chain fatty acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Heat shock proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,BCAR1 gene|BCAR1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,TEK gene|TEK,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sleep Deprivation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MST1R gene|MST1R,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,ITGA5 gene|ITGA5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,epithelial cell differentiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Human Papilloma Virus Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AUGMENTS,VCP gene|VCP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GLI1 gene|GLI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"PTH protein, human|PTH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoid Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,IL8 gene|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,DNAJA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"progesterone, micronized",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,"Carcinoma, Ductal, Breast",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Paget's Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,"[M]Adenocarcinoma, metastatic, NOS",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,"CTTN protein, human|CTTN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SNX9 gene|SNX9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PML gene|PML,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Post-Transcriptional Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Epstein-Barr virus DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Vitamin D Deficiency,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
CAUSES,BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIRN10A gene|MIR10A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SULF2 gene|SULF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Metaplastic carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CD4 gene|CD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RORA gene|RORA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,"DICER1 protein, human|DICER1","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Little's Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Uridine Diphosphate Sugars,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Functional RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mitogen-Activated Protein Kinase 13|MAPK13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,9-deoxy-delta-9-prostaglandin D2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Eicosanoid
DISRUPTS,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,bone morphogenetic protein 6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin B1 Intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,CDKN1C gene|CDKN1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TP53 gene|TP53,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RHOC gene|RHOC,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,LATS2 gene|LATS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RELN gene|RELN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AUGMENTS,"PER2 protein, mammalian|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,mitochondrial DNA replication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,peptide T amide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"HDAC5 protein, human|HDAC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FYN gene|FYN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FOXO3A gene|FOXO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,hepatitis B virus X protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NOTCH1 gene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogens,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Hormone
AFFECTS,LAPTM4B gene|LAPTM4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Activated-Leukocyte Cell Adhesion Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Fusion Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,parathyroid hormone-related protein|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,PAWR gene|PAWR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BCL6 gene|BCL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Growth Factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,ITGB3 gene|ITGB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MIRN423 gene|MIR423,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Tomography, Emission-Computed",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DICER1 gene|DICER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Peutz-Jeghers Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Pancreatic carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,SYK gene|SYK,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,HNRPM gene|HNRNPM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmaceutical Preparations,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Saethre-Chotzen Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"UBD protein, human|UBD",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ERR1 protein|ESRRA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Oncogenes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
COMPLICATES,Sterol Regulatory Element Binding Protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MMP2 gene|MMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,alpha-Fetoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Fusion Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BLM gene|BLM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DDR2 gene|DDR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SMYD3 gene|SMYD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"HDAC5 protein, human|HDAC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ARHI gene|DIRAS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CYP2B6 gene|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ARHI gene|DIRAS3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,participation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Organic solvent product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Angiogenesis Factor,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of prostate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Transcription, Genetic",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,High Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Monocyte Chemoattractant Protein-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Gene Products, Protein",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Oncogene, RET|RET",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,protein kinase D,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"CHEK1 protein, human|CHEK1",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Vitamin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Invasive Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Nucleolar Organizer Region,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hormone level abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,monocyte activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,retinoic acid receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Nucleosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Myristic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Cell Cycle Checkpoint Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Gonadotropin-Releasing Hormone Analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,NOS3 gene|NOS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Recreation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of thyroid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alcohol consumption,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CD4 gene|CD4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptor beta|ESR2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Down-Regulation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LAPTM4B gene|LAPTM4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PSMD10 protein, human|PSMD10",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CLDN1 gene|CLDN1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,PRL gene|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sex Hormone-Binding Globulin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Liver and Intrahepatic Biliary Tract Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Cytotoxic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,DNAJC27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Secondary malignant neoplasm of lymph node,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Endocrine therapy,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Hormone
PREDISPOSES,TRANSCRIPTION FACTOR,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RBL2 gene|RBL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MASS LESION,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Anesthesia, Conduction",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TGFBR2 gene|TGFBR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sequela of disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Radiation therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast Microcalcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endocrine Gland Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,TRANSCRIPTION FACTOR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oncogenic Viruses,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Encounter due to Screening for malignant neoplasm of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Infiltration,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glutamic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Fibroblast Growth Factor 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,genetic element,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SBEM protein, human|MUCL1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,WT1 gene|WT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PTGS2 gene|PTGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CHES1 gene|FOXN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Phospholipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,XRCC5 gene|XRCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Candidate Disease Gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Placental Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,NFKBIA gene|NFKBIA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cholesterol Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,TNFRSF1B gene|TNFRSF1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Morphogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen-progestin preparation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,CCAAT-Enhancer-Binding Protein-delta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ZNF365 gene|ZNF365,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LHX1 gene|LHX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERCC3 gene|ERCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNASE3L gene|DROSHA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogenic,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Ductal Carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,oncoprotein p21|CDKN1A|SLC12A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Single Nucleotide Polymorphism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Dietary Modification,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,ETV4 gene|ETV4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ovulation Induction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SRC gene|SRC,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,FCGR3A gene|FCGR3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,S 1 (combination),Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CONSTITUTIONAL ORIGIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Bone Morphogenetic Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Epstein-Barr Virus Infections,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TRANCE protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Syndrome,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,Angiogenesis Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PMS2 gene|PMS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,fatty acid amide hydrolase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
PREDISPOSES,Endocrine System Diseases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
COMPLICATES,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,XRCC1 gene|XRCC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Phytoestrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,ID2 gene|ID2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,LATS1 gene|LATS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MDM2 gene|MDM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,ubiquitin-protein ligase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,HMGN2 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,"Genome, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GJB2 gene|GJB2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTH-Parathyroid hormone level result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Recurrent Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MIRN106A gene|MIR106A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,v-myb Genes|MYB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Circadian Rhythm Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,CDK6-associated protein p18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ubiquitin-protein ligase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,reverse transcription polymerase chain reaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TSLP protein, human|TSLP",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Secondary malignant neoplasm of spinal cord,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,bone sialoprotein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,PIM1 gene|PIM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Oligonucleotides, Antisense",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Solvents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Pancreatic carcinoma,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,centromere protein F,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIRN133B gene|MIR133B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WISP1 gene|WISP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Paracrine Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LIMS1 gene|LIMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SIX1 gene|SIX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SULF1 gene|SULF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Dopamine Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
DISRUPTS,MAGI2-AS3 gene|MAGI2-AS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cell-Free DNA,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,beta-site APP cleaving enzyme 1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Enzyme
AFFECTS,systemic administration,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chronic disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,KDM6A gene|KDM6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Interferon Signaling Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,Fibroblast Growth Factor 2|FGF2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,UGT1A4 gene|UGT1A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ATOX1 gene|ATOX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"KISS1R protein, human|KISS1R",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,DNA Repair Gene,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
CAUSES,DNA Modification Methylases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Promoter Regions, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GAS1 gene|GAS1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,F2R gene|F2R,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00668 gene|LINC00668,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,tumor protein D52|TPD52,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SH2B3 gene|SH2B3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Carcinogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,MRTFA gene|MKL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FDG-Positron Emission Tomography and Computed Tomography Scan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,lead,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,SEPT7 gene|SEPT7,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Apolipoprotein E|APOE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,GATA3 gene|GATA3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,AGO1 gene|AGO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antineoplastic Agents,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,CSK gene|CSK,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptors, Progesterone",Breast cancer stage III,0.0009990009990009,Female Breast Cancer,Hormone
AFFECTS,Microinvasive tumor,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estrogen Receptors,Breast cancer stage III,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Antagonists,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,ATF4 gene|ATF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PBX1 gene|PBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,VLDLR gene|VLDLR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,WNT6 gene|WNT6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SIRT3 gene|SIRT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TGFB1 gene|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZBTB1 gene|ZBTB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CXCR2 gene|CXCR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IQGAP1 gene|IQGAP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,PSMG3-AS1 gene|PSMG3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HER2/Neu Positive,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,FBXW5 gene|FBXW5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,EPDR1 gene|EPDR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SPINT1-AS1 gene|SPINT1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCR1 gene|CXCR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR26B gene|MIR26B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,TUFT1 gene|TUFT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Alternative Splicing,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,ZG16B gene|ZG16B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Photosensitizing Agents,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,KMT5A gene|KMT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNHG7 gene|SNHG7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SETD2 gene|SETD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"BMPR1B protein, human|BMPR1B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PKM gene|PKM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lymphangiogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Nucleic Acid Probes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Germ-Line Mutation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MEDAG gene|MEDAG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNAs,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Protein Quaking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,STIP1 gene|STIP1|TFIP11|NECAB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of oropharynx,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Non-infiltrating lobular carcinoma,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Neoplastic Process
DISRUPTS,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TPX2 gene|TPX2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IFNGR1 gene|IFNGR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,VEGFA gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR374B gene|MIR374B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,AQP3 gene|AQP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metric (substance),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Substance
PREDISPOSES,FGD5-AS1 gene|FGD5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNHG15 gene|SNHG15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNA 19B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,ZNF213 gene|ZNF213,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SRSF1 gene|SRSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAT3 gene|FAT3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Low expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Burden,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Transgenes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL6ST gene|IL6ST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cytokinesis,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Biologically Active Substance
AFFECTS,NME1 gene|NME1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,HOXB7 gene|HOXB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary carbohydrate intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,FBXO15 gene|FBXO15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RNA Polymerase I|ERVW-4,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,FGD5-AS1 gene|FGD5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TRAPPC10 gene|TRAPPC10,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,CT83 gene|CT83,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,cytokine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
DISRUPTS,PSMC2 gene|PSMC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cell Adhesion Molecules,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,FTO gene|FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,4-aminohippuric acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,PTPRT gene|PTPRT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Serine-tRNA Ligase|TRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,BRD4 gene|BRD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDCD11 gene|PDCD11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AUGMENTS,AEBP2 gene|AEBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HOXA1 gene|HOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DPP8 gene|DPP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ACE2 gene|ACE2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCNT gene|PCNT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TIMM17A gene|TIMM17A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCR5 gene|CXCR5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,DPP7 gene|DPP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Phytochemical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,PALB2 gene|PALB2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Lymphocyte antigen CD82|CD82,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,SMUG1 gene|SMUG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SEMA4C gene|SEMA4C,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,SEPTIN9 gene|SEPT9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,UBQLN1 gene|UBQLN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,human papillomavirus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
PREDISPOSES,ADAR gene|ADAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RBMS3 gene|RBMS3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOX10 gene|SOX10,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ribosomal Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Interventional procedure,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immunohistochemistry,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,CDK1 gene|CDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Indicators,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,ADAMTS9-AS1 gene|ADAMTS9-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NAA50 gene|NAA50,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammatory Bowel Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,FBXL16 gene|FBXL16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Triglycerides,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Lipid
PREDISPOSES,PVT1 gene|PVT1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,VIRMA gene|VIRMA,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,HOTAIR gene|HOTAIR,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,LINC00174 gene|LINC00174,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,BCLAF1 gene|BCLAF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NR2F1-AS1 gene|NR2F1-AS1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,GNG13 gene|GNG13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IGLC2 gene|IGLC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm Metastasis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Food Consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"herstatin protein, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IRAK3 gene|IRAK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNA 1246,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,WTAP gene|WTAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"NOS1 protein, human|NOS1|NANOS1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CALCIUM/VITAMIN D,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Food
PREDISPOSES,CGAS gene|CGAS,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cellular Apoptosis Susceptibility Protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,carbohydrate analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,TRIM72 gene|TRIM72,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fatty-acid synthase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
DISRUPTS,MicroRNA 205-5p,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,cholesterol,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Lipid
PREDISPOSES,secretory protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,DUSP8 gene|DUSP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Adrenal Gland Hyperfunction,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body position,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PSAT1 gene|PSAT1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,CCNE1 gene|CCNE1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,SIN3A gene|SIN3A,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MicroRNAs,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,YTHDF3 gene|YTHDF3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"RNA, Long Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PNO1 gene|PNO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GSDME gene|GSDME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRANSCRIPTION FACTOR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FERMT1 gene|FERMT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,G-Protein-Coupled Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR449A gene|MIR449A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,CDK18 gene|CDK18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,ILF3 gene|ILF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ROS1 gene|ROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCNA2 gene|CCNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NSRP1 gene|NSRP1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SOX13 gene|SOX13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MAFG-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00665 gene|LINC00665,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,JAG1 gene|JAG1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PIEZO1 gene|PIEZO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CHAC1 gene|CHAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Retinoblastoma Protein|RB1,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SDC1 gene|SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,H19 gene|H19|HILS1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,CDH2 gene|CDH2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Candidate Disease Gene,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,SERPINB2 gene|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DST gene|DST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ISYNA1 gene|ISYNA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TLR2 protein, human|TLR2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TFE3 gene|TFE3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,"FRAP1 protein, human|MTOR",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Vitamin D Analog,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Food
AFFECTS,ST8SIA6-AS1 gene|ST8SIA6-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Primary Sj??gren's syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"ERCC5 protein, human|ERCC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SLC16A3 gene|SLC16A3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ELOVL5 gene|ELOVL5,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factor beta Receptors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Biologically Active Substance
DISRUPTS,PTPN18 gene|PTPN18,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SPI1 gene|SPI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SARS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tumor growth,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SEMA3B-AS1 gene|SEMA3B-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antibody-Drug Conjugates,HER2-negative breast cancer,0.0,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Phytochemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Chemoimmunotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AUGMENTS,hla gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,SAA1 gene|SAA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PRSS22 gene|PRSS22,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,glutamic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Thyroid dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"PTK2 protein, human|PTK2",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Heterogeneous-Nuclear Ribonucleoprotein U,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,MIR217 gene|MIR217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TP53 gene|TP53,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Circulating MicroRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Emotional hypersensitivity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,USP46 gene|USP46,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,BCAR4 gene|BCAR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genetic Carriers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TMEM9 gene|TMEM9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP10 gene|USP10,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,Neoplastic Cell Transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hormone Receptor Positive,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,Positive Regulation of Apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IFNK gene|IFNK,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Surviving free of recurrence of neoplastic disease,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGSF9 gene|IGSF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Liver carcinoma,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,TP53 gene|TP53,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,omega-3 fatty acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,CMTM7 gene|CMTM7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, Duplicate",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Sphingolipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,GDF2 gene|GDF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ENPP1 gene|ENPP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ANXA1 gene|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,fructose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,GLIS3 gene|GLIS3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCG1 gene|ABCG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mucin-1 Antigen,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AFFECTS,"estrogen receptor alpha, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,DACH1 gene|DACH1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
DISRUPTS,"DKK3 protein, human|DKK3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DPT gene|DPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CLDN6 gene|CLDN6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,NORAD gene|NORAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LONG INTERGENIC NONCODING RNA PINKY|PNKY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Cancer Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MIR223 gene|MIR223,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SPARCL1 gene|SPARCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SFRP2 gene|SFRP2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,"YAP1 protein, human|YAP1",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"SFRP1 protein, human|SFRP1",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Immunologic Factors,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Immunologic Factor
AFFECTS,TPBG gene|TPBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptor Status - Clinical Trial Eligibility Criteria,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Pathologic Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,DSCR9 gene|DSCR9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"DDIT3 protein, human|DDIT3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,nerve growth factor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
DISRUPTS,ARHGAP25 gene|ARHGAP25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NLRP12 gene|NLRP12,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXW2 gene|FBXW2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"RTN4 protein, human|RTN4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,PEDS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IL19 gene|IL19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNAJB6 gene|DNAJB6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE3B gene|UBE3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZNF703 gene|ZNF703,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Extraction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,OTUB1 gene|OTUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MAF1 gene|MAF1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Squalene monooxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"plY protein, Streptococcus pneumoniae",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of thyroid,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KLF5 gene|KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Does ask questions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,zinc pyrithione,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Transgenes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,SFRP2 gene|SFRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SOCS3 gene|SOCS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Focal Adhesion Kinase 1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KDM2A gene|KDM2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SIAE gene|SIAE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,secreted frizzled related protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LINC02086 gene|LINC02086,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SERPINA5 gene|SERPINA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GRAMD1B gene|GRAMD1B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,DACH1 gene|DACH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PIK3CB protein, human|PIK3CB",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GBP1 gene|GBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MBD4 gene|MBD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Vitamin supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,gene therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MUTYH Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carcinogens,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,Malignant neoplasm of thyroid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CHD4 gene|CHD4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLC7A11 gene|SLC7A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CREB3L4 protein, human|CREB3L4",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,NOTCH3 gene,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,EPYC gene|EPYC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,EIF4E gene|EIF4E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"DICER1 protein, human|DICER1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MGP gene|MGP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,VAMP7 gene|VAMP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Discharge, body substance",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Substance
AUGMENTS,QSOX2 gene|QSOX2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,NUP155 gene|NUP155,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF410 gene|ZNF410,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Culture Media, Conditioned",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Luteinizing Hormone-releasing Hormone Agonist,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
PREDISPOSES,Sugars,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
CAUSES,"CDK12 protein, human|CDK12",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MIR190B gene|MIR190B,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,Friend Leukemia Integration 1 Transcription Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SCARNA4 gene|SCARNA4,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,"RAI3 protein, human|GPRC5A",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"PLK1 protein, human|PLK1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,JMJD1C gene|JMJD1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PPP1R21 gene|PPP1R21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,BICD1 gene|BICD1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SLC16A3 gene|SLC16A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hypertensive disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,ANXA9 gene|ANXA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Mutation,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,EMP2 gene|EMP2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,NDUFB3|TNFAIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Topotecan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ACSL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body mass index,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,anthracene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Methylcholanthrene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MTRR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MTA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,DYRK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Velcade,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lycopene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SMURF1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Etodolac,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Well in self,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,TARBP2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Annexin A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GATA3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,beta-cryptoxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Signal Pathways,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TARBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SELENOP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,polyphenols,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Weight Gain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,pleiotropism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Enhancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognostic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,kahweol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,INPP5J,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,heparanase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fitness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Nitrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CENPN,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Reproductive History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Menopausal Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KISS1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Regular exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ZNF410,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diabetes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nuts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Psychosocial problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Red meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Hypothalamic inhibiting factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Heterocyclic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Primigravida,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Stromal Cell-Derived Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Taxotere,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Receptors, Opioid, delta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,AKR1C3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Radial scar,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,methyl 4-azidophenylacetimidate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Catechol O-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,dihydroxyacetone sulfate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Estradiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Taxanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fulvestrant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,BSG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,6-sulfatoxymelatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Methylnitrosourea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Not significant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Citrate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Bilateral salpingectomy with oophorectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Wine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Smoking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,sulfuretin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,HSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Iodine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Clusterin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Eosinophilia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Insulin Resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MAD2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Urokinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gamma-tocotrienol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oxidative Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,palm oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tongue feature,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Blueberries,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,inhibitors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Threonine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Medical History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Genomic Stability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,bevacizumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prior Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Medical Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Xenograft procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ginkgo biloba extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,chemokine receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vimentin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oxidoreductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Baclofen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ORALIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,alpha-carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Treatment Protocols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,DHX9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cigarette Smoking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,stromelysin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Worried,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Raloxifene Hydrochloride,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,ANO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Operative Surgical Procedures,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,alpha Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Carrier status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Doxorubicin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,distilled alcoholic beverage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Flap Endonuclease-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Whole milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PARITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lymph Node Involvement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body Weight Changes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,osteopontin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Ether, Ethyl",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,humoral defense mechanism (sensu Vertebrata),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,gonadotropin inhibitor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adverse effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High fat diet NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Conflict (Psychology),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYR61,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Childbirth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Previous pregnancies 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Infertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Proanthocyanidins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Chemotherapy-Oncologic Procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Systemic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Folate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypical lobular hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BCHE|SNORA73A|ENOPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,Norplant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Menopausal symptom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,E-Cadherin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
DISRUPTS,Galectin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hyperinsulinism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Ethylnitrosourea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Free estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Operative Surgical Procedures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KAT6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Methylnitrosourea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Hydroxyestrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dietary Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mastectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Dactinomycin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Early Diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Combined Oral Contraceptives,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dysplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dehydroepiandrosterone Sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tetradecanoylphorbol Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,PREDICTED,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,methylurea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Fibronectins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tenascin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cholestyramine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ovulatory,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,4'-deoxydoxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Imidazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,paracrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"Fats, Unsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Early menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Triceps skin fold thickness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pregnancy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CATHEPSIN D|CTSD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PNMA3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,body mass,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Histopathology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fluoroscopy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cystic Fibrosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Therapeutic procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Alkaline Phosphatase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Methoxamine,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,diphenyl,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Relaxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Fucose,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Glycol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Chemotherapy, Adjuvant","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,adjuvant therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,estrophilin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Breast Fibrocystic Change, Proliferative Type",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,G-Actin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Theophylline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cisplatin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aggressive behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Screening mammography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
COMPLICATES,Schistosomiasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Gonadorelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Chemotherapy, Adjuvant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polychlorinated Biphenyls,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dietary fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Brain hemorrhage,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alleles,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"(meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(II)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Long menstrual cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tobacco,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Receptors, Nuclear",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,beta catenin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Beer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Antioxidants,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CAMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Silicones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Glycosylated hemoglobin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,maspin|SERPINB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Psychological adjustment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,diagnostic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,High weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Microsatellite Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mismatch Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Urokinase Plasminogen Activator Receptor|PLAU|PRAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Venoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pre-Eclampsia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Curative Surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,methylurea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dietary intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thromboembolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dieldrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,fascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Polychlorinated Biphenyls,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sausage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,cofactor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Intrinsic factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,GGCT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Amines,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Etiology, operative procedure, as cause of",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,estrone sulfatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Beer intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,trilostane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Development of the breasts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Breast Feeding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,B-pyridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mastodynia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NFKB1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,AROMATICS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Symptoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KLK14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tocopherols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Permeability,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,ATP7B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,GGCT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tryptophan|TYRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Mastitis, associated with childbirth",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SLC19A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bone Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CYR61,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Peptidyl-Dipeptidase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Immunologic Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SNAI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Mammary Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Soybean Oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PPIG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,11q13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Raloxifene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Chronic Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,maspin|SERPINB5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aneuploidy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Kininogenase|KLK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,BONE MASS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BIRTHPLACE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Skin problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mammographic breast density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,mammary gland development,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,19p13.3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Leucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,EMSY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Normal growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Environmental Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,stressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,connexin 26,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Stromal Cell-Derived Factor 1|CXCL12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Somatomedins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SPRY2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,protective factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Raloxifene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Oxidative Stress,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prenatal Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diastolic blood pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Short menstrual cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Osteoporosis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cruciferous Vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,isoflavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SLC25A18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Juice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Hemoglobin, Glycosylated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Granulocyte Colony-Stimulating Factor,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Isoleucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fat tissue increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,indole-3-carbinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Abruptio Placentae,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vegetable intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Postmenopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lobular hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Iron intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Hyperparathyroidism, Primary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Magnetic field,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Obesity,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,sulforafan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hyposensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,decaffeinated coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,mammaglobin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,ADAM12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Integrin beta3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Motility,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,CDV3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SR-2508,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PBRM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,Adverse effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,caspase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,hemagglutinin I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Menopause, Premature",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,APOA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Combined Modality Therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,beta-adrenergic receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biguanides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KLLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MLLT11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Drink,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Indigotindisulfonate Sodium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Catechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Garlic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Xeroderma pigmentosum, group C",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ultrasonography,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Androgen therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,erlotinib,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Sentinel Lymph Node Mapping,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAD50,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sedentary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BLCAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,14q31,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"2,5-dichloro-4-bromophenol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DUSP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast tenderness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,gemcitabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Screening mammography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pumpkin seeds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fruit intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Decreased translucency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,atorvastatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Collagen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nitrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Angiopoietin-2|ANG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Mucins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Folate intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Animal Feed,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body mass index,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atypical hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,BRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypoxia,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Serine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,lycopene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SRSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Nuclear Receptor Subfamily 4, Group A, Member 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,paclitaxel liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Interferon Alpha, Human|IFNA1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Insulin, Long-Acting",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Radiotherapy, Adjuvant",Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Taxol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,SPDEF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,VEGFA,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,BEX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypical antipsychotic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,METHYLATE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NCOA3|ANIB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Xenograft Model,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Progestins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,response,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RASSF1A,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thyrotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HDAC9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ITGA11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TOX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Physically active,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Niacinamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,epigallocatechin gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Paravertebral anesthesia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Psychotherapy, Multiple",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body Weight decreased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,fisetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,GM2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR655,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,peoniflorin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phosphatidylethanolamine N-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SPRY1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Depressed mood,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Fibronectins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Lipopolysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,14q24.1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,SOAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dietary fiber intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atypical hyperplasia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ARNTL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PORPHOBILINOGEN SYNTHASE|ALAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Histone Deacetylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Physical activity,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tubulin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MBTPS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ZNF423,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,6q25.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TRIM25,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR520C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Tetradecanoylphorbol Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,C6orf106,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,UBE3A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Receptors, Interleukin-1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,G0S2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Phosphoric Monoester Hydrolases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Death (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,F Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TFF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Advance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Curcumin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PLAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,docetaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Overweight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Lymph,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SETD7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,PIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CYP27A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,P2RY6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,MAGI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,diallyl disulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Performance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dietary Component,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transcript,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Metabolites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,stanniocalcin 2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Paclitaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,synaptotagmin I|RELA|SYT1|GORASP1|WNK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,EPHB2|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Soluble ErbB-1|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CYR61,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Primary Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CAMK2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,HOXD10,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Honey,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Polymerase|ERVK-9|ERVK-19|ERVK-11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Synaptophysin|SYP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ADIPOR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ISL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Granulocyte-Macrophage Colony-Stimulating Factor|CSF2|LAMC2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tocopherols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Anthocyanins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DMXL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Curcumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,POU5F1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Stromal Cell-Derived Factor 1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,myricetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ethanol,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasonography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PITX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SUMO1P3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Autophagy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SOHLH2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Clomiphene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,discoidin domain receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NEK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,O-GlcNAc transferase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ACKR3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cisplatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Dinoprostone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Transcriptase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reading,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,HRG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thrombosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GGN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SLC4A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Crisis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Calcitriol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RICTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,GACAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,preference,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Twin birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PSMB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PRMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,gefitinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cruciferous Vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,FBXL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BDE-99,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Risedronate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,recessive allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,HORMAD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,EREG|ESR1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,N-Cadherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,16q12.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,C3|ERVK-2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypothyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prognosis bad,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cell Cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,resveratrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADAM17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sunflower seed oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sun Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cytokeratin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,KDM1A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Transcript,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
CAUSES,Coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,RAP1A|RABGEF1|TERF2IP,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Mutate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,piperine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SPC24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tubulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LSINCT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,decaffeinated coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,high-dose chemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LINC00310,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Black tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Premarin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,EPHB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,EIF4G1,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,baicalein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,erbB-2 Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,racial differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Histologic type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Raloxifene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CDC16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ARHGAP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hyperthyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Compete,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Head circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cell motility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immunologic Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ARF6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alcoholic Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Progestins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,health-related beliefs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypoxia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,ZD 6126,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Mucins,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tyrphostins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Organochlorine pesticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lean body mass,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Beta Carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Osteoporosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Daily drinker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thinness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pain relief,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha-carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Amitriptyline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Somatomedins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,BNIP3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Endometriosis, site unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Insulin Resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,celecoxib,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PRSS3P2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Physical activity,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,leptin receptor|LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,sulfotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ibandronate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RGS17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Behavior showing increased motor activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fever,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Anthracyclines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Almond Nut,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Enkephalins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PRKD1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atypia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD55|TCN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Waist circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,tibolone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Diagnostic Neoplasm Staging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pancreatectomy,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,personal experience,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,syndecan 2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Minipill,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Energy Metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sentinel Lymph Node Biopsy,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,8q24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydroxyestrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DDT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Berries,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Peptidyl-Dipeptidase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,binge drinking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,17q12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,response,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FCER1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stearoyl-CoA Desaturase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Recombinant Erythropoietin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prolactin Receptor|PRLR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,capecitabine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Tocotrienols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,hemiplegia; ascending,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MUTYH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Beta-carotene intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pulse vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,claudin 6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tretinoin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Epirubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,UQCRFS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,pterostilbene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Duffy blood group phenotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Asthma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sleep disturbances,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,argatroban,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,taxane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Osteoporosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HERC4,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,responsibility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,[X]Unspecified osteoporosis with pathological fracture,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,OSU 03012,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Methylenetetrahydrofolate reductase (NADPH)|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Abdominal obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dimethyl Sulfoxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,research outcome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tomatoes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ID1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interstitial Collagenase|MMP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,APOBEC3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SULT1A1|SULT1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast size,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Underweight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RNF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Botanicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KLF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Weight fluctuates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Carboplatin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Equine laminitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GAL3ST1|SLC35A1|CASZ1|CST12P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diethylhexyl Phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypoxia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lymphedema,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,tibolone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Seizures,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bendroflumethiazide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FLII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,aurora kinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ultrasonography,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Peanut butter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Strenuous Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diffuse Scleroderma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Symptoms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Diet,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Gastrin|GAST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TLR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hypersensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Organochlorine pesticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nephroblastoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pork,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dietary Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Epithelial hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,resistin|RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Curcumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vegetables,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Reflexology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,vinorelbine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Willing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MAP Kinase Kinase Kinase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CHD5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Caffeine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,TWIST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cyclophosphamide/fluorouracil/methotrexate protocol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,XRCC6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Histopathology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Androgen Receptor|AR,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Diet, Mediterranean",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fish intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,feral,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,5-Alpha reductase inhibitor,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Follistatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Inflammatory Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TGFB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Engine Exhaust,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Receptor, Angiotensin, Type 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mass Screening,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Microsatellite Repeats,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Sentinel Lymph Node Biopsy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chinese cabbage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Screening mammography,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Environmental Tobacco Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Defense Mechanisms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Expressed Sequence Tags,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Red meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Skin necrosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOX10,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Autoantibodies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dinoprostone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PREDICTED,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vitality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KMT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,bicalutamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,oleuropein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ALKBH3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cytochrome P-450 CYP1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SLC45A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,sulfotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RHBDD1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Gelatinase B|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Discrepancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Needle biopsy procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cyclin-Dependent Kinase 10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,exemestane,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hot flushes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GGT1|GGTLC5P|GGTLC3|GGT2|GGTLC4P,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,cyclin D3|CCND3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,USP11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Ethanol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic Resonance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MAP2K3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,P-Cadherin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Doxorubicin Hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,QUINTILE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mass of body structure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Calcium Channel Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Strenuous Exercise,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,receptor activator of NF-kappaB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Exposure to,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Red breast,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Iron, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,White bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Endometrial Hyperplasia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"1,4-dioxin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Lasofoxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"1,4-dioxin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MTA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Human Development,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cullin 1|CUL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,erbB-2 Receptor|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,IARS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Proteasome inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Interleukins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ORALIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Trans Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Corticosterone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tryptophan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,TBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Body mass index procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DANCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Urokinase|PLAU|PRAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,survivin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Primary idiopathic dilated cardiomyopathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SNORA7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,NanoGel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Positive Lymph Node,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Physiological stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anisotropy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Exons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RPE65|UVRAG|TP63|CKAP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LINC00968,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNHG7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Biopsy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP1B1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PLK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GALNT16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,taxane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Red meat,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Digital mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LINC00460,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CUL4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,honokiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TUFT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Glucocorticoid Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SCUBE2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"N',N''-diacetylspermine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Gelatinase A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Electromagnetic Energy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NCAPD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Radiotherapy, Adjuvant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ginsenoside M1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Metformin hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Spermine Synthase|SMS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hip circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PCB 180,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,silybin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KDM5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognosis good,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Combined Modality Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,sulforafan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Secondary Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PRNCR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,everolimus,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stable weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ATP8A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CGRRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ZMYND10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Chemotherapy Regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dense breasts NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Low absolute lymphocyte count,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,clinical aspects,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,claudin 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Breast Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,MK 2206,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Breast-Conserving Surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Secondary Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Menopause Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Exogenous Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reproductive History,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Histamine H1 Antagonists,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Hormone
PREDISPOSES,Family history,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,beta catenin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,citronellol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,osteopontin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"ATP Binding Cassette Transporter, Sub-Family G, Member 2|ABCG2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,sulforafan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypersensitivity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Discordance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Calcium-Sensing Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,tissue-factor-pathway inhibitor 2|TFPI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,neoplasm-associated factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,High Level,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Signs and Symptoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Subjective:Finding:Point in time:^Patient:Narrative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Aggressive behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Muscle Strength,Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Quintile,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FGFR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stiffness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mammographic Breast Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Physical Inactivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,daunorubicin liposomal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,bisphenol A,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Pharmacotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,huaier,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Increased risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,concise,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,YES1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RUNX1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,interleukin-10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pathologic Response,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,antiporter,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Neuropilin-1|NRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Finding of body mass index,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fumigant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclin B1|CCNB1,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,calycopterin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,arctigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fibrin fragment D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,pristimerin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sedentary lifestyle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,kusunokinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Late Relapse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,risk factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TNF wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Puberty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,magnesium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,ergocalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,naringenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Flavanones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,wogonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,podofilox,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Antimalarials,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,sunitinib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hyperthyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ACVR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Screening procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,baicalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,simvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Excessive dietary caloric intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,APOBEC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Organophosphate pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Uptake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Chemotherapy, Adjuvant",Carcinoma breast stage I,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oils,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,c-Mer Tyrosine Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Moderate risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Present,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Progranulins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Thymidylate Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Anthracyclines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hypoxia-Inducible Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,cryptotanshinone,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Biological Neural Networks,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,mortalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Zearalenone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,resistin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lamin B2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,High Level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Elasticity Imaging Techniques,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,hereditary factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Risk Scores,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Uncertainty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Bilateral mastectomy,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,iron,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Lactates,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoadjuvant Chemotherapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immune Checkpoint Blockade,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Obesity, Abdominal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leisure physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,leptin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Calcium intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypoxia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,hydroxyl group,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Secondary Neoplasm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ovarian failure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunologic Surveillance,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,COVID-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Hypoxia-Inducible Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Zinostatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ropivacaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Body mass index procedure,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognostic Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ENTPD1 wt Allele|ENTPD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ropivacaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LOC100505851,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LOC105371267,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,receptor operated channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Graphene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydroxymethylglutaryl-CoA reductase,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thrombophilia,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Xenograft procedure,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Full Term Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cerebrovascular accident,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Hepatocyte Nuclear Factor 3-alpha|FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coronary Arteriosclerosis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ZBTB7A|AKIRIN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,fluorouracil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,baicalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stress,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Transcript,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,TLR1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endoplasmic Reticulum Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,COVID-19,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,EHD1 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fiber intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,New Diagnosis Procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ergocalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,high weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,2-(4-morpholinoanilino)-6-cyclohexylaminopurine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,High residue diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,granzyme B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pathologic Complete Response,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CARD.RISK,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,liquiritigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Autophagy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vital activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,oxaliplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Agonist,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Obesity, Visceral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ultrasound scan finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tramadol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Life Expectancy Less than Five Years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,tegaserod maleate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sports,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hypoxia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Screening mammography,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,physiological aspects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Chemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Keratin-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cisplatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Score,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolism,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Has difficulty doing (qualifier value),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"tropomyosin-related kinase-B, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pediatric Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hyperactive behavior,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,Players,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Endoplasmic Reticulum Stress,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,purinoceptor P2X4|P2RX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic Field Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypersensitivity,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,anhydroicaritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Adipokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Frailty,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dietary Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Receptor, PAR-1",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,dietary fiber intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diabetes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Chemotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Post-mastectomy radiotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,si-wu-tang,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Comorbidity,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AFFECTS,gamma-Secretase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ergocalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Helicobacter pylori,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SCG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,CD47,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Aurora Kinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,intrinsic factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Claudins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Sleep,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,catalpol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mammographic Breast Density,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Diet, Paleolithic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Inhibitor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,pigment epithelium-derived factor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Screening procedure,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Cerulenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Life Expectancy Less than Five Years,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,arsenic trioxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Liposomes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Diagnosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,metformin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,tiliroside,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Programmed cell death ligand 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Hypoxia Inducible Factor Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,genistein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Catechols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,AXL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Metabolic marker,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,beta-arrestin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prolactin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,green tea extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,eriocalyxin B,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,dietary fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Senility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,toosendanin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lactates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,clinical aspects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,eltrombopag,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,factor VII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Obesity,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,COG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasonography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Salpingo-oophorectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immune checkpoint inhibitor therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lactates,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,TYMS|PYCARD,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Fibronectins,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Life Expectancy Less than Ten Years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Severe (severity modifier),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ROR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Peripheral Nerve Sheath Neoplasm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,doxorubicin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Inflammasomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Metabolite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,alpha Catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Obesity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,interleukin-6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Protons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Performance,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,zoledronate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Caspase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,astragaloside IV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,mammaglobin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Secondary Neoplasm,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AUGMENTS,Ferritin Light Chain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,beta catenin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mitosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,risk factors,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,euphorbia factor L1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,ketamine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,andrographolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,signaling cascade,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Phosphates,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Obesity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Sesquiterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vacuum assisted biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR223 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,taxane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Inhibitor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,hydroxypropylbetadex (0.58-0.68 MS),Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,chelidonine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Chlordan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Shift worker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Stress, Psychological",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,calcifediol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Low Level,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HSP90 Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Equilibrium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Proliferative vitreoretinopathy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Complementary therapies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,clinical aspects,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,icariin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oxidoreductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Personal status - Adopted,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Tea Extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ubiquitin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Healthy Lifestyle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clinical Significance,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Secondary Neoplasm,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Performance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Obesity,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,baicalein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,thiostrepton,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Progranulins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Personal Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nitric Oxide Synthase Type II,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Motility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PAK1|PKN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Methotrexate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Adenosine A1 Receptor|ADORA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammary Neoplasms,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,indole-3-carbinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,bortezomib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,survivin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Connexins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,MMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PITPNM1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CIP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,BST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ethnic differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Catenins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,nitidine chloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KIFC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PSMB6|YY1|DLL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,cilostazol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,UBE2N,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,STMN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IQGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,profilin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KISS1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Neuromedin U|NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR98,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CENPA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,isoliquiritigenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Centchroman,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Estradiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,dihydroxyacetone sulfate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Leisure Time,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclophosphamide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thymidylate Synthase,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Orosomucoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CTCF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Phosphotransferases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,estrone sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Glutamate Carboxypeptidase II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KISS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Supraventricular arrhythmia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PFN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Sodium Selenite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,GRHL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,1-Phosphatidylinositol 4-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PELP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOX11,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,Interleukin 4 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CMA1|SLC16A1|MCAT|MCTS1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,gamma-secretase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carboxypeptidase U,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoplasm,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Epinephrine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reserpine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aspartic Endopeptidases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,chromosome 17q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Milk intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Caseins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Menstrual cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reserpine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Circadian Rhythms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,retinol acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Selenium intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Vinyl Chloride,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,N-acetyltransferase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,retinyl methyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,inhibitors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Xeroradiography,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AFFECTS,Bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,leptin receptor|LEP,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,Cyclin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Metabolites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Puberty, Female",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,valyl-valyl-valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,20q13.2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Somatotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BONE MASS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,No past history,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Molecular Abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Indoles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cadherins,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Retroviridae,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,EYA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Pill,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reproductive History,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hyaluronan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aromatic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CA1|S100A10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Binding Sites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Urea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Melatonin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Fenretinide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sterility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Benzanthracenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Absolute Alcohol,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Polyunsaturated fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PHENYL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,adjuvant therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Estrone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,hormonal changes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fluorouracil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TAG 12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Term pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alkaline Phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alkaline Phosphatase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Advance,Breast cancer stage II,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Athletics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Height / growth measure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ARGINASE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Seizures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Testicular Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammography,Breast Mucinous Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Haloperidol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Hysterectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ovariectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Prolactin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Neuromedin U|NMU,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,"Liver Failure, Acute",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Ovariectomy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Monoterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Hydrocortisone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,melanoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neurotropism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,2-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aminoglutethimide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Antipyrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Levamisole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,transglutaminase 1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Hydrocortisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Goserelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Visual impairment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Scanning,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Introns,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Flutamide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,CATHEPSIN D|CTSD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dichlorodiphenyl Dichloroethylene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
CAUSES,Acetyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"(meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(II)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Mixture,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Date of birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Short stature,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin D1|CCND1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Phenothiazines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Vegetable Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,6-pyruvoyltetrahydropterin synthase|SLC25A3|REG1A|PTPRU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Beans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Integrins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
COMPLICATES,Pathological fracture,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nulliparous,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mean blood pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,glypican 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"Smoking, Passive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ultraviolet Rays,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GRB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Premature Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Mitogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fibroadenoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"Receptors, Nuclear",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cytochrome P450 3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,estriol 3-sulfate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Disintegrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pre-Eclampsia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Endostatins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Encounter due to prophylactic surgery, unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Scanning,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,psychological stressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Depo-Provera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Stress, acute",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,3MC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Methylcholanthrene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Ibuprofen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Beta Carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ESRRA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,specific immunity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Kininogenase|KLK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ZHX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Telomerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Guanosine Triphosphate Phosphohydrolases,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Apple,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Female genital tract problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Embolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ADAM23,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CANADIAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mass in breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Prolactin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammary Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Creatinine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Receptiveness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGKV2D-40,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Methylcholanthrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,WNT7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Therapeutic procedure,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Synucleins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Androgen therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,death receptor-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Iodides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Paroxysmal atrial tachycardia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyperglycemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Thrombospondin 1|THBS1|CRISP2|PRSS55,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Increase in blood pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,AKR1C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EVL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Contraceptives, Oral",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Fibrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CHEST PATHOLOGY,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,WNT7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Spray,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,N-Cadherins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Dairy Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SLC25A18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Climacteric discomfort,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Microdochectomy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Molecular Chaperones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Integrins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prolactin level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ADRA1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pregnanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PRL increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Molecular Target,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tocotrienols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Biopsy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,E-Cadherin,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
DISRUPTS,allyl sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Tetanus Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Biological Models,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mouse Pancreatic Intraepithelial Neoplasia-1B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lymph Node Involvement,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Betaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,gamma-Glutamyl Hydrolase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Integrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Disclosure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SIRT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tea intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CATHEPSIN D|CTSD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Diethylstilbestrol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Detectors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,prolylarginine|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cortisol level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NEK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Thrombospondin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Aldosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FANCA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Cyproterone Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Development of the breasts,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
CAUSES,PIN1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Alpha tocopheryl succinate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Obesity,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Guanosine Triphosphate Phosphohydrolases,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alar,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,estradiol-17 beta-glucuronide,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptors, Notch",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Thymidine Phosphorylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Study models,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hyperthyroidism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SLC25A4|CD5|IL1RL1|TRAPPC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,erlotinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,lapatinib,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Telomerase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,JAG2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,PARP1|COL11A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD27,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vanadium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SPN|DEAF1|PPP1R9B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sex Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,TWSG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Development of the breasts,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,PIK3R1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CD24,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Levonorgestrel,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Epicatechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SH3KBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Double Strand Break Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SLC9A3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Homeostasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,2q35,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cell physiology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sphingosine-1-Phosphate Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Nicotinic Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,8q24,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,src-Family Kinases|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Microsatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,B3GNT2|B3GNTL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,FRAGMENTS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,WWP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Calcium, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Calgranulin B|S100A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BRAZILIAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,6q22.33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,brightness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,SPN|DEAF1|PPP1R9B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,FHL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Sodium Valproate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RPE65|UVRAG|TP63|CKAP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Enhancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cadherin 5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,METHYLATE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SNAI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,patient family history,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Receptors, Cytoplasmic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MS4A1|BBS9|IGKV7-3|SPANXB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Very high,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Paraffin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAB1B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,PYRUVATE CARBOXYLASE|PC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Annexin A1|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,IL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Arthralgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PIAS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Chemotaxis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,treatment method,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,betaine-homocysteine methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CYP4Z1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PRICKLE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IGF2BP2|IMMP2L|SPPL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,furanodiene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,2q33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,IL33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,OTUD1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Neurofibromin 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Annexin A3|ANXA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,galangin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,tubeimoside I,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Sulindac,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PAQR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pyrimidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SOX17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,myristoylated alanine-rich C kinase substrate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,IKBKB,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Osteopenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RHOBTB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SYF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Enhancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CTSO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PK 11195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NEUROD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Diphosphonates,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KDM6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,butylbenzyl phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prolactin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Recombinant Interferon-gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Myosin Light Chain Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pain relief,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic field,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Curcumin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Treatment Protocols,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,cyclopamine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GTF2H1|SQSTM1|KHDRBS1|NUP62|DCTN4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,sphingosine 1-phosphate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Iodine-131,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Morphine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Triazoles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ADAMTS18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Birth length,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,beta catenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Helminths,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,RAB11FIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,molecular chaperone GRP78,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TCP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,EHMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZEB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,pertuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nelfinavir,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,cucurbitacin B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,imbalance,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Hypogonadism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Atenolol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mammographic breast density,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,STX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Methylene blue,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,EIF4G2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,epigallocatechin gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammary Neoplasms,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,HIF1A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,exemestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,BCYRN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SRPK1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,capecitabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Body Weight decreased,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Calcitriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Factors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neprilysin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,EIF4G1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,resistin|RETN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Monoclonal Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cereals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Estradiol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,TCF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UGT2B4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,IQUB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SYVN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Sponges, Gauze",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LIMK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Luciferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PCDH17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DLG5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Quercetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CDK14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Does stand,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BIBR 1532,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,extracellular signal-regulated kinase 3|MAPK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PKM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SPRY4-IT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Alkaloids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADAM12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,LINC01116,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,OIP5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,polyphenols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Blue light,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,phenyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Heparitin Sulfate,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Study models,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hesperidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PDK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Garlic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Multiple Myeloma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anesthesia procedures,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Soybeans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclical mastalgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Yogurt,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UGT8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PSMD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GSTM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,src-Family Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chicken Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,S100A7,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CD24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYTH3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,2-chloroethyl ethyl sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Flavonols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Alcoholic Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Depressed mood,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ZFHX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD247,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Measles-Mumps-Rubella Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Loss of Heterozygosity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,WWOX,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,polymorphic microsatellite markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Menstrual cycle,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Reliance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PSYCHIATRIC HISTORY,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Histamine H2 Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,interleukin-23,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Acetaminophen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diphosphonates,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,benzanthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,adjuvant therapy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Strenuous Exercise,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AFFECTS,Gel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Insulin, Glargine, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,IL13Ralpha2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ataxia Telangiectasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Analgesics,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Insulin Receptor|INSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Calcium Channel Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,alcohol effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Female Homosexuality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,delta-hexachlorocyclohexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DPF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Personality Traits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Paraoxonase 1|PON1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hydroxyestrones,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,checkpoint kinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HSD11B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tenascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CXC Chemokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Simvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,bevacizumab,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Moderate Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Uniparental Disomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rubidium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,19p13.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Plasminogen Activator Inhibitor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Sitting height,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,E2F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,6/4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,capecitabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pregnancy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Metric,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RABGEF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Behavior,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AFFECTS,Thromboembolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,response,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NBN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HFE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Chemotherapy-Oncologic Procedure,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Enrich,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nipple discharge NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Symptoms,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Histopathology,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Neutropenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Asthenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Nicotine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacotherapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Physical activity,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NANOG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Breastfeeding performance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Overweight,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Depressive Symptoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anorexia Nervosa,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,crocetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,delphinidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Common wart,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LAPTM4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,COPS5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Breast Feeding, Exclusive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,everolimus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Xenograft Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Stress,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast neoplasm screening,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Multiple alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Deficient knowledge,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Taurine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Menopausal Status,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Benzodiazepines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,LINC01585,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Natural Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Physical activity,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Ibuprofen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prognostic Factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Verbal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hot water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Methotrexate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Consanguinity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Verbal,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,TBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Multiple Sclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Obesity, Morbid",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,F2RL1|NR1I2|SLC52A1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rheumatoid Arthritis,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NFKB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GHRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Animal fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,peroxiredoxin I|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GHSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Estrone sulfotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Recombinant Interferon-gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Breasts asymmetrical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Interleukin-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HSD17B6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Positive Lymph Node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Systemic Scleroderma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Life Style,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PIWIL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ANLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ethnic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gynecomastia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,WWC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adverse effects,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,pertuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Whole-Brain Radiotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Perceived comfort level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,phenylpyruvate tautomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FANCM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Obesity,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,CCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Levonorgestrel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mimicry,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Operative Surgical Procedures,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,1-Phosphatidylinositol 3-Kinase|PI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sclerosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,flavan-3-ol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Galectin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PARK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,alpha Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Calcium Channel Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bleomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Coronary Arteriosclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alcoholic Beverages,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Neoplasm,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,KDM4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cerebrovascular accident,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MDM4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,KPNA2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Positive Finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MFG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,desires,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,bufadienolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PGK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZNHIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SEMA3C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ginsenoside Rk1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Pimozide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,ZNF423,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Antidiabetics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adriamycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,caveolin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,ZNHIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SNHG7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOX8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Myocardial Ischemia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,phthalates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Leucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,shikonin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,NFE2L3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lysyllysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,G3BP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CBX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Interleukin-4,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,PPM1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Mitomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cell motility,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Liposomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Natural Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Phenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,preference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PIK3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC00339,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,VIRMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VIRMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Compete,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"3,4-Methylenedioxyamphetamine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Bariatric Surgery,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Integrin alphaVbeta3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,IDO1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,kaempferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nephroblastoma,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Diphenylamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,anillin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Poly(ADP-ribose) Polymerases|WDTC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FBXL19-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Treatment Protocols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,gadoterate meglumine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PCB 138,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SLC4A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UDP-Glucuronosyltransferase 1A1|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pigment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Formance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,hippo signaling,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Albendazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Activator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Interleukin-17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydrogel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Glioblastoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,small molecule,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Profilins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,HAND2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pre-op diagnosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Letter:Finding:Point in time:{Setting}:Document:{Provider},Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,rosemary extract,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Integrin alpha3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,socioeconomic differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,epigallocatechin gallate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Adriamycin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Underlying,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Microsatellite Instability,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,mica,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Chemotherapy, Adjuvant",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATM,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,glypican 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adipokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CTCb regimen,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,lumican,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tissue-factor-pathway inhibitor 2|TFPI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Marital Status,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,interleukin-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BET Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diagnostic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Integrin alpha5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,lovastatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,hexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Account number:Identifier:Point in time:^Patient:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FZR1 wt Allele|CDH1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,FGFR1 wt Allele|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Abnormal metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,aquaporin 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Herbicides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,caspase-3|CASP3,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pivot,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,erastin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,acetylglucosamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,purpurin 18,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,hesperetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Geldanamycin Analogue,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Flavonols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dysbiosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Therapeutic Effect,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diphosphonates,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR22 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,arbutin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diet high in saturated fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOSL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD8A wt Allele|CD8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,sunitinib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,brazilin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,leptin,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TT genotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Vitronectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CYP27B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sphingomyelins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Sleeve,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Rheumatoid Arthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclin-Dependent Kinase Inhibitor p16|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,periodate-oxidized adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Erythropoietin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Breast Imaging Reporting and Data System,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnosis,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ciclesonide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ryanodine Receptor 3|RYR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,patient characteristics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Weight decreased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,amygdalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Copy Number Polymorphism,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,SOY ISOFLAVONES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,verteporfin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,butein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,si-wu-tang,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Bilateral mastectomy,Unilateral Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,paclitaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Diphosphonates,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,interleukin-10,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,COVID-19,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pain relief,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Connexin 43|GJA1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,pristane,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,ruthenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,tripterine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Health behavior,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Phosphatidylinositide 3-Kinase Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Basis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High Level,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gamma-glutamyl transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Discoidin Domain Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Photochemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diuretics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Transcript,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pills,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,paracrine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ferroptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Central Serous Chorioretinopathy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pathologic Complete Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,paclitaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tobacco smoking behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sirolimus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Brominated Diphenyl Ethers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Flap Endonuclease-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,>40 years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclin-Dependent Kinases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,niclosamide,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Pyroptosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LOC105371267,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ITGA2B wt Allele|ITGA2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,phthalates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoplasm,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CATHEPSIN D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Possible,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,AZD4547,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,GANT 61,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Body mass index procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Liposomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immunologic Adjuvants,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Decreased translucency,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Performance,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,astaxanthin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,Hypoxia-Inducible Factor 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AMACR wt Allele,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AA genotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Genomic Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,endosulfine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,COVID-19,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,brazilian,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Healthy Lifestyle,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,fluvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,interleukin-6,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Immune,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Sleep Apnea, Obstructive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HMMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,1 time,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tea without milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Infantile Neuroaxonal Dystrophy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,doxorubicin liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sigma-2 receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,False Positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Multifactorial,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Post-mastectomy radiotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Antibodies, Bispecific",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CCL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Basis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIR191 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Monoclonal Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,fluoxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,canagliflozin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,catalpol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Score,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Transsexual (finding),Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Anabolism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrus,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,diltiazem,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,resveratrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Emodin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clinical Significance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,N-acetyltransferase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,water channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Risk Scores,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Present,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,1-Phosphatidylinositol 3-Kinase,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"neoisoliquiritin, (E)-isomer",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Phosphotransferases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cell Cycle Arrest,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,arginylproline|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tripe,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Candidiasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Treatment Protocols,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Neuregulin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,LBH589,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Histone H3 Lysine 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Low Level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,paclitaxel,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ANTXR1 wt Allele|ATR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ROS1 wt Allele|ROS1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Mitophagy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,chaperone-mediated autophagy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dairy Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Therapy,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anxiety,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,stanniocalcin 2|STC2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
CAUSES,Secondary Neoplasm,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,F-Actin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vegetarian diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Marital Status,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CARD.RISK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,kaempferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,dydrogesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Inflammatory Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Luteolin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Magnetic Resonance Imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,copper,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Negative Surgical Margin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Agonist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,stanniocalcin 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Methylnitrosourea,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Pharmacotherapy,HER2-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,16 alpha-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,hydrocortisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,oxybenzone,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Menstrual period late,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pediatric Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,lysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Psoriasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,DEGS1 wt Allele|DEGS1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacotherapy,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AFFECTS,polyphyllin D,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,olive oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Poly(ADP-ribose) Polymerase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Parafibromin|CDC73,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ligands,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CD69,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Life Expectancy Less than Five Years,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Phenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Toll-Like Receptor 1, human|TLR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Biological Markers,Stage 0 Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ketogenic Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cell Survival,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,OLT1177,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Secondary Neoplasm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AFFECTS,Cardiorespiratory Fitness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,STMN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Waist Circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,olaparib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mammographic Breast Density,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,1+,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ferroptosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CELSR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rhythm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thrombospondin 1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Dormancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lutein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diagnosis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,Mouse Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cell Death,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,idebenone,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Tenascin, human|TNC|TNNC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TLR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ezetimibe,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,Follistatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,mitochondrial calcium uniporter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ononin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,tanshinone II A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,oncostatin M receptor|OSMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Anthocyanins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Insulin used,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,resveratrol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,CA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cardiovascular morbidity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IKZF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Interleukin-24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,Acrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,KDM5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Menopause, Premature",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CETN1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Combined Modality Therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Menstrual migraine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Eclampsia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,APOBEC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immunologic Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Whole Cell Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,XBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cytochrome P-450 CYP1A1|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MAP3K3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,UDP-Glucuronosyltransferase 1A1|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NANOG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,TISSUE TRANSGLUTAMINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TLR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Quinones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Progestins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,[D]Nausea and vomiting NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,JAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,8q22,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
DISRUPTS,Deferoxamine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Specimen from breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR27B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RUNX1|MECOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ANKRD12|ANKRD11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Interleukin-8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RHOBTB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ID1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Quantitative Trait Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,MRPS30,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Annexin A2|ANXA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Endostatins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SH3KBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nitrite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ARF6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Extracellular Signal Regulated Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immunoglobulin G,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Antiperspirants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,asparaginylendopeptidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,20q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Interleukin 7 Receptor|IL7R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Livebirth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,BMPR1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Laminin Receptor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ACR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Metabolic Rates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CATHEPSIN D|CTSD,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Antibodies, Anti-Idiotypic",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Carotenoids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Fibroadenoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Estrous Cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Irregular menstrual cycle NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Pregnancy, Multiple",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,fulvestrant,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HSD17B4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nifedipine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mechanics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Body mass index,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,LRRC32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Signal Pathways,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,salinomycin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Reconstructive Surgical Procedures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GALNT14,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Cadherins,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,Manganese Superoxide Dismutase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Tretinoin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Para 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dessert,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Trihalomethanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ZNF121,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Paraffin,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,Retroviridae,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cytologic finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GATA3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Etoposide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Collagen,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,activity level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Biological Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Trans-Activators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Athletic Training,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aromatic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha-Lactalbumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Prolactin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Operative Surgical Procedures,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Photosensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Electromagnetic Fields,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Phosphotransferases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
COMPLICATES,Hypercalcemia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,onapristone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Paraffin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
DISRUPTS,Monoclonal Antibodies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Debrisoquin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Gonadorelin|GNRH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Urea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Dimethyl Sulfoxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,beta-hexachlorocyclohexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Gamma-glutamyl transferase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Interferons,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Bromocriptine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,methylurea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prognostic Factor,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PIP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Wound Healing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High income,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lutein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,X-Pro dipeptidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,New finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Obesity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CATHEPSIN D|CTSD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,tissue-factor-pathway inhibitor 2|PPP5C|TFPI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fever,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,regular physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NBEAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,C2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,BUB1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Glucagon|GCG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,MFT 279,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GATA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,folligen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,sodium-iodide symporter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Indomethacin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Increased body mass index,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Integrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Insulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Decapeptyl,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Radium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interstitial Collagenase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Allelic Imbalance,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Electromagnetic Energy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,checkpoint kinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Passive smoker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hypokinesia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Psychometrics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,I Kappa B-Alpha,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Triethylenemelamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Lymphoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Chromosome abnormality,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Kininogenase|KLK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CLARITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Retroviral Vector,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Saturated fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"N,N-dimethyl-4-anisidine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,skills,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,EMSY,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reproductive Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Venous Thrombosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Quantitative Trait Loci,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prempro,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,maspin|SERPINB5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Dehydroepiandrosterone Sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ID-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Soy bean product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Angiogenic Switch,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ID1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cryptococcus,Cancer en cuirasse,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Infertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,EEF1B2P2|BHLHE22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Decreased density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,apomucin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,NELFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Granulocyte Colony-Stimulating Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MFG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Catechol O-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyperprolactinemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estradiol,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,lariciresinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Raloxifene,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Anovulatory,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sore to touch,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gegenhalten,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,pleiotrophin|PTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,epigallocatechin gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,beta catenin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,WISP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Endopeptidases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,anti-apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Environmental stimuli,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Asparagine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cytochrome P450 3A4|CYP3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,polyphenols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Breast Cyst,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mannose Binding Lectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Stanolone,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ghrelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ovarian Cysts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Thrombospondins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Catecholamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Oxytocinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Encounter due to puberty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TSPYL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SIPA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PPAR gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Operative Surgical Procedures,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Walking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABCC11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Thrombolytic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,14q24.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,NRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MTNR1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MTNR1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Titanium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,mTOR Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Acetyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SULT1A1|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Potato,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Breast tenderness,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Autoimmune thyroiditis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,OPN1LW|CRCP|RAB11FIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PREDICTED,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NEK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cigarette smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Sulfatases|ARSH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCDC88A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diabetes Mellitus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Somatomedins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Phototherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Granulocyte Colony-Stimulating Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UTS2R|SLC14A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Compete,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Magnesium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Calgranulin A|S100A8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cytochrome P450,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ETV4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Minisatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PPAR gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,S100A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Niacin intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SIX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Arrestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,BACH1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,PHB2|SIL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Advance,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SLX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Tetradecanoylphorbol Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Catechol O-Methyltransferase|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MRE11,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,hesperetin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BRIP1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AUGMENTS,ING5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,Angioendotheliomatosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Paclitaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RPRD1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,XPO5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Natural menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,sphingosine kinase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NKD1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,benzyl isothiocyanate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oxides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ABCB10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,shikonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KLF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,fucoidan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin E,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Lupus Erythematosus, Systemic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NBAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SULF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,arctigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,xanthohumol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interstitial Collagenase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BVES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,POU5F1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MSI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ANXA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,curcumol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Transferrin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phosphotransferases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,pomegranate juice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,YAP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ITGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,discoidin domain receptor 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Complement 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HVCN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGKV6D-21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tenascin|TNC,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,C1GALT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Bone remodeling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,caveolin 1|CA5A|CAV2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lactate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diabetes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,bakuchiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,TFF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,pregnane X receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MT2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,isoalantolactone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LEF1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,HIST2H2AC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fluoxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sinomenine hydrochloride,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,TARDBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,exemestane,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADAM33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VTCN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FCRL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Interleukin-1 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Antibodies, Anti-Idiotypic",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SHARPIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,methyl 4-azidophenylacetimidate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Polycomb,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,S1PR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SP7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RNU4-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,meleagrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Brown rice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Transcriptase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,salinomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ANKLE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,skills,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AUGMENTS,sigma-1 receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MAPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,TGFBR1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,sphingosine kinase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ischemia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,S100A4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Stem cell transplant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Therapeutic procedure,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Multiple malignancy,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,SUCLA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Neoplasm,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,CDCA7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,diallyl disulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Relaxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GEN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,4-chlorophenyl methyl sulfide,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Difficulty sleeping,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PRI-2191,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Collagen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Toremifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Dietary Component,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-1 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Isoprostanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,WWC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,phenidone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,MALAT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,fibulin-3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Chitosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LGALSL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,aloperine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hydrogels,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adverse effects,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Test Result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fibrosis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Membrane receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Glycine Hydroxymethyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Luteolin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,TLN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Gelatinase B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,midkine|MDK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,pregnane X receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cigarette Smoking,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BITTER MELON,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,crystalloid,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHI3L2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
CAUSES,3MC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TMEM25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CD247,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Axillary Lymph Node Involvement,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,CATHEPSIN D|CTSD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Skim milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Symptoms,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atypical lobular hyperplasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,personal responsibility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,beta-hexachlorocyclohexane,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Growth,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,RHCE|FIP1L1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ischemic stroke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SALL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cathepsin K|CTSK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,paxillin|PXN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Metformin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CTHRC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CTHRC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Hydroxyl Radical,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Depo-Provera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ductal Breast Hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,prednisolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,5-hydroxymethyl-2'-deoxyuridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diabetic Retinopathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ERBB2|NEU1|NEURL1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aspirin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Dairy Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PAX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Paclitaxel,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,OR10J3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic regimen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Allelic Imbalance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,2-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Early Diagnosis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lobular Neoplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasonography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,small molecule,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Noscapine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S100A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,response,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SLCO1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Systemic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,osteopontin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Zeranol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ZNF365,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Leg length,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Worried,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Calgranulin B|S100A9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,B3GNT2|B3GNTL1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,coping resources,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,DDX5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ORAI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Creatinine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-17,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,osteopontin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Berberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,AG 14361,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Amenorrhea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fluoxetine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oral form estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,beta Sitosterol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estradiol acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,KDM3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,May-Hegglin anomaly,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,crocin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,meningioma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Deferoxamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Rifabutin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Diabetes Mellitus, Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,XIST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Glucocorticoids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,oncostatin M|OSM,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Not significant,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fertility problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyperparathyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,household cleaner,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Behavior,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ethanol Metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,acadesine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,NR4A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Insulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Malaise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SPSB1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Cytochrome P450,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ligands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cookie and/or cracker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Heregulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Kininogenase|KLK4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Uterine hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Clinical Protocols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Beef,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Saponins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Plasminogen Activator Inhibitor 1|SERPINE1|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Saponins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Maximum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,versican|VCAN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Unreported,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SGCB|APOBEC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,4-hydroxy-2-nonenal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PROCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SELPLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mammographic breast density,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,8-oxo-7-hydrodeoxyguanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Carboplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DAND5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,loss; bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,lobaplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,arginylarginine|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Toll-like receptor 9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoplasm,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Atypical lobular hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Not significant,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hemoglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Propranolol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cosmetic surgery,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NF-kappa B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammaplasty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fat graft,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Initiative - finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Calcium Channel Blockers,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Adverse effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Injectables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Local Anesthetics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Puberty,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AFFECTS,"Absorptiometry, Photon",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Osteocalcin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Alendronate,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KDM4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,TINCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DDT EXPOSURE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Benzanthracenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vimentin|VIM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,phospholipase C beta2|NEUROD1|TUBB4B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATG9A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MUTYH,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Morphine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LINC00339,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MKNK1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,nicotinamide phosphoribosyltransferase|NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,VEGFA,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,HOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fluphenazine Hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Naloxone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Glucosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FOXP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNORA7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnesium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CASC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta catenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LINC01857,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tissue Model,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Schizophrenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CASC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,glycogen synthase kinase 3 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NR0B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,schisandrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Treatment Protocols,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,racial differences,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,COPB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Binding Sites,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,tropomyosin-4|TPM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KDM1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,saikosaponin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RHPN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,LINC00460,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RASSF1A|RASSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SATB1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ENOLASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ACSF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NCK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ENO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BODY HEIGHT:LENGTH:POINT IN TIME:^PATIENT:QUANTITATIVE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,mastitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PCB 153,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,STIM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NBEAL1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AUGMENTS,PCB 153,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,acetylacetone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADCY4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AZIN2|GADL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PCB 118,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,caspase-8|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Electromagnetic Energy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PALB2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Neuropathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,C11orf74|C17orf49,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Markers,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,regulatory loop,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Enrich (product),Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,CGRRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PPAR gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PRDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Thrombospondin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,MIR223 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nuclear Receptor Coactivator 3|NCOA3|ANIB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MAP2K4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,blood test result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,quinoline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Deoxyuridine,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,High Confidence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Markers,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,thrombin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,prasterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,thymoquinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cyclin D1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Markers,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diagnostic Imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognosis bad,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Adriamycin,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Primigravida,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Binge Drinking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGFBP7|SFPQ,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Small Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,platinum,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,pioglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,gonadorelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,rhein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Profilin 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypersensitivity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mitotic Activity,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LMNB1,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,ESM1 wt Allele,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cereal intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Extensive Necrosis,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TMPO wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,risk factors,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD163,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neurosurgical Procedures,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,LMNB1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,3-methylquercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Transcript,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Industrial fungicide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Biological Factors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Negative,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TAC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alleles,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,WWOX wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Illness (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glucocorticoid Receptor,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Hyperphagia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Synthetic glucocorticoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Family history,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Family history,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Benzo(a)pyrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Aurora Kinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Transferrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Deodorants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Copy Number Polymorphism,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Color doppler ultrasound,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,osthol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cathepsin L,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,osthol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PARP inhibitor therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,thymoquinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Insulin Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,estradiol,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,saffron extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,beta-2 Microglobulin,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,small size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Smoking,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alleles,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aquaporin 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,2 times,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,interleukin-10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Botanical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,research results,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Childbirth,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UGT1A7 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Modest-Temperature Hyperthermia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Artificially Sweetened Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mood:-:Point in time:^Patient:-,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,jolkinolide B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dietary Intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Smoke Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,pyridine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,cyclin B2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Xenograft procedure,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Copy Number Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Stilbenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Intravenous therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Oils,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast Density,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Coronary Arteriosclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Normal weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Periodontitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Response to treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Parity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,mortalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypersensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tanshinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sinomenine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TSHZ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Taxol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Very Important,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AFFECTS,"Receptors, KIR2DL4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Rhythm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDC42,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,PDE5A wt Allele|PDE5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pregnancy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,inermin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Therapeutic procedure,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Sulfatases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,diallyl trisulfide,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,corynoline,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Micelles,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,cytochrome b561,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,File Being Validated,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,docetaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,eribulin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,fulvestrant,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,4 times,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MRPS7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,sirolimus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,homocysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Calcinosis universalis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,GLI1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,carbidopa,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,heparanase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MUC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lipopolysaccharides,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,lidocaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Early Diagnosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Ligands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Mevalonate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunogenic Cell Death,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,BARRIER,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Basis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,dihydrotanshinone I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Low-Dose Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,health knowledge,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,panobinostat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ENOLASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,HER2-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,perfluorooctanoate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,thiamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,birth control pill use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Differential Diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,sauchinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Targeted Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MVP wt Allele|RPSA|LRP1|PTPRA|MVP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CBFB|NFYA|NFYB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,caspase-3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Energy Balance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Improved,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Leisure behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,cyclic guanosine monophosphate-adenosine monophosphate,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Cobalt dichloride,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Hexokinase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Metabolic Profile,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Hexokinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Pyrenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fruit extracts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Players,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Liposomes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,histone deacetylase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immune,HER2-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Ferritin Light Chain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypothalamic inhibiting factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Triple Negative Breast Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,xiaoyaosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gravidity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cytochrome b561,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Obesity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Suppressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,Thrombotic Microangiopathies,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Alkaloids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,pristane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ginsenosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ethanol,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,40-49,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,interleukin-6|IL6,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Interleukin-16, human",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,polyphyllin II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,mahanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,doxorubicin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Perimenopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,FZR1 wt Allele|CDH1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CXCL8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hemoglobin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,butylbenzyl phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Receptors, Opioid, kappa",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,AMACR wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endometriosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ESR1,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tobacco,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tea,Breast cancer stage II,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pivot,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor|ERBB2,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Score,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carney Complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"interleukin-1, beta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,pimozide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Movement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Androgen Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Patient Derived Xenograft,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Male-to-female transsexual (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Autoantibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,claudin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,humanin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,scopolamine,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Upstaging,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Therapy,bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Therapy,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,taurine,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Multiple Sclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Targeted Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Bee Venoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Urolithin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Protective Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tissue texture abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Basal Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,phosphatidylinositols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Folliculin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nitric Oxide Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,20q13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,TBX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TIMM50,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Stromelysin 1|MMP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Integrin alpha4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,intraoperative radiotherapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Menopause,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
DISRUPTS,BRMS1L,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,11q13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cyclin A1|CCNA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tangeretin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Glutamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Heregulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,beta catenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,STF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SLC39A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Annexin A1|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Organized pneumonia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Methotrexate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,IFNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptors, Opioid, delta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Androgen Receptor|AR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Pads,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypoxia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Autophagy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Genuineness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,BAG3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNAI1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NOP14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Rectal hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Activins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,WRAP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Environmental Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SNAI1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,TRIM62,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Wound Healing,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,osteoblast cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Congestive heart failure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,octylphenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ADGRF5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Salts,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FH: Father NOS,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,carnosol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"1,4-dioxin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,icariin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MIR200A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PIK3R1|PIK3R2|ARHGEF7|CBFA2T2|PPP1R13B|PPP1R12C,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Physical activity decreased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,retinyl methyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High Vegetable Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Levodopa,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,receptor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Gin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Clomiphene,bilateral breast cancer,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,glycosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Brachytherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nifedipine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ukrain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin D1|LMOD1|BBS9,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TARBP2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,MAPKAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Edema,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Voluntary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Sulfones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Herpesviridae,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Microsatellite Repeats,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Z-alpha-chlorochalcone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,R-38486,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclophosphamide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MENSTRUAL STATUS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Common Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Menopausal Status,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Mechlorethamine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Goiter,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,OK-432,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tall stature,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Esters,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atrophic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Excessive self-esteem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Confident,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Dinoprost,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,FGF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrosing adenosis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,Epoprostenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pregnancy review,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Zuclomiphene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,EMD 16795,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Silicones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ergocornine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Cisplatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,2-Acetylaminofluorene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Microsatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adipositas,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Drink,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Neoplasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,TP73|ARHGAP24,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,thermography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Calcium Glucarate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Psychological Impact,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,p65|RELA|SYT1|GORASP1|WNK1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Dietary Fats,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Microsatellite Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,2-chloroethyl ethyl sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Jogging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pregnenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,casein kinase II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Overweight,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,8-hydroxy-2'-deoxyguanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Integrin alphaV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB2|NEU1|NEURL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SLC39A6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Diet,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Menopausal hot flushes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Amphiregulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,estrone sulfatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Selenium,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Ethylnitrosourea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,"N,N-dimethyl-4-anisidine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Surgical biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Technetium Tc 99m Sestamibi,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
CAUSES,Hexestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,stanniocalcin 2|STC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Early menarche,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptor, Melatonin, MT1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mitotic Activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Alpha heavy chain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"1,2-dibromo-3-chloropropane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Slow acetylator status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ibandronate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ATP12A|HK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,P-Cadherin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prenatal Exposure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,BAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,adjuvant therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Phosphorylcholine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dydrogesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Calgranulin B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SPOCK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RUNX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,8q24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cold temperature,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,helicase|HFM1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AFFECTS,Fanconi's Anemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,TNF,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RANTES|CCL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Recombinant Interleukin-8|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Angiotensin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,E-Cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Apigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AROMATICS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tanshinone II A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Puberty, Precocious",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Estrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Oxidoreductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Delayed menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PPAR gamma|PPARG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ASAP1|MYCBPAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glycol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PARP1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,polyphenon E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Activins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Plants, Edible",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Analgesics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Disintegrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,prohibitin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phosphatidylinositols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,leucylproline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Connexins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,podocalyxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ERbetacx,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,"Receptors, Cell Surface",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,GSDME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Norgestrel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Amphiregulin|AREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Body mass index,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RAD50,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
CAUSES,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,EGLN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CD24,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,anti-apoptosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CTCFL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LIN28A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Simvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD70,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,Janus kinase 2|JAK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Histologic type,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,nuclear receptor coactivator 1|SRC,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Liposomes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,KDM8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Disulfiram,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,IDO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,healthful behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"2,5-dichloro-4-bromophenol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lemon extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,invariant chain|CD74,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,survivin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,Introns,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FAN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Aluminum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,RBBP7,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,quinoxaline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,YBX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,isoflavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"Receptors, Nuclear",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,CYP2S1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fenretinide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AUSTRALIAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UTS2R|SLC14A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RAD51,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,NRDC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S100A1|S100B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Field crops,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Core needle biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NOV,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammary Neoplasms,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,NCOA7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolic Marker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CBX7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,caveolin 1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BEX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Growth,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,SOX18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,intraoperative radiotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ATP2B2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAD51B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,diindolylmethane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S Phase Arrest,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ASAP1|MYCBPAP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Gelsolin|GSN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Primary Neoplasm,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,aurora kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CRY1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CIP2A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Berberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vimentin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,IL2-inducible T-cell kinase|ITK|SLC22A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,KIF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ATG4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Chloroquine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TMEM88,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Cysteine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SFRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PFN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diphosphonates,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Overweight,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PARK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,molybdenum disulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,OIP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHEST PATHOLOGY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,oleocanthal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neuromedin U|NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Angiopoietin-2|ANGPT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DEAE-Dextran,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Disaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,docetaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reproductive History,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AUGMENTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,dieckol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Lovastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic Touch,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Smoking Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Phenformin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Taxanes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,teleocalcin,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ligustilide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TNFAIP8L3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LGR5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,matrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CCR7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Glucuronosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,interleukin-17E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MAGEA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Somatostatin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SLC9A3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RCCD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,NBAT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Neuropilin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"kallikrein 5, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Endothelin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ethanol,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,NSUN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cadherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MTA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Trichloroethylene,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Non-alcoholic fatty liver,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Age at menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sleep behavior finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NOD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,receptor,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GSTM3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SIRT7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aptamer,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FABP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,E2F7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hydroxyestrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KRT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Isoprostanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Coffee intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,WWOX,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PPM1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,GATA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,everolimus,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,decorin|DCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dessert,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PHF5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ITGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,thymoquinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cucurbitacin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,dronedarone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Menarche,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,kaempferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Encounter due to prophylactic surgery, unspecified",Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,zileuton,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,APC,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,Stanolone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Loops,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Fibronectins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Ceramides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Spectroscopy, Nuclear Magnetic Resonance",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ANAPC15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,lapatinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UGT1A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Integrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Emodin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Raloxifene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fasting,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TOB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fatty fish,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,caveolin 1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Endopeptidases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Osteoporosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phenelzine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Oral Contraceptives, Low-Dose",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nortriptyline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Overweight,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diet,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Overoptimism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nonpuerperal mastitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Behavioral change,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Smoking,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alkaline Phosphatase,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,RFC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Health-related behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Androgen Receptor|AR,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,phenylalanyl-glycyl-valyl-statyl-alanyl-phenylalanine methyl ester,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Gonadotropins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,bexarotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diabetes type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ataxia Telangiectasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TMEM131L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,16q12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Macrophage Colony-Stimulating Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Goserelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biotinidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UBE2S,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mastectomy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Vincristine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dietary Supplements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Excessive weight gain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Drinking pattern,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Prunes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cosmetic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Autoimmune hypothyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alcoholic Beverages,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VASOMOTOR SYMPTOM,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,epigallocatechin gallate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tipifarnib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Activins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MUC4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PALB2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,lapatinib,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,trichostatin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KLK5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,deceased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cyclin-dependent kinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,overdiagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,NR5A2|P2RX5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diabetes Mellitus,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KRT20|C17orf97,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,zeaxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,heparanase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CD40 Ligand|CD40LG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,interleukin-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Calgranulin A|S100A8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Physical therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Muscular Dystrophy, Facioscapulohumeral",bilateral breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diabetes Mellitus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KIF2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Apoptosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AKR1C4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ABCC10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CCDC91,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MT1A|MT1B|MT1E|MT1F|MT1G|MT1H|MT1JP|MT1M|MT1L|MT1X|MTNR1A|ALG1|MT1IP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,psychological distress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PALB2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Alcohol products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mammography abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Copper,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,germin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoking,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,Hyaluronan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,diindolylmethane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sleeplessness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Soluble ErbB-1|EGFR,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Silence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PELP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fertility care,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Urokinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rye flour,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Clusterin|CLU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,regular physical activity,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mitotic/Spindle Checkpoint,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,claudin 6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,NEK2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Somatotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Glutamate-Cysteine Ligase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PERP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammaplasty,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mammographic breast density,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Autoimmunity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Sunlight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PARD6A|PWAR6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cardanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,None|SLC16A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Corn Oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Zinc,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Non-Viral Vector,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,aglepristone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,White bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Disability NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Calcium, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-18,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,chemokine receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Integrin alphaV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PROX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Dioxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cisplatin/cyclophosphamide/etoposide protocol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PINX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,BST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Tryptophan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Baresthesia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Taurine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,LPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Amphiregulin|AREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RPS6KA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Peroxisome Proliferator-Activated Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vimentin|VIM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,COPS5,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,ZNF350,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Air Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Hyperostosis, Diffuse Idiopathic Skeletal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD151,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fenretinide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunomodulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HADHA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,N-acetyltransferase 1|EREG|ESR1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Antiplatelet therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TIMELESS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Annexin A2|ANXA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Work stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RHBDD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Heparan Sulfate Proteoglycan|HSPG2|SDC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,LAMTOR5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PGD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Liver Cirrhosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Brain Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oranges,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Edema,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SESTAMIBI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aspirin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Lamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Body mass index,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LINC00518,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,DDT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Overweight,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,thrombospondin 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Histone Deacetylase Inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,AQP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ranolazine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,exemestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Repeat Surgery,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PIP5K1C,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SOCS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,AQP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ENPP2|SMG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PDLIM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Supportive care,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RBMS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,VIPR1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,triptolide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,targeting,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,Metformin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phosphorus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rosacea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PUF60,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,oncostatin M|OSM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dexamethasone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phthalimides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,HDAC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,VIM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CISH,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Honey bee venom,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,C-Phycocyanin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ATP-Binding Cassette Transporters|ATP8A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SNHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anaplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyperglycemia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MDM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,E-Cadherin|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Chinese herbal medicine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TIMM13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Cyclin-Dependent Kinase Inhibitor 2A|CDK4,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,silybin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PCB 138,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP2C8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TRIM44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Quinoxalines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PXDNL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TUFT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Silence,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Premenopause,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PTP4A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDK12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,JPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UBE2V1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Chalcone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,everolimus,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,ethylene oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FAM53A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Microbicides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,paclitaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HULC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,silence,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Promoter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"nuclear receptor subfamily 1, group H, member 2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR30A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ibrutinib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,Ubiquitin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Copy Number Polymorphism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,"Antibodies, Blocking",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TT genotype,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,29+,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,Polyunsaturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Patient Derived Xenograft,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,olaparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Contrast enhanced spectral mammography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SFN,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Transcriptome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Macrolides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rheumatoid Arthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD44,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Iodides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,prolactin,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,subharmonic imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,OSW 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Second line treatment,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Suppressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,methanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOSB,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Postmenopausal state,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,risk factors,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cadherins,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic resonance imaging of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Flavanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Epigallocatechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,apigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AGR2,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Epicatechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,P-Cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Easy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CTBP1-AS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,silence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Caffeinated coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,5-methyltetrahydrofolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hypertrophy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,lapatinib,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,rucaparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Kynurenine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,mTOR Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Markers,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Crown-Like Structures of the Breast,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,xanthomicrol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Crown-Like Structures of the Breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Receptors, Adrenergic, beta-1|ADRB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,polyphenols,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,rasagiline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Neutrons,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dietary Alcohol,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,mannose receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,gemcitabine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pulmonary Metastasectomy,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATM,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Neoplasms by Site,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Systemic Therapy,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,honokiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Low BMI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ethanol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,pembrolizumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CHAF1A wt Allele|KAT2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High birth weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mean score,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,water channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,vinorelbine,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Cytochrome P450|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DEGS1 wt Allele|DEGS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atypical hyperplasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Second line treatment,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Markers,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Reactive Nitrogen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Programmed cell death ligand 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR506 wt Allele,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,NF-kappa B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,lutein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,voacamine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,directive therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"3,3'-diindolylmethane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Interferon-alpha,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Response Modifiers,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Imbalance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Chlorpyrifos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Treatment Protocols,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interstitial Collagenase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proton Pump Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Increased prolactin level,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PET/CT scan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UBA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,DEAD Box Helicase p68|DDX5|KHDRBS1|POLD3|GATAD2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,rutecarpine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,bruceine D,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ovary; insufficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZBTB7A|AKIRIN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MCM3AP-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Metronomic Chemotherapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Adriamycin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammaplasty,Stage 0 Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,aspirin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,oleyloxyethylphosphorylcholine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Overdiagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,erbB-2 Receptor|ERBB2,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,"leptin receptor, human|LEPR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FGFR4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,atezolizumab,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Parity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,limonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasound Tomography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Parallel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ergocalciferol,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
COMPLICATES,Lymphedema,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,interleukin-21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Low health literacy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TIMM8A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Free triiodothyronine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Targeted Therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Male fertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Uptake,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,exenatide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Mortality, Premature",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Receptor, PAR-1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,asparaginylendopeptidase,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD44,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Asbestos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,somatostatin receptor 1|SSTR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,TIMM8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Blood group AB,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cooking Practices,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mean score,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dysbiosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Alkaloids,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chemokine CXCL12,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oral intake,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,AMACR wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,calreticulin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NU 7441,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prognostic Factors,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Purinoceptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sorafenib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,trichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,nesiritide|NPPB,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,isoleucylvaline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Histone Demethylases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,maintenance of pluripotency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR382 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,trichostatin A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Flash,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Autophagy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,sauchinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"interleukin-1, beta",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prolactin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,parecoxib sodium,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vigorous physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biomodulin T,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vigorous physical activity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ocular Cicatricial Pemphigoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Chalcone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Psychosocial procedure,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,hydrochloride,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Systemic Therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Anthropometric Measures:-:Point in time:^Patient:-,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,sirolimus,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,morusin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,quinacrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,polyphenols,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Challenge:Type:Point in time:^Patient:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Emodin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Angiotensin II receptor antagonist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,propofol,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,pirarubicin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,beta-Glucans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,rebastinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,zoledronate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,berberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Synapsin I,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,interleukin-8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,thymidine kinase 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,formononetin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,leptin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dried fruit intake,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Raw vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inflammatory Response,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,polyphyllin II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SB 203580,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,hydnocarpin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Decreasing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,venetoclax,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,doxorubicin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chest asymmetry,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Androgens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,takinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Proteome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABCB1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Diet, Western",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,directive therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carney Complex,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,factor XIII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Breast-Conserving Surgery,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,momordicoside K,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Soybeans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ezrin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Reproductive History,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Viscosity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,PDZK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,tibolone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
CAUSES,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Soy Milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TRPM7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neuregulin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GSTO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LECT2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,p-hydroxycinnamaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,maspin|SERPINB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,arginylarginine|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Biosensors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOXD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ARF6,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,arsenite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,catalpol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,pigment epithelium-derived factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Health behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,NFKB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Angiotensin II Type 1 Receptor Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LIN28A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Diet good,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,BMP4|BMP4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Signal Pathways,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,deferiprone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Genistein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,3/4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOXP2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoking,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,WWTR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Tungsten,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Botanicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,RAB22A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,docetaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Heme,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,fraxetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Animal fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Molecular Chaperones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,lard,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Neoplasm,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pteridines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PCSK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Reserpine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-6,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Positive Test Result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nitric Oxide,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,Study models,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,FABP7|MAS1L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Flap Endonuclease-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Gastrointestinal Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,E-Cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,thymalfasin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Progestogen only oral contraceptive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Technetium Tc 99m Sestamibi,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Potato,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Integrin beta3|EEF1B2P2|BHLHE22,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,NLRP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Gynecomastia,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Fluorouracil,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammary Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,family background,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Antispasmodics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Chromosome 11 Short Arm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Caffeine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydralazine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Skin problem,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,cell motility,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Intraductal Hyperplasia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fibroadenoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Buserelin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,benzanthracene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHEST PATHOLOGY,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Thiotepa,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"Milk, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fibronectins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mitoxantrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Peanut Agglutinin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PREMARIN USE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Androsterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,limonene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Histologic type,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Angiostatins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Leucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,rac-PK beta|AKT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Immunoconjugates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,NME2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Fetal Growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,formestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Equine laminitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HSPB8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Telomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,perlecan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Amphiregulin|AREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cyclin D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Study models,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Brain Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Therapy responder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NF-kappa B,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Punctate inner choroidopathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,resveratrol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,17q23,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,sphingosine kinase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endopeptidases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Environmental Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Brain hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Molecular Pathology,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thrombus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,response,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Serpins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Uterine activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Transcript,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,fulvestrant,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Colony-Stimulating Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Isothiocyanates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fanconi's Anemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LRRC15,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Angiotensinogen|AGT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,4-nonylphenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,P-Selectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CLSPN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Doxazosin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LZTS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Fibrinogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,adduct,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tomography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Clusterin|CLU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Acne,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Wine intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coumestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Lymphoid neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Xeroderma pigmentosum, group C",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Membrane receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Pulmonary Embolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,E2F4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Mucinous Neoplasm,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Paroxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PSMA5|AP5Z1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Neoplasm,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Body mass index,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,CXCR4 Receptors|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Farnesyl Transferase Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Ethylene Oxide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Complex Extracts,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Biopsy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IL6R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Stromal Cell-Derived Factor 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SULT1A1|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ethylene Oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,BEX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,semapimod,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hamartoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Plasmin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammaplasty,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PES1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,INPPL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KLLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PIWIL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,chemokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP3A5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,adjuvant therapy,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Medical care, unspecified",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,TWIST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADIPOQ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ZNF703,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Progestins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,PELP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Annexin A6|ANXA6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,thymidine kinase 1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Chromosome 10 Short Arm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CD24,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,butylbenzyl phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Plasminogen Activator Inhibitor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SIX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dipyridamole,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,PARD6A|PWAR6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TUBB4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,plumbagin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,SIX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,6-bromo-2-naphthyl sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,beta catenin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin-Dependent Kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,FOXO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,corrigendum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Beta-glucuronidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CLDND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dietary Supplements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,plumbagin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNHG12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Ceruloplasmin|CP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,interleukin-22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SOX17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pyruvate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MC1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dichlorodiphenyldichloroethane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dexamethasone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MSI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Diethylstilbestrol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,IL33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TRPV4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Berries,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Margarine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ABCB6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NUP155,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,atorvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,kinase inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Adenomatous Polyposis Coli,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Glioma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,UBE3A,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,NUMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,liraglutide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mammography finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thiamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TARDBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PIWIL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MMP,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Hyperinsulinism,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,KLF17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SHARPIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DACT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,APBA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Late pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,jatrophone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CISH,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,PPM1D,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
COMPLICATES,Fibrosing adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,BCYRN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,nucleolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Anaphylaxis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ARRDC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SENP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,grasp,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CCR7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lasso,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIK3R1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,uptake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Collagen Type IV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Recombinant Interferon-gamma|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADH1C|ADH5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PARP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ATF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Taxol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Receptors, LH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Liposomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tobacco use,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,N NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Sentinel Lymph Node Biopsy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,wogonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Glutamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Embryonic Development,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,pentabromodiphenyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,OIP5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dietary Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NF-kappa B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rest,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Black tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,response,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,norethindrone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,IQGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oxytocin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Galactosamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Homeo Box Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Early Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Apoptosis,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chromosome 15 Short Arm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Superoxides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIP,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Immunoglobulin Fc Fragments,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,vigilin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PTPN13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,FADS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fish Oils,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Atypical hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,stromelysin 3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,FMO5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Endostatins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Loss of Heterozygosity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Optimistic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adrenergic Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SULT1A1|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lecithin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BONE MASS,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CAMP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Freund's Adjuvant,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Low Birth Weights,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Rh Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SSM,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Contraceptives, Oral",bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Contraceptive methods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MIR519D,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Puberty stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Butter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vegetable Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Speaking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Weakly positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,adjuvant therapy,Breast cancer stage II,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Breast Fibrocystic Change, Proliferative Type",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,poor health,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,nimesulide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Flavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Short Tandem Repeat Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADRB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Magnetic Resonance Spectroscopy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Biopsy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Ill-at-ease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,pterostilbene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PKP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ethanol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cadherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Acetaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ezrin|EZR,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Silence,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Asleep,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Obesity,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Interleukin-17,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LPCAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CALML3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ODAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MRE11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RPS6KB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Macrophage Chemotactic Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,butein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,heparanase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,estrone sulfate,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,atovaquone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Chemokine (C-X-C Motif) Ligand 1|CXCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estradiol,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Computed Tomographic Colonography,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VASOMOTOR SYMPTOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,osteopontin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cadherin 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Connexin 43,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fruit intake,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Interleukin-12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADAM29,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estradiol + norethindrone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,GAL3ST1|SLC35A1|CASZ1|CST12P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Chemotherapy-Oncologic Procedure,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,EMSY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypical hyperplasia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dinoprost,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Chemotherapy, Adjuvant",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin Resistance,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cytokeratin 18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interstitial Collagenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nickel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Breast Feeding,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,BCCIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHI3L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Somatostatin analog|SST,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Interferon Type II|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL1RN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cyclin D1|CCND1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"Breast Fibrocystic Change, Proliferative Type",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,sake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Xq25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Infectious Mononucleosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,EGFL7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PROM1,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,DCSTAMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,gefitinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,GLIS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,perfluorooctane sulfonate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Riboflavin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alcoholic Beverages,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Infant feeding method NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Weight Gain,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DMD|BEST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Wine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,Metaplasia,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aldehydes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Biopsy,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,phenethyl isothiocyanate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Black tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Performance,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,oridonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Poultry Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammography,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Cognitive Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,high-dose chemotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oxytocin Receptor|OXTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,S100A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Does hit,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Iodine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,pigment epithelium-derived factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diphosphonates,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
DISRUPTS,SOSTDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Catechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Night sweats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Flavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,hydroxytyrosol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,REXO1|ZFP42,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Night Nurse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,NEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Female,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body Weight decreased,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cerebrovascular accident,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Powerlessness, low",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pregnancy,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atypical lobular hyperplasia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Endothelin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polymerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mammographic breast density,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Lasofoxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Estrus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Analgesics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adenosine Triphosphate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Mitoxantrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,protopanaxadiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CDCA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SDCBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,no positive axillary nodes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Gout,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tyrosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Acetaminophen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TRIM33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SLC50A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FUT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LINC01638,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PIMREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Interleukin-17,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,strictinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,phenyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SLC50A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ezrin|EZR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta catenin|CTNNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Coal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RNF115,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,S100B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HCP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,nitric oxide receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RUSC1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,TFF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PCB 180,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Gold,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Energy Balance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HAX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,angiotensin II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,cedrelone,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Flavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Catechol O-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phototherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Therapy,Breast cancer stage III,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,punicalagin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Late menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,STARD8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cream,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,chalcomoracin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hexokinase 2|HK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,insulin detemir,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prophylactic treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fibromyalgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,compromise,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,"Sleep Apnea, Obstructive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chlorpyrifos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CCL5,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CTCb regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Phosphoric Monoester Hydrolases,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,aluminum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,risk factors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prolactin Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Polybrominated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Primary care provider:Identifier:Point in time:Provider:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,limited use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,betaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,risk factors,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Multiparametric Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Lyophilized powder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,removal technique,Stage IV Inflammatory Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,glycerin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,acetylcysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Markers,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CXCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Interferons,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Scoliosis, unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,erbB-2 Receptor|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR451A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,leptin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Biopolymers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Luteolin,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Piperlongumine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,thidiazuron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,methylate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoplasms by Site,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Behaviorial Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,mitoxantrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Systemic Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,B3GNT2|B3GNTL1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Thymidylate Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Screening mammography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mouse Model,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,sanguinarine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clinical Significance,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast size,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,Triple Negative Breast Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Profilin 2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Performance,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Neoplastic Process
DISRUPTS,dendrophenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hydrogel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Receptors, Opioid, kappa",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Physical stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,metoclopramide,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tripterine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cell Cycle Checkpoints,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Reaching,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Antibodies,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cytochrome P-450 CYP1A1|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Monoclonal Antibodies,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,melatonin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,docetaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,nucleolin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Benzimidazole derivatives, antinematodal",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Moderate risk,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,peroxiredoxin I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,calreticulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,piperine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cultured Milk Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hesperidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Copy Number Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Matrix,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,cannabinoid receptor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LRP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Very rare,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LGALS3BP,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SARS-CoV-2 P.1 variant,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Inhibitor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,oleuropein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,erbB-2 Receptor|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Histological type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,BACH1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,monooxyethylene trimethylolpropane tristearate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,interferon type II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,calcitriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tanshinone,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
DISRUPTS,anhydroicaritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,interleukin-10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Agonist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,kinase targeted therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Inhibitor,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Histone deacetylase inhibitor,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,perilipin 2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,estradiol high,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immune Checkpoint Inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,dinaciclib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MAP Kinase Kinase 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mouse Model,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Incomplete penetrance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,pioglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,quercetin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Hypothalamic inhibiting factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,aucubin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Citrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cyclin D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Copy Number Polymorphism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,polyethylene glycols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Ryanodine Receptor 2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Breast Measurement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Negative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,plumbagin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,erbB-2 Receptor|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Hypoxia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Free Energy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inhibitor,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Parafibromin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Osteoporosis,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,Histone deacetylase inhibitor|HDAC9,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Plasmids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOY ISOFLAVONES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Vimentin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clusterin,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydroxymethylglutaryl-CoA reductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Light Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Drinker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CREB1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,bufalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Alanine Aminotransferase 1, human",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,cytidylyl-3'-5'-guanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Snacks,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,First line treatment,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,glabridin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Toothache,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Increased risk,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,caveolin 1,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Global Longitudinal Strain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Chemotherapy,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coherent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Chemotherapy,HER2-negative breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Patient age,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Natural Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,dihydroartemisinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Luteolin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Severe (severity modifier),Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,disulfiram,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immune Tolerance,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Menstrual status:Type:Point in time:^Patient:Nominal:Stated,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Chemotherapy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Parafibromin|CDC73,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,euphorbia factor L1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Mammary Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Micelles,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,platinum,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD160,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Polygenic Traits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Basis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,graphdiyne,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Obesity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Response Modifiers,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hippo Signaling Pathway,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,beta sitosterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF148,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Possible,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,quercetin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clinical Significance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DHP107,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FZR1 wt Allele|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,interleukin-1 alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cheese intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Origin of Life,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tyrosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,dasatinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immunogenic Cell Death,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Carboplatin/Etoposide/Melphalan Regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pubertal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hypoxia,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,phosphatidylethanolamines,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Withanolides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Triterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,cyanidin 3-O-glucoside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,OGG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hypoxia-Inducible Factor 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ultrasonography,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,DYRK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mitomycin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,miltefosine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Heparitin Sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PSD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gamma synuclein|SNCG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,camalexin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CUL3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Streams,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TOX3,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Annexin A2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,ORAI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fluvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,KDM6B,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,TRPV6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,bexarotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RAC-Alpha Serine/Threonine Kinase|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,dihydroceramide desaturase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CIP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Creatinine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Stearates,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Ubiquitin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Angiotensin II Type 1 Receptor Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RBBP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fat graft,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Benzimidazoles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,lysophosphatidylethanolamine,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Does hit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Flavonoids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,osteoblast cadherin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HOXD@,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,TFF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lovastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,EPHB2|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,GTF2H1|SQSTM1|KHDRBS1|NUP62|DCTN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,APOA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,genistin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,GRPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TRIM62,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tipifarnib,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Autophagy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LRIG1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,erlotinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dimethyl sulfone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Acetate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Thrombospondin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,icaritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biopsy finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GFRA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,formononetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,8q22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ataxia Telangiectasia,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stress,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,retinyl methyl ether,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Negative Finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aneuploidy,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,"technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Ethinyl Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,E-Selectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Fruit, Citrus",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ETV4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Plasminogen Activator Inhibitor 1|SERPINE1|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Glutaminase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cheese,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Androgenic precursors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aminoglutethimide,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Monoclonal Antibodies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Relate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Histological finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prednisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Caffeine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoking History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Sialyltransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CATHEPSIN D|CTSD,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Monoclonal Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Polymerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Dietary Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Insulin Receptor|INSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Non-smoker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fluphenazine Hydrochloride,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Lymphoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NODULAR DENSITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Study models,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Glucagon,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Insulin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Autologous bone marrow transplant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,beta-Chemokines,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,PIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Microsatellite Instability,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Laminin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Raw vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CDKN2A|CDKN2D|F9|REG1A|IL23A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Inositol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Inositol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Differential Diagnosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PRMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aneuploidy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mitogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Bilirubin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,cyclin E2|CCNE2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SPARC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ID-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Globo-H,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Metformin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,Platinum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,EGb 761,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nulliparity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,B-pyridine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Meal pattern NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fumarate Hydratase|FH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vidal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,E-Cadherin|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fluoxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ERA-923,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,CD151,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tretinoin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Multiparity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Tankyrase|TNKS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Beans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,integrin-linked kinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,zeaxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoking,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD109,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,SRC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Heterocyclic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Aromatic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Integrin alpha6beta1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Angiopoietin-2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,LMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fetus size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ERbetacx,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,multicatalytic endopeptidase complex,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Abnormal result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WISP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,WWP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Eating habit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,alanylalanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MUC5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclophosphamide,Breast cancer stage II,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Nuclear Receptor Subfamily 4, Group A, Member 1",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Bloody nipple discharge,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,trans-resveratrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,phospholipase C beta2|NEUROD1|TUBB4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cytochrome P-450 CYP2D6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Prolactin Receptor|PRLR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cyclin D1|CCND1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADIPOR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Bone remodeling,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,ADRA1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypoxia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,osteopontin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,N-Cadherins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LSP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Stromal hyperplasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,UNC45A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CISH,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,artesunate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adrenergic beta-Antagonists,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Selectins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Paraffin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,heparanase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Calcium, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,denbinobin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,FAT4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,prophylactics use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HDAC9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ethanol,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,COPS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,KDM1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cigarette Smoking,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,metabolic abnormality assessment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,UHRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,asparaginylendopeptidase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Transcript,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,UHRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,heparanase|HPSE,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,NUCB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Keratin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polyethylene Glycols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,flavanone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Acetaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Physiologic Responses,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SMYD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dimethylformamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Systemic poison,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Stereotactic radiotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,lard,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Angiotensins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nicotine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,osthol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,ginkgetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,HOXD13,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,diallyl trisulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,citrate lyase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,Breast cancer stage III,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,PPP2R1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ADIPOR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interleukin-1 alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MMP12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,DANCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,baicalein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Benzodiazepines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Neprilysin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Anthocyanins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Mesothelioma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Lipopolysaccharides,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Dysplasia, fibrous",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SYNJ2BP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,phenylpyruvate tautomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Camellia sinensis extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SRCIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Receptors, Calcium-Sensing",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,17beta-HSD 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PNPLA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,L-2-amino-4-phosphonobutyrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RUNX2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Mitosis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Riluzole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Androgens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Tiron,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,sorafenib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Paclitaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Cytochrome P-450 CYP2E1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Dendritic Cell Vaccine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,cyclin B2|CCNB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,atamestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,N-(4-aminophenethyl)spiroperidol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GACAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Aspartate Transaminase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,UBAP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Bombesin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BRIP1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AUGMENTS,indole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,AKTIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,LMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,JAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Acetylcysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Diet,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,fisetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,chemokine receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,rhodioloside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,HOXB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Nitric Oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,YBX1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,proteomic profiling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mastectomy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,SNAI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MFAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hyperinsulinism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MTDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diabetic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Genistein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD24,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,mixed drink,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Thrombospondin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Diet,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CYP2A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Wound Healing,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Depo-Provera,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydrocortisone,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Violence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Methotrexate,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Permeability,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SULT1A1|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Menopausal Status,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SFRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SLC13A2|SLC13A5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,bone metabolism,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Androgens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Lactate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,telomerase activity,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Seasoning,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Test Result,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathologic stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Janus kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,B VARIANT NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Shock,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gonadorelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,VEGFA,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MED28,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immunoglobulin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MED28,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,claudin 6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PLEKHF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Associated symptom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,2q34,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fucoidan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,5-7-oxo-zeaenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,EGFR|ENAH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,coactivator-associated arginine methyltransferase 1|CARM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ACKR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Chloroquine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Does play,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Weight maintenance regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RAP1GDS1|KIFAP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIP,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,proneurotensin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dehydroepiandrosterone Sulfate,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EGb 761,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,mortalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CACNA1A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,osteopontin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,XIST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-6|IL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,COX5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,AHNAK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,no positive axillary nodes,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,chitotriosidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PROSTATE SPECIFIC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Adjuvant response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,E-Cadherin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Platinum salt,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Insulin Receptor|INSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CREB3L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fibroadenoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FANCM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,6/6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Thyroxine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Gastrin|GAST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Peanuts - dietary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Compete,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Crystallins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MSX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,valdecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Mitomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PRRT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EGFL7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta catenin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LRRC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Nitric Oxide Synthase Type II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Thromboplastin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BMP1|PRCP|PGPEP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,baicalein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PFAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diet,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,tibolone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,collagenase 3|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Histopathology,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Chondroitin Sulfates,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,phenethyl isothiocyanate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CYLD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TBX3,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
DISRUPTS,gefitinib,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Oxytocin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ferritin level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Norethindrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DACH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyperinsulinism,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Venous Thrombosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,USH2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cigarette smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NET1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MXD1|MAD1L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Flavonols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,Pancreatic leak,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Bilateral oophorectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Depo-Provera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neck Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,gamma-Glutamyl Hydrolase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CATALASE,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Leeks (dietary),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vasospasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Micellar Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Oxalates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MED19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Performance,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ECT2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LINC00461,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,USP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,DKK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIP5K1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Feeding and dietary regimes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ENPP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BITTER MELON FRUIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PVR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Juice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Glucocorticoids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,LRP6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Relapse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cyclin-dependent kinase inhibitor 1B|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Natural Products,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Paraoxonase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Interleukin-1 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ZEB2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CKS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,beta-elemene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lipocalin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,caspase-8|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,IL17F,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,claudin 6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Gangliosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,AFAP1L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,AMD3465,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,shogaol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Osteoporosis, Postmenopausal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Translocase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EZR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Monoacylglycerol Lipases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABRAXAS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,HULC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PARITY,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Proanthocyanidins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Anthocyanidins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,26S proteasome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Enrich (product),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"interleukin-1, beta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,rucaparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,fucoidan,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Thromboplastin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,ROR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,chloroxoquinoline,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,bis(4-hydroxyphenyl)sulfone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ZFP36L1|BRF1|MST1L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,nobiletin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CALCIUM HOMEOSTASIS,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Targeted Therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Aptamer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Xenograft type of graft,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Risk Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Graft acceptance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,marizomib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ergocalciferol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Transcriptome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AGR2,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,DLG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mevalonate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,dinoprost,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Epicatechin-3-Gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pathologic Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PROM1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Contralateral Prophylactic Mastectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Androgen Receptor,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Xenograft Model,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Cytologic atypia,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,platinum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Unlikely,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CXCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cyclovirobuxine D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Salts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fluid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Periodontitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Ganetespib,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Phosphoinositide Phosphatases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mastectomy,Stage IV Inflammatory Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Iodides,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
DISRUPTS,ciclesonide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Breast normal,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Systemic Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Ferritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Red Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,heparanase,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Patient age,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Digital Mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,No effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Insulin Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,EPHA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,rutin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Decreasing,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,MLN4924,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin-Dependent Kinase 4,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ataxia Telangiectasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathologic Complete Response,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Neoplasm, Residual",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Glucocorticoid Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Transferrin,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,other medicated shampoos in ATC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,FGFR1 wt Allele|FGFR1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Medical record number:ID:Pt:^Patient:Nom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-12 Subunit p35,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dovitinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,physiological aspects,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Possible,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,cell cycle regulator,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Recurrent pregnancy loss,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Disaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ACTG2 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cell Growth,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,COVID-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrillar Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Phosphotransferases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,REPLETE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SMYD3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Alkaloids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Whole Grains,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ergocalciferol,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,Limonins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ipatasertib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,rosuvastatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Reproductive Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biological Markers,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,1 time,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,paclitaxel liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,imipramine,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,AMACR wt Allele,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,limited use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,cyclin B2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Individual Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Experimental Result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pneumocystis jiroveci pneumonia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ginsenoside Rg3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Antioxidants,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,skill,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,alpha Karyopherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Anthropometric Measures:-:Point in time:^Patient:-,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TaqI POLYMORPHISM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,inhibitors,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pathologic Response,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,RET,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Contrast used,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,clopidogrel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"3,3'-diindolylmethane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Alkaloids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,vemurafenib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Histone deacetylase inhibitor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,ezrin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta-2 Adrenergic Receptors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,lycorine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Performance,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Operative Surgical Procedures,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
CAUSES,Mucosa-Associated Lymphoid Tissue Lymphoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,mannose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MTOR wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Alanine Aminotransferase 1, human",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KMT2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,20-40 years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Retinoblastoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Treatment Protocols,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diesel Exhaust,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Problem,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,BARRIER,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,taxifolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,macroautophagy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Androgen Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Increased risk,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,cinobufagin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Increased size (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CD103|ITGAE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,risk factors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,brusatol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hepatitis C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Menopause,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Suppressor,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,bruceine A,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,pimavanserin tartrate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Histone deacetylase inhibitor|HDAC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,hydroxypropylbetadex (0.58-0.68 MS),Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Piperlongumine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immune,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnosis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Anoikis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dichloroethylenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Not significant,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,paraffin,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,multicatalytic endopeptidase complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Screening mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,thyme oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,maduramicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Present,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Bacteroides fragilis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,epiberberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Benign foot rot,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bloody nipple discharge,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,decanoylcarnitine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,Fibrous Dysplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tegafur,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Signs and Symptoms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Score,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Multiple Sclerosis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,NF-kappa B,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Increased risk,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Receptor, Melatonin, MT1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Behavior,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Warfarin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MAD2L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Deoxycytidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,phosphatidylinositol 3-kinase gamma,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fluorouracil,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PITPNM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Psoralens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,BRD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Janus kinase 1|JAK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,exemestane,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,invariant chain|CD74,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,helicase|HFM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,GPR161,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Brain-Derived Neurotrophic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SOD3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Blood flow,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Pyrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SIX2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TUNAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,andrographolide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HOXB13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,UBE2I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,chymotrypsin A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Spironolactone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ceramides,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,Nitric Oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Adriamycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ATP6V1C1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic procedure,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Red meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MAGEC2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thiopurine S-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATP1B2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NANOG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pteridines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,combretastatin A-4 disodium phosphate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chronic heart failure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Ro 48-8071,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TAAR5|NR2E3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Placebos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oxidoreductase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,GAD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Galactosyltransferases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,proteomic profiling,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Gynecologic Surgical Procedures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,beta-cryptoxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NDP,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,Multiple Myeloma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Norepinephrine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Tuberculosis, Pulmonary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Retinoid X Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Integrin beta3|ITGB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Calcitonin Receptor|CALCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Leucovorin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,MLLT11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aspirin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,particle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,6p12,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,E-Cadherin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Endobronchial metastases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fibrinogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,IGFBP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diabetes Insipidus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SLOPE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Calcitonin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Adrenalectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adriamycin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,16 alpha-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Estriol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Large Cell Lymphoblastic Lymphoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Caseins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Orchitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FCE 21336,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TAG 12,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body measure result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Idarubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha-Lactalbumin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fucose,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Nuclear Receptor Subfamily 4, Group A, Member 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Difluoromethylornithine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Shock,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Enovid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Platinum,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERVW-1|ERVK-20|ERVK-18|ERVK-32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Interferons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypophysectomy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Stimulant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clinical finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BAG3,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
CAUSES,Telomerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Readiness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Operative Surgical Procedures,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Immune status,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Antihistamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,butyrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,stanniocalcin 2|STC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fluoranthene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,17q21,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Sterically Stabilized Liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Nitrosamines,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Early Diagnosis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Histidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Androgens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Silicones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Somatropin|GH1|GGH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Ether, Ethyl",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,small molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Plants, Edible",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Risk factor, cardiovascular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pregnancy History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,telomerase activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Watermelon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Genomic Instability,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HSD17B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Fibrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SLC39A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,AVP,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Chocolate milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,fulvestrant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Coping Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,dominant allele,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,SLIT3|SLIT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CTCFL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Therapeutic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cheese,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,WNT5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Alanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CXC Chemokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SLC3A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Gonadotropins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Endopeptidases,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cysteinylglycine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aspirin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,myricetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Adriamycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,prolyl-proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Heterocyclic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Eating,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Siramesine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CALCIUM PHOSPHATE CRYSTALS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Quantitative Trait Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,5-Trimethoxyamphetamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,5'-NUCLEOTIDASE|TRIM33,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,ADAMTS4|ADAMTS3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha 1-Antitrypsin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Prolactin Receptor|PRLR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Benzodiazepine Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,gemcitabine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dancing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,valylvaline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Toremifene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,glypican 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,doxifluridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Doxorubicin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Transient Receptor Potential Channels,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Phosphorylcholine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Fruit, Citrus",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Stanolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,4-octylphenol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,RA 25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glucocorticoid Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PARP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Apigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADIPOR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,17q21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,BHLHE41,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,arrestin3|ARR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,versican|VCAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Insulin, Regular, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,vinorelbine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,HRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HOXB9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Phosphatidylinositols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,thyroid microsomal antibodies|TPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,bakuchiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Herceptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FABP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KLF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,HRG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PANDAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Lymphoma, Large-Cell, Diffuse",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Antiretroviral Therapy, Highly Active",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Proteome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,germacrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ADAR1|ADAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,chemokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PORPHOBILINOGEN SYNTHASE|ALAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Clinical Treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyaluronan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,DDX3X,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,[M]Skin appendage adenoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,SLC19A3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,May-Hegglin anomaly,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,multicatalytic endopeptidase complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,angiogenin|ANG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,DOK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,NKX2-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,pyridoxine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GPR55,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cathepsin L|CTSL,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Anthracyclines,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CCT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DEFA1|CBX5|DEFA1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stopped work,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,cyclin-dependent kinase 3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,preference,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AFFECTS,DMPK|IGHD1-7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NF-kappa B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TRIM28,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Consanguinous Mating,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Biotin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PAQR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PTF1A,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,temozolomide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SUMO1P3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Echinococcosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immune defect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SLC4A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,5'-NUCLEOTIDASE|NT5E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PRDX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,phospholipase C delta 1|DLK1|DLL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Interleukin-18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Acetate,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TRPS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,nuclear receptor coactivator 1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,inorganic phosphate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,RBM38,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,F2-Isoprostanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,stromelysin 3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IkappaB Kinase beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ADAMTS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cantaloupes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Quinones,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Glucocorticoid Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,D4-GDI,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,Benzodiazepine Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,alpha Catenin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BANCR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,LINC00310,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gonadotropins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Smoking,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PTGER1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pancreatitis,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,fulvestrant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Lysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Is informed,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NFKB1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fatty fish,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Combined Oral Contraceptives,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Serpins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hydroxyl Radical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lindane,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Irritable Mood,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cytochrome P-450 CYP1A1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TWSG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Endometriosis, site unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PTGIS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,nuclear receptor coactivator 1|SRC,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TBXAS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MNX1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Light,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Coconut milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Epithelial hyperplasia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FAU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,PPAR gamma|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,2-hydroxyestrone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Non-Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Bioluminescence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RUNX2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,MED28,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Family problems,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TOX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,C19orf12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sexual exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Physical therapy exercises,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,prohibitin|PHB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DDX3X,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neprilysin|MME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,daidzein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inorganic arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prolactin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,drospirenone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SLC5A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Norethindrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,chronic stressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Expressed Sequence Tags,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Metformin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADAM12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Lamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"Insulin, Regular, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Metric,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Chemotherapy, Adjuvant",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ixabepilone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,pertuzumab,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,BAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Bulimia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tissue Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"2-methyl-5,6-cyclopentapyrimidine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,crocetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Study models,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DIO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,French fries,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Opioids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FOXP3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Digoxin,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,AGAP2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Aspirin,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CNTN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prolactin|PRL,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Epirubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,allograft inflammatory factor-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,matriptase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Olive oil - dietary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,VDR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FOXQ1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Antimony,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Telomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Sterically Stabilized Liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PGLS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,2'-Deoxythymidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunoliposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,inhibin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Interleukin-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Harvest of stem cells,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dioxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TGM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,GC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Positive Lymph Node,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,perchlorate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ASAP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Calcium Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FTY 720,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,C1QBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PITX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammography,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,membership,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,astaxanthine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,tomography,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CD151,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,thrombocytosis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHD8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Environmental Tobacco Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AOX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,hepcidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RHBDD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Obesity,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AFFECTS,GABARAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SEMA4C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Systemic Therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Gynecological history NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrinogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cataract,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Antithrombin III,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,METHOTREXATE TREATMENT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Glutamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Environmental Tobacco Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,citron rho-interacting kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MUTYH,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Opioids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IMPAD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,desires,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TMEM68,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ovariectomy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ENPP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,syringin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,KPNA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Propofol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FRZB,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic regimen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PSMD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CYP4Z1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,FOXP3,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,SNHG6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,beta-Chemokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Redness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CYP4Z2P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RANTES|CCL5,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CST1|CLSTN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Azurin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Macrophage Chemotactic Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LINC00968,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Intraductal Hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Moderate Exercise,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PHLDB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vitronectin|VTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,LINC00707,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,C1orf106,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sedentary lifestyle,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AUGMENTS,heparanase|HPSE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,metabolomics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Porifera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,survivin|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phosphotransferases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,ADCY4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Integrin alpha4beta1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,E-Cadherin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Toll-Like Receptor 5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC01614,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EIF4A1|EIF4A2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,other medicated shampoos in ATC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Minisatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,derivatives,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,stevioside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Healthy Lifestyle,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AUGMENTS,copper,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,gamma-Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,multiple pathologies,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,peer support,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,rasagiline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DOK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,veliparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,artesunate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Pads,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cannabinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Checkpoint kinase 1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,vinorelbine,HER2-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Marital Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,assessment.initial,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ethyl acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,N-acetyltransferase 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PROM1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Adjuvant Therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CLDN15,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Multiple malignancy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,catechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Energy Metabolism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,methacrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypersensitivity,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NEDD9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SHC3 wt Allele|GDF1|RNH1|PPP1R13L|SHC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,timosaponin AIII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MVP wt Allele|RPSA|LRP1|PTPRA|MVP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mastitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Insulin Resistance,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,phosphorus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Anticoagulants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Human cells,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,pseudouridine synthase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AXL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PTTG1 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Heating,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADIPOQ wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Risk Scores,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Chemotherapy,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Geographic pattern,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,dihydroartemisinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Biological Factors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Bariatric Surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,hippo signaling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Social Risk Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sodium metavanadate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Anthracyclines,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,prenatal exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Post-mastectomy radiotherapy,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognosis bad,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Imaging Techniques,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Paste,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,multiple pathologies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Neurofibromatosis 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Syndecan-4,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Vitiligo,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,R & C,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Negative,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,lapatinib,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Handling,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,pamidronate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,estrophilin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Very Important,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fulvestrant,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,everolimus,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FBXL20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,6-Phosphofructokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,phytochlorin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CK-34 beta E12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Interleukin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,>65 years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Monosaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aurora Kinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Antral Follicle Count,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,mifepristone,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aquaporin 1|AQP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,removal technique,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
DISRUPTS,UNC 0638,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,echinacoside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Metabolite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CI 994,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,rasagiline,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Early Diagnosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,tissue markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Antibodies, Anti-Idiotypic",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Hepatitis B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hypoxia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,liraglutide,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,norethindrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ergocalciferol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,vexibinol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mammographic Breast Density,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Diet, Healthy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
COMPLICATES,Acne,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"Peroxisome Proliferator-Activated Receptor Gamma, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Diet, High-Fat",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Late chronotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ginsenoside M1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VARIANT OF UNKNOWN SIGNIFICANCE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Catabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,pimozide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aurora Kinase A,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,andrographolide,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Apoptosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Protac,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Liver Cirrhosis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Breast present,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,1 time,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,survivin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,calcium,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Oxysterols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CBL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,erbB-2 Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Cytochrome P450,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,multiple pathologies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,caveolin 1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hematoxylin,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Elective Surgical Procedures,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,metformin,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ROS1 wt Allele|ROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,carbidopa,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,stigmasterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Small Molecule,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Coitus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CD274,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,benzopyrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Endometriosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Biological Response Modifier Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,iron increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ST8SIA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dietary Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,olaparib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Benign Prostatic Hyperplasia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,pyridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,lapatinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neuregulins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasound-Guided Core Biopsy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,acrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Uveitis,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Amides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High Level,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Adjuvant Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,pimagedine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,myosin VI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,doxorubicin liposome,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,Proteome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Place of Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fixatives,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor|ERBB2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,benzopyrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,3 times,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,royal jelly,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,BARRIER,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Aurora Kinase A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,personal health,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,metformin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,interferon type II|IFNG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,bruceine D,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,Feces,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasonography,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,sevoflurane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Postoperative chemotherapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,calcium,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dietary Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Platelets, CTCAE",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Analgesics, Opioid",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,hydrocortisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Osteopenia,Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cantharidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,pregnane X receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,White meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RARB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Aurora Kinase A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,risk factors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,echinacoside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Matrix,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CYP3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,abemaciclib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cell markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,beta-eudesmol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,antineoplaston A10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,vasomotor symptom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lindane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Decreased Immunologic Activity [PE],Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Intrapartum fetal hypoxia,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,metacresol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,elongin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,astaxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Receptor, PAR-1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Comorbidity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"glutamate carboxypeptidase II, human|FOLH1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fat-free mass,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"N-succinyl-1,2-dioleoylphosphatidylethanolamine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha-adrenergic receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Oral form sodium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phentolamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,TET1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin-Dependent Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EB 1089,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RARRES1|GPRC5A|MED15,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,heparanase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Quantitative Trait Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,alkylglycerophosphoethanolamine phosphodiesterase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Biological Phenomena,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrosing adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Anticoagulants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,pigment epithelium-derived factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NEDD9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,XBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RECK,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,GRN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HOTAIR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mucins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phosphatidylethanolamine N-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,discoidin domain receptor 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Annexin A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABL2|RERE,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,SPAG5,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Benign ovarian cyst,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,hormonal changes,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AUGMENTS,PKM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Methylnitrosourea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,THY1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Weaning,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,IGKV1-16|FAM49B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FOXA1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Paclitaxel,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PITPNM3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,HIC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Organochlorine pesticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MCM3AP|FIG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TNFRSF12A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CTSG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Kinesin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phosphatidylinositols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,IL33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,OPRM1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Medical follow-up,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ADGRF5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,sulfamate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Malondialdehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"3,4-Methylenedioxyamphetamine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,pioglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,rosiglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Telomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Cocci,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KRT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CCL28,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,calusterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,DELIVER,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Physical findings,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,prohibitin|PHB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Primary biliary cirrhosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ELP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,DDT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lactalbumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,paclitaxel liposome,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,CTU1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Thrombospondins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,particle,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thrombospondin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Running,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Asthenia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,midkine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prolactinoma,bilateral breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Misonidazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Abdominal obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,cholanthrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adriamycin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lymph Node Involvement,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Caffeine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"3,4-Methylenedioxyamphetamine",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Dietary Fats,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cholestyramine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,radical mastectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Rheumatoid Arthritis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,ptaquiloside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Cycasin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Bromocriptine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prolonged periods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Transferase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Trimetrexate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Paroxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bone Density,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PTPRF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,heparanase|HPSE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Fenretinide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Proline,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Free Radicals,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sedentary lifestyle,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Physical activity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Nitrites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Endopeptidases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sarcoidosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,LGD 1069,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,chemokine receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"polio, NOS",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Treatment/Psychosocial Effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Silicones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,chromosome 11q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,6-nitrochrysene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,17q23,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Tenascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,beta-hexachlorocyclohexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,inhibitors,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SLC12A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adrenalectomy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Thyroidectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Polyamines,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Fats, Unsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Premature Birth,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AFFECTS,Angiogenic Switch,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,"Liver Failure, Acute",Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,Estradiol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CD55|TCN2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Durapatite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SELPLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gruyere cheese,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Study models,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,chemokine receptor D6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DPYS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HFE,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NUCLEAR MITOTIC APPARATUS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CLEC14A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Thrombospondins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Angiotensinogen|AGT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Sermorelin|GH1|GGH,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Night shift worker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ASAP1|MYCBPAP,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NELFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ITGB3BP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,isopeptidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Breast radiotherapies,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADH1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Adenomatous Polyposis Coli,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,methyl group,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,gamma-Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tocopherols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,exemestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PREDICTED,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RNF115,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Aromatic Amines,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NOD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hyperandrogenism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Grapes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PDIA6,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Thalidomide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,multicatalytic endopeptidase complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,andrographolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atrophy of vagina,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,docetaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Aborted pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,5'-NUCLEOTIDASE|NT5E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-8|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNAI1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PPIA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Alpha tocopheryl succinate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Stearates,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,estrone sulfate,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dihydrofolate Reductase|DHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Acrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Silicon,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Xenograft procedure,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognostic Factor,bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAB27B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PARP1|COL11A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,D4-GDI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TIMM17A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ADM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,erbB-2 Receptor|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,docetaxel,Breast cancer stage II,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,exemestane,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SOX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alleles,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Interstitial Collagenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Quinones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ERBB2|NEU1|NEURL1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,Garlic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,VEGFA,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Body mass index procedure,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AVP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SPDYA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CD24,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cytochrome P-450 CYP1B1|CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ORALIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Lithium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,nuclear receptor coactivator 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,phenylalanylphenylalanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Norepinephrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,S100A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MAPK15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Velcade,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,GATA3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,collagenase 3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,HSPA1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,casein kinase II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tristetraprolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SUSD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,iturin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PSPHP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Genistein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Naphthalene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Purines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,toll-like receptor 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Interleukin 6 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Growth stimulant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,SLOPE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PTGER2|SPAG11B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,AMOTL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tubeimoside I,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,1/24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SH3PXD2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LY6K,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cofilin|CFL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MLLT11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FBXO42,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CMTS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ARGININOSUCCINATE LYASE|ASL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Platinum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transcript,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SOD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,costunolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ZNF143,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fibrosing adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,EIF2S1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Increased effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NF-Kappa B p65,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Hazards, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NF-AT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,indoleamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,EHMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ethylene glycol,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Pasta intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Beads,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Thioridazine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SCARA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CDCA7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,DDAVP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Pyruvate Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Prolactin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,nicotinamide phosphoribosyltransferase|NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Morphine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Doxorubicin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,B-pyridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Alkanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Prior Therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SNHG14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ACKR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,LACTB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,IkappaB Kinase beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Granulocyte Colony-Stimulating Factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Diet, Fat-Restricted",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NNT-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KISS1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,IL32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ferrocene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PPP2R2A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,schizandrin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CHI3L1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,osteoactivin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,N-myristoyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,caspase-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Platelet Factor 4|PF4,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Chromosomal Rearrangement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,P3H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,lymphocyte product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,IkappaB Kinase epsilon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ZIC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Polymerase|ERVK-9|ERVK-19|ERVK-11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LBH589,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADRA1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,8-hydroxy-2'-deoxyguanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thromboplastin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,WWC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Mammographic breast density,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,PGC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Estradiol Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,cryptochrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,REPS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Somatostatin analog|SST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Atherosclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,versican|VCAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Urokinase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tenascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fat tissue increased,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Androgen Receptor|AR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Tegafur,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Desipramine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Serpins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Size of lymph node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADH1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,decisiveness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,caffeinated beverage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pharmacotherapy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cultural differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Epiregulin|EREG,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fertility,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Buformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RGS17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RGS17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cytochrome P-450 CYP2D6,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Mayonnaise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ING1|LTB|CENPK,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fibromyalgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Signal Pathways,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body mass index,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Increased Metabolic Rate,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,PROM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Signaling Molecule,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,STARD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Estratest,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GLO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Doxorubicin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BMP4|BMP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Primigravida,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PPARGC1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DDIT4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Axillary Lymph Node Involvement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Leukocyte Elastase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,[D]Mammogram abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NEUROD1|TUBB4B,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hay fever,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Recombinant Interferon-gamma|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,URI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ABCC5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IL17F,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,POP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CSH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,patient characteristics,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Smoking Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estrone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Mangifera indica extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,NAP1L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Stathmin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cigarette Smoking,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,astragaloside IV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PRRX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,crocin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ING5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Annexin A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Proton therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,brucine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,histone deacetylase 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KLHL7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,stem cell therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cytochrome P-450 CYP2D6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACACA|BMS1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,decorin|DCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,inhibitors,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Financial circumstances,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta catenin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,2q33-q34,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PERP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,NEK2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Interleukin-10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Osteonectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Subarachnoid Hemorrhage, Aneurysmal",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,thiopurine,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body mass index,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Boiled potato,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypothyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHEST SYMPTOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ERBB2|NEU1|NEURL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Ritonavir,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Soluble ErbB-1|EGFR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,RANTES,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Microsatellite Repeats,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Local Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Thymidylate Synthase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CD68,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DES EXPOSURE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SABER,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BABAM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hematoxylin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mitogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SCREEN TECHNIQUES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,erbB-2 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adenomatous goiter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PFKFB4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disintegrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Abdominal circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,tibolone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LAMTOR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cooking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Lymphedema,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diuretics,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Trihalomethanes,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Histologic type,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Iron, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,JMJD6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cadaverine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,FRA16D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Thioglucosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dietary fat intake,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PNU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MED19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fruit,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,UBE2N,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,GJB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Chemotherapy, Adjuvant",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ENPP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KRT8,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,PTCSC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,AQP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,salinomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Mandibular right first molar abutment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cathepsins B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FAM84B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,AQP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ca(2+)-Transporting ATPase|CA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,therapeutic use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,verbenone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,moderate drinking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RBM12B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CASC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,EIF4EBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FUT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,1-Phosphatidylinositol 4-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cullin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Transferrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIEZO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Vinegar,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Interferon Type I,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,UCHL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Kinesin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,BCL11A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Dipeptidyl-Peptidase IV|DPP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,lysyllysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FAM13A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LINC01133,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,APOBEC3B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,honokiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Ephrin B Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Obesity,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATXN3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,PCB 118,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CERS6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ingredient,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,cardamonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,RAB1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin-Dependent Kinase Inhibitor 2A|CDK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,paracrine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Adrenergic Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PCB 101,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Docosahexaenoate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bleomycin|BLM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MDM1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cathepsins|CTSS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SORBS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,erbB-2 Receptor|ECD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,p65|RELA|SYT1|GORASP1|WNK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Annexin A1|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SOX5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,OGDHL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Postmenopause,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,SP 1049C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,talazoparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,insulin isophane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alcohol intake above recommended sensible limits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Infertility risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,levothyroxine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,ceramide kinase,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Primary Neoplasm,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,cisplatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptor, Notch4",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,chitosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,IGFBP7|SFPQ,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,physiological aspects,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,prothrombin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cisplatin,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,methylene chloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,tryptophan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,OSW 1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Saponin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Late Relapse,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,EXT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cyclin B1|CCNB1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Growth pattern,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Biological Markers,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ELK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Hypoxia,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Ginkgo biloba extract,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fenamole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rocky,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Lactones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sapphire,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Antioxidants,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MIR451A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,bis(4-hydroxyphenyl)sulfone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,S100P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,glycogen synthase kinase 3 beta,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ingredient,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,triptolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Isolate - microorganism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Potassium Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,resistin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Treatment Status,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,shikonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Suppressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,berbamine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Discoidin Domain-Containing Receptor 2, Human|DDR2",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Cycle Control,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malaria,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Collagen Type IV,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Echogenic,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,crocin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Open Reading Frames,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,methylate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ginsenoside Rh1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,cryptotanshinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,cyclin A2|CCNA2,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,alpha-hydroxyglutarate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,metformin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Challenge:Type:Point in time:^Patient:Nominal,HER2-negative breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CUL4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"BAG Family Molecular Chaperone Regulator 3, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Mouse Model,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,cinnamic aldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thyroid microsomal antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Increased risk,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PCYT1A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Beta-glucuronidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ruyiping,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Multiparity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Glucocorticoids,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,MIR31 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Breast Density,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,erbB-2 Receptor|ERBB2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Progranulins,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,MIR34A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cyclin-dependent kinase inhibitor 1B|IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PITPNM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cell Growth,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,T-Cell Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ketamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Analgesics, Opioid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"N-methylsulfonyl-12,12-dibromododec-11-enamide",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Polyphenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Core needle biopsy,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CSTB wt Allele|CST6,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,Molecular Target,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Thioredoxin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,quiescence,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,chromosome loss,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,decitabine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,docetaxel,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,False Positive,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,chemokine receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,cytidylyl-3'-5'-guanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,curcumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Orosomucoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Married (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Androgen Receptor,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ESR1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Premature Menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Postmenopausal status NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fatty pancreas,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,MIR451A wt Allele,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Calcium Signaling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Sodium Butyrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ethanol,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,dehydrodolichyl diphosphate synthase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oxysterols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,sinomenine hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,>40 years,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Cell Cycle Checkpoints,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypersensitivity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Warburg Effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Revival,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fluid flow,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Segmental Mastectomy,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,Methylnitrosourea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Discoidin Domain Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,inecalcitol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,specific immunity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnosis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Molecular Target,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Membrane Potential, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,asparagine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Leisure physical activity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,margetuximab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PROM1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,gamma-Glutamylcyclotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adipokines,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ezogabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,VDR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Radiosurgery, Stereotactic",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tandem Repeat Sequences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Wild Type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Offered,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Pesticides,Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,copper,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,navitoclax,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,dihydrotanshinone I,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,inhibitors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,pertuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,chromium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,sulfoenolpyruvate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,icariin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Pyruvate Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dietary Intake,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Performance,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,Pyrimidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Soluble Interleukin-6 Receptor Subunit Alpha, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,NAD+ kinase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Fibronectins,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Skin tanning,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MYC,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Experimental Result,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnostic assessment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Puberty,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Oral health,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TNF receptor-associated factor 6|TRAF6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,AKR1A1 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ethanol,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,Acetyl-CoA Carboxylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Secretome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,histone deacetylase 2,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"interleukin-1, beta|IL1A|IL1B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,abemaciclib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,MAP kinase kinase kinase 7,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Treatment Protocols,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cathepsin Z,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Basis,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasonography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nicotinamide N-Methyltransferase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,garcinone E,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,GW 4869,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,imipramine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,interleukin-8,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,TAF8 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Lactates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,metformin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Performance,Papillary carcinoma of the breast,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Terpenes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,magnoflorine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,directive therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,interleukin-10,HER2-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,iridium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fresh fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Post-mastectomy radiotherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,oxaliplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Dried fruit intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aptamer,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Tobacco,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Detected (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Liposomes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,tomography,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,ROS1 wt Allele|ROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Systemic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Nuclear magnetic resonance normal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,reserpine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Cytokeratin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,scopolamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,CD8A wt Allele|CD8A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Histone Deacetylase|HDAC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Scutellaria barbata extract,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Erianin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Total body fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Secretome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Triterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Mammary Neoplasms,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Histopathology finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
